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Abstract 
Background: Rheumatoid Arthritis (RA) is a chronic systemic inflammatory 
disease, which targets the synovial membrane and joints of patients, resulting in 
irreversible bone damage, and disability. It is marked by an influx of 
inflammatory immune cells into the synovium, disrupting the natural resolution 
of inflammation and resulting in the establishment of chronic disease. The 
development of new treatments for RA is limited by our incomplete 
understanding of disease pathogenesis.  Macrophages are critically important in 
the pathogenesis of RA and have been studied intensively due to their ability to 
initiate and amplify both systemic inflammation and local tissue damage by 
production of cytokines such as Tumour necrosis factor (TNF) α and Interleukin 
(IL)-6. Our understanding of the molecular mechanisms underlying monocyte and 
macrophage activation in arthritis remains unclear.  MicroRNAs (miRs) are a 
novel class of post-transcriptional regulators.  They are short, non-coding RNA 
molecules that bind to complementary sequences, typically in the 
3’untranslated region (UTR) of target genes, resulting in mRNA degradation or 
sequestration.  miRs have been shown to impact various aspects of mammalian 
biology including cell proliferation, differentiation and the immune response.   
Aims: To define a specific miR profile of CD14+ cells separated from peripheral 
blood (PB) and synovial fluid (SF) of RA patients.  Thereafter, to determine the 
functional targets of these dysregulated miRs, and determine if they play a role 
in maintaining the pro-inflammatory nature of macrophages in RA. 
Methods and Results: We identified a miR profile of SF CD14+ cells in RA.  The 
majority of this study concentrated on miR-125a which was shown to be 
upregulated in SF CD14+ cells and PB CD14+ cells of patients who respond well to 
conventional disease modifying anti-rheumatic drug (cDMARD) therapy when 
compared to healthy controls.  In these cells miR-125a negatively correlates with 
clinical measures of disease activity disease activity score 28 (DAS) erythrocyte 
sedimentation rate (ESR), simple disease activity index (SDAI), clinical disease 
activity index (CDAI), tender joint count (TJC) and swollen joint count (SJC) 
whilst positively correlating with serum levels of anti-inflammatory IL-10.  This 
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miR was also inducible by lipopolysaccharide (LPS) in monocytes and expressed 
at high levels in macrophage colony stimulating factor (M-CSF) macrophages. 
Using miR sponge technology we generated a macrophage like, miR-125a null 
environment in Phorbol Myristate Acetate (PMA) differentiated THP-1 cells.  We 
demonstrated by Enzyme linked immunosorbent assay (ELISA) that miR-125a null 
cells display a hyper inflammatory response to LPS and produce significantly 
higher levels of TNFα, IL-6, CCL4 and CCL5 when compared to a reporter 
control.  This phenotype was confirmed in primary human macrophages in which 
miR-125a was inhibited through transfection with an antagomir.  These cells 
produced significantly higher levels of TNFα, IL-6, IL-12 and CCL4.  Interestingly, 
macrophages in which miR-125a was inhibited expressed significantly lower 
levels of anti-inflammatory IL-10.   
Prediction algorithms identified members of the Toll Like Receptor 4 (TLR4) 
signalling pathway and inflammatory cytokines as potential miR-125a targets.  
Through luciferase reporter assays we identified a potential regulatory 
relationship between miR-125a and TLR4, TNF receptor-associated factor 6 
(TRAF6) and CCL4, which may account for the inflammatory phenotype of miR-
125a null macrophages.  Interestingly overexpression of miR-125a in primary 
human macrophages results in increased IL-10 production, but also increased 
TNFα production, highlighting the complicated nature of miR regulation.  We 
demonstrated a potential relationship between miR-125a and the inhibitor of 
Nuclear Factor Kappa Beta (NFκB), Tumour necrosis factor alpha-induced protein 
3 (TNFAIP3), which may account for increased TNFα production after miR-125a 
expression 
Conclusions: This study demonstrates that the miR profile of CD14+ cells from 
RA patients is different than those of healthy controls.  We have identified miR-
125a as a negative regulator of macrophage generated inflammation.  Based on 
our data we postulate that under normal conditions, miR-125a fine tunes the 
macrophage response to LPS/TLR activation and prevents an overactive 
inflammatory response by regulating NFκB activation, and the production of pro-
inflammatory cytokines.  This is accomplished by targeting members of the TLR4 
signalling pathway and pro-inflammatory chemokines themselves.  However, at 
sites of chronic inflammation, such as in RA, this regulation is impaired.  This 
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may be due to the masking of the effect of miR-125a by the increased expression 
of its targets during chronic inflammation, and the lack of response to IL-10 of 
macrophages within the RA joint.  Additionally miR-125a regulation may be 
impaired due to the dysregulation of other important miRs within the RA 
macrophage. 
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PTPN22 protein tyrosine phosphatase N22 
PU.1 Spi-1 proto-oncogene 
PUMA p53 upregulated modulator of apoptosis 
q-PCR Quantitative polymerase chain reaction 
RA Rheumatoid Arthritis 
Rab5a Ras related protein 5a 
RANK receptor activator of NF-κB 
RASF Rheumatoid arthritis synovial fibroblast 
RF Rheumatoid factor 
RISC RNA induced silencing complex 
SCID Severe combined immunodeficiency 
SDAI Simple disease activity index 
SE Shared epitope 
SF Synovial fluid 
SHIP-1 inflammation Phosphatidylinositol-3,4,5-trisphosphate 
5-phosphatase 1 
SHM somatic hypermutation 
SJC swollen joint count 
SLE Systemic lupus erythematosus 
SNBTS Scottish national blood transfusion service 
SNPs single nucleotide polymorphisms 
SOCS1 suppressor of cytokine signalling 1 
STAT Signal transducer and activator of transcription 
TAB1 TAK1-binding protein 2 
TAK1 Mitogen-activated protein kinase kinase kinase 7 
TAM Tumour associated macrophages 
TCR T cell receptor 
TCZ Tociluzimab 
Tf Transcription Factor 
TGF transforming growth factor 
TIMP Tissue Inhibitors of Metalloproteinases 
TJC tender joint count 
TLDA Taqman Low Density Array 
TLR Toll like receptor 
TLR4 Toll like receptor 4 
TNF tumour necrosis factor 
TNFAIP3 Tumour necrosis factor, alpha-induced protein 3 
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TNIP2 TNFAIP3-interacting protein 2 
tolDC Tolerogenic dendritic cell 
TRAF2 TNF receptor-associated factor 2 
TRAF6 TNF receptor-associated factor 6 
TRAP Tartrate-resistant acid phosphatase 
Treg Regulatory T cell 
TTP Tristraprolin 
Tyk2 Tyrosine kinase 2 
Ub ubiquitin 
UTR Untranslated region 
VEGF vascular endothelial growth factor 
WB Western Blot 
WT Wild type 
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Chapter 1 Introduction 
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1.1 Rheumatoid Arthritis  
1.1.1 Introduction 
Rheumatoid Arthritis is a chronic inflammatory disease of unknown aetiology 
that affects approximately 1% of the population.  The aberrant immune response 
affects the synovial membrane and joints of patients, resulting in irreversible 
deformity, bone damage, and disability[1].  Typically, noticeable symptoms 
occur between the ages of 30-50 years, with swelling and pain in multiple joints, 
and evolution towards a symmetric polyarthritis [2].  RA is characterised by an 
influx of inflammatory immune cells into the synovium and failure of the natural 
resolution of inflammation, resulting in the establishment of chronic disease. 
This in turn drives local mechanical failure of the joint.  Due to systemic nature 
of the immune response, RA is associated with many comorbidities such as 
cardiovascular diseases, metabolic syndrome, bone pathology, particularly 
osteoporosis, and cognitive dysfunction, especially fatigue [3].  Together this 
promotes progressive social, economic and personal decline, deteriorating 
quality of life and reduced life expectancy.  Thus RA comprises a disease of 
substantial unmet need, which merits detailed dissection, pathogenetic 
resolution and consequent new medicine development. 
1.1.2 Classification of RA 
Clinical manifestations of RA vary depending on disease stage and activity.  
Therefore disease identification is dependent on classification criteria defined 
by the 1987 American College of Rheumatology (ACR) outlined in Table 1.1.  
Patients are diagnosed with RA if they present with at least 4 of the 7 criteria 
outlined. 
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Table 1.1 ACR classification criteria for diagnosis of RA adapted from [4] 
 Criterion  Definition 
Morning Stiffness In and around the joint lasting >1hr for 6 weeks 
Arthritis ≥ 3 joint areas Synovitis in 3 or more joints simultaneously for 6 
weeks 
Arthritis of hand and 
wrist 
At least 1 swollen area for 6 weeks 
Symmetric arthritis Simultaneous involvement of joints on both sides of 
body for 6 weeks 
Rheumatoid nodules Nodules observed by a physician 
Serum Rheumatoid 
Factor 
Presence of abnormal amounts of RF in serum  
Radiographic changes Presence of erosions or bony decalcifications on 
radiographs 
   
These criteria have provided the gold standard for RA identification over the 
past 25 years; however they may have limitations in allowing early diagnosis of 
disease.  Therefore an update to these criteria has been issued, the 2010 
ACR/European League Against Rheumatism (EULAR) classification criteria. This is 
to facilitate the identification of patients who would benefit from early 
intervention.  Patients requiring this early intervention must present with 
clinical synovitis in at least 1 joint, or have synovitis that cannot be explained by 
another disease diagnosis.  
Classification criteria based on ACR/EULAR 2010 are calculated using a score-
based algorithm, outlined in Table 1.2.  To be diagnosed with “definite RA”, a 
patient needs a score of ≥6/10 by adding the score of categories A – D. 
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Table 1.2 2010 ACR/EULAR classification criteria for diagnosis of RA adapted from [5] 
Criteria Score 
A. Joint Involvement  
1 large joint 0 
2-10 large joints 1 
1-3 small joints 2 
4- 10 small joints  3 
> 10 joints (at least 1 small) 5 
  
B. Serology (At least 1 result)  
Negative RF and ACPA 0 
Low RF or low ACPA 2 
High RF or high ACPA 3 
  
C.Acute-phase reactants (At least 1 result)  
Normal CRP and normal ESR 0 
Abnormal CRP or ESR 1 
  
D. Duration of symptoms  
< 6 weeks 0 
≥ 6 weeks 1 
  
 
1.1.3 Epidemiology of RA 
Various incidence and prevalence studies have been carried out over the past 
few years that suggest a large amount of variation in disease occurrence 
amongst difference countries and populations.  Studies suggest that those 
suffering from RA are more likely to be detected in developed countries with a 
prevalence of 0.5-1.1% in Northern Europe/North America, compared to a 
prevalence of 0.1-0.5% in developing countries [6-10].   Whether this reflects a 
true biologic phenomenon or a reporting bias arising from health care priorities 
is unknown at this time.  In general, rates of RA have been falling in the 
developed world over the last decade.  The reason for this is not known, 
although altered environmental exposures, for example smoking, may be partly 
involved.  
1.2 Risk Factors for RA 
Mortality rates in those suffering from RA are higher than in the normal 
population with survival decreasing 3-10 years depending on age of disease onset 
and severity [11].  The underlying aetiology of RA has proven difficult to 
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elucidate, as although defined by a specific set of clinical features, RA is now 
understood to be a multifactorial disease.  The significant variations in disease 
incidence and prevalence between different populations have led to the 
investigation of RA specific risk factors that exist within populations.   
1.2.1 Genetic Risk Factors 
There is overwhelming evidence that development of RA has a genetic 
component:  
1.2.1.1 Twin and Family Studies 
To determine the role of genetic factors in the development of disease many 
studies have evaluated the concordance of disease between related individuals.  
This is measured using the parameter λR, which is the ratio of prevalence of 
disease among first-degree relations, compared to the general population.  For 
diseases heavily reliant on genetic abnormalities, such a cystic fibrosis (CF) the 
λR is high at 500, whereas the λR for RA is more modest at around 2-4 [12-14].  
The most powerful strategy to demonstrate the inheritability of RA is the use of 
twin studies [15, 16]. 
1.2.1.2 Major Histocompatibility Complex Associations 
A variety of approaches have been taken to resolve the genes associated with 
the risk of developing RA.  Initial studies were primarily by association.  
However, of late the application of Genome Wide Association Studies (GWAS) has 
proven most informative.  Even more recently, meta-analyses of these GWAS 
have yielded further insights. The major genetic risk factor identified to date is 
the presence of HLA-DRB1 alleles.  It has been demonstrated that the majority 
of RA patients share a short sequence in their MHC Class II molecules which lead 
to the elaboration of the shared epitope (SE) hypothesis [17].  The RA SE refers 
to a 5 amino acid motif in the DRβ chain of MHC Class II coded by several HLA-
DRB1 alleles.  The role of MHC Class II in antigen presentation lead to 
speculation that the SE would lead to the presentation of arthritogenic self and 
foreign peptides resulting in the selection of pathogenic T cells, however the 
mechanism of antigen presentation by the expression of the shared epitope 
remains unclear [18, 19].  More recent studies have also suggested that the SE 
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itself may act as a signal transduction ligand by activating cell surface 
calriticulin (CRT), an innate receptor, resulting in the activation of the nitric 
oxide pathways [20].  Additionally, the shared epitope has been shown to be 
arthritogenic due to its effects on osteoclasts.  Holoshitz et al have 
demonstrated that in-vitro treatment of both murine and human cells results 
with a synthetic SE peptide induces osteoclastogenesis and the production of 
TNFα and IL-6.  Administration of this peptide to mice with collagen induced 
arthritis (CIA) resulted in early disease onset, with a higher number of 
osteoclasts present in the joint, and therefore a higher level of bone erosion 
[21].  Although, the function of the SE remains unclear, what is clear is that the 
presence of the SE is associated with severe disease [22].    
1.2.1.3 PTPN22 
Although the MHC locus contributes strongly to the genetic risk in RA it can only 
explain around 30% of inherited risk, therefore other genetic factors must also 
play a role [23].  New technology has allowed the identification of many other 
associated risk loci within RA.  GWAS studies have identified single nucleotide 
polymorphisms (SNPs), which may point to the identity of genes that, in turn 
play a role in predisposition to disease [24].  One of these, a SNP in lymphoid 
tyrosine phosphatase (LYP), encoded by the protein tyrosine phosphatase N22 
(PTPN22) gene.  This phosphatase is involved in T-cell receptor (TCR) signalling.   
The SNP results in altered amino acid expression by substituting an Arginine to 
tryptophan resulting in a gain of function for LYP and reducing T cell responses 
to antigen stimulation [25].  This finding seems paradoxical as it is thought that 
autoimmunity is more likely to arise from hyper responsive, not hypo responsive 
TCR signalling.  However, as the strength of TCR signalling is one mechanism of 
selecting autoreactive T cells for deletion in the thymus, reduced receptor 
activation may impair normal T cell selection, and allow the survival of these 
potentially pathogenic T cells [26].  Recent studies have also implicated LYP in 
the activation of integrins and therefore cell migration, demonstrating that 
expression of the disease associated LYP mutant is associated with a failure to 
regulate T cell migratory responses.  In addition to effector T cells, PTPN22 has 
been shown to regulate the generation and function of Tregs.  PTPN22-/- T cells 
exhibit higher levels of Rap1 phosphorylation and increased IL-10 production, 
resulting in increased suppressive activity when compared to their wild type 
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counterparts [27].  Therefore, PTPN22 has been shown to be a critical regulator 
of both effector and regulatory T cells in-vivo.   
1.2.1.4 TNFAIP3 
TNFAIP3 encodes the ubiquitin editing enzyme A20 that is involved in negative 
regulation of NFκB signalling. Two RA associated SNPs have been mapped to this 
locus to date.  One of these is a missense mutation that substitutes a 
phenylalanine residue to a cysteine at position 127, resulting in impaired A20 
regulatory function.  The other, downstream of the TNFAIP3 promoter, reduces 
the avidity of NFκB binding and transcription of A20, again impairing it’s 
function [28, 29].  The contribution of these SNPs to disease is highlighted using 
mouse models.  Genetic ablation of TNFAIP3 in mice results in the spontaneous 
development of a severe polyarthritis that resembles RA.  These mice have high 
serum levels of pro-inflammatory cytokines including TNFα, which is consistent 
with sustained NFκB activity in macrophages [30].  A recent study by Lamkanfi et 
al, has also suggested that TNFAIP3 is also a regulator of inflammasome 
activation and IL-1β production in arthritis.  They have demonstrated that in 
TNFAIP3 knockout mice, the arthritis which develops is not dependent on TNF-
R1, but on IL-1R and inflammasome activation.  This activation usually occurs in 
2 steps, with the first being an activation signal, usually through a TLR, resulting 
in NFκB dependent upregulation of the Nod-like receptor protein 3 (NLRP3) 
inflammasome protein, pro-IL1β and pro-IL18.  As NFκB expression is regulated 
by TNFAIP3, they have shown that knock-out (KO) macrophages produce higher 
levels of these proteins, resulting in a higher production of pro-inflammatory 
TNFα, IL-6 and IL-1β.  They therefore hypothesise that TNFAIP3, reduces the 
pool of NLRP3 available for inflammasome generation and pro-inflammatory 
cytokine production, and that mutations in this molecule will prove pathogenic 
[31]. 
Other genetic loci have also been implicated in disease susceptibility including 
peptidyl arginine deaminase (PADI4).  SNPs within this region are important as 
PADI4 belongs to a family of enzymes that can post transcriptionally convert 
arginine residues to citrulline.  Antibodies against these citrullinated self-
proteins (anti-CCPs) are detected in RA and associated with disease severity 
[32].  Indeed, a recent study by Suzuki et al has demonstrated 17 SNPs within 
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this gene, 8 of which are strongly associated with RA.  These SNPs associate in 
distinct haplotypes, and this study has demonstrated a particular ‘susceptible 
haplotype’ which is more frequent in RA patients.  Expression of this susceptible 
haplotype is associated with higher levels of anti-CCP antibodies, and therefore 
may be important in the break of tolerance to citrullinated peptides witnessed 
in RA [33].  This SNP appears to be influential only in Asian populations [34]. 
A recent GWAS study, published in Nature, of over 100,000 subjects of European 
and Asian descent, identified a further 42 SNPs bringing the total identified to 
101.  From this study, it was shown that the genetic risk for RA is shared, in 
general, among European and Asian populations, and that around 2/3 of RA risk 
loci are shared with other inflammation and immune related diseases.  
Interestingly, the study also demonstrated that RA risk associated genes, 
significantly overlap with genes associated with haematological cancers.  Many 
of the genetic risk loci identified contained genes that were already the targets 
of drug therapy, for example Tyrosine kinase 2 (Tyk2), associated with IL-6R, 
and therefore already the target of Tociluzumab.  This study also demonstrated 
how genetic data could be integrated with other biological data to drive drug 
discovery.  For example Cyclin dependent kinase (CDK) 6 and CDK4, identified 
here as RA risk genes, are already approved targets for drugs to treat many 
forms of cancer.  One of these drugs, flavopirodol has been shown to ameliorate 
disease in animal models of RA [24].  
1.2.2 Gender 
Incidence of RA is higher in females when compared to males with a ratio of 3:1, 
suggesting a role for X-linked genes and hormones in disease susceptibility [35].  
Studies concerning oestrogen exposure and RA have generated varied results.  
One study has suggested that oral contraceptive use after diagnosis may protect 
women, but that there is no effect of prior consumption on RA development 
[36].  What is clear however is that many women with RA experience remission 
during pregnancy with an increase in the production of anti-inflammatory 
cytokines affecting disease activity [37].  After the age of 45 the incidence of RA 
in men increases and approaches that of age matched women, suggesting 
decreased androgens are associated with disease onset [38]. 
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1.2.3 Environmental Risk Factors  
Although genetic risk factors confer susceptibility, a concordance rate between 
monozygotic twins of only 15%, demonstrates that additional factors must 
contribute, before a genetically susceptible individual develops RA [39]. 
1.2.3.1 Smoking 
 The major environmental risk factor identified to date for disease 
development is cigarette smoking [40].  Smoking is associated with the 
production of rheumatoid factor (RF) in both RA sufferers and the general 
population [41, 42].  In addition smokers are more likely to develop extra-
articular features of RA such as lung disease and vasculitis adding to disease 
severity [43, 44].  It has been hypothesised that cigarette smoking can trigger 
citrullination of self-proteins, and that these modified proteins are more prone 
to bind to the HLA-DR SE for presentation.  This would result in an immune 
response to citrullinated proteins in individuals expressing the SE, resulting in 
the production of Anti-Citrullinated Protein Antibodies (ACPAs) [45, 46].  
Citrullination is the post transcriptional modification of arginine residues of 
proteins by which peptidylarginine is converted to peptidylcitrulline.  This 
reaction is catalysed by PAD enzymes, of which 5 isoforms have been described 
(PAD1-4 and 6).  In healthy physiology, citrullinated proteins are present in a 
variety of cells and tissues, for example citrullination of keratin within the skin 
enables the final stage of keratinocyte differentiation, however, recent studies 
have identified this modification in various pathologies including RA and Multiple 
Sclerosis (MS) therefore it appears that tolerance to citrullinated proteins is lost 
in RA [47, 48].  Increase in PAD2 and PAD4 have been demonstrated in the RA 
synovium [49]. Furthermore RA patients can now be split into two clinically 
relevant subsets based on ACPA expression [50].  ACPAs are present in only 2% of 
the normal healthy population, but in over 60% of RA patients, [51].  
Citrullinated proteins are not present in the normal joint, but can be generated 
in response to apoptosis and inflammation [52].  During inflammation, 
citrullination of various different joint proteins has been demonstrated, 
including vimentin and fibrinogen.  Antibodies from RA patients have been shown 
to react with the citrullinated, but not the normal forms of these proteins [53].   
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In addition work by Lundberg et al has identified citrullinated α-enolase as 
another potential autoantigen.  This protein is highly expressed in the RA joint 
and antibodies are found within the joint to only the citrullinated form of this 
protein, and are specific for disease [54].  Lundberg et al identified a dominant 
B Cell epitope in citrullinated α-enolase, CEP-1, which reacts with 37-62% of RA 
sera, but only 2% of healthy controls.  This epitope shows high sequence identity 
with bacterial enolase, and anti-CEP-1 antibodies react with both forms of the 
citrullinated proteins.  This suggests the immune system may be primed by 
bacterial infection, and tolerance may be broken by a reaction to bacterial 
enolase, resulting in a chronic response to the human form of this protein, found 
within the joint [55].   
1.2.3.2 Infection 
Several infectious agents have been implicated as risk factors for RA. Infection 
with Porphyromonas gingivalis (P. gingivalis) results in the development of 
periodontitis in genetically susceptible individuals.  Periodontitis is also a 
chronic inflammatory disease that results in bone resorption within the mouth 
[56].  Levels of P. gingivalis correlate with anti-CCP antibody titres [57].  P. 
gingivalis also express a PAD enzyme which can citrullinate both bacterial and 
host proteins, with citrullinated α- enolase being found within the SF of RA 
patients [54, 58].  This suggests infection with P. gingivalis may result in the 
activation of the host immune system to recognise these modified proteins in 
genetically predisposed individuals.  Additional infections have also been 
implicated in RA pathogenesis such as infection with the human parvovirus B19 
that can cause joint manifestations, in which symmetric arthritis develops in the 
small joints of the hands and wrist.  B19 DNA has been detected in affected 
joints and presence of DNA is associated with expression of the RA associated 
shared epitope [59].  However B19 DNA has been found to persist in joint tissue 
of both individuals who go onto develop RA and healthy individual who do not.  
Therefore the relationship between RA development and B19 infection remains 
controversial [60].  Another DNA virus with a proposed role in increasing the 
susceptibility to RA is Epstein Barr Virus (EBV).  This association has been 
identified for many years, as sera from RA patients contains high levels of 
antibodies against EBV antigens [61].  The HLA-DRB1*401 associated motif QKRAA 
is found on EBV glycoprotein gp110.  Healthy individuals have antibodies and 
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antigen specific T cells against this motif, whereas RA patients have a lower 
response, this may result in a higher EBV viral load, and an on-going immune 
response [62].  In addition to viral infection, the presence on mycoplasma DNA is 
found in the PB of around 53% of RA patients, suggesting a systemic 
mycobacteria infection [63].  Additional studies have also implicated Escherichia 
coli (E.coli) and their production of heat shock proteins (Hsps) in the initiation of 
RA.  Hsps are a family of evolutionary conserved proteins that play an important 
role in cell physiology under normal and stressed conditions.  These proteins are 
evolutionarily conserved between bacteria and humans and have been 
implicated in disease pathogenesis, due to their sequence similarity [64].  Hsps 
are categorised by their size, with Hsp40 being the most intensively studied 
within the joint.  E. coli derived Hsp40, or DNAJ, and its human equivalent Hdj1, 
2 and 3 have been implicated in disease pathogenesis.  Studies have shown the 
presence of anti-DNAJ antibodies in both RA and Juvenile Idiopathic Arthritis 
(JIA), and these antibodies have been shown to cross react with both human and 
bacterial forms of the protein [65].  Additionally, high levels of human anti-
DNAJA1 and anti-DNAJA2 antibodies have been demonstrated in the sera and 
synovial tissue of RA patients [66].  Although the exact role of bacterial and 
human Hsp40s in the autoimmune response requires further investigation, these 
observations suggest those proteins have relevance in the induction of RA.  
The association of infectious disease and the predisposition to RA development is 
based on the presence of DNA of, and high antibody titres to infectious agents in 
RA sufferers compared to healthy controls.  However no consistent evidence has 
emerged to identify a single infection for RA development. 
1.3 Co-morbidities associated with RA 
Although RA is generally characterised by a destructive immune response within 
the joint space, RA patients, in common with those suffering from other long-
term chronic disease, suffer from various co morbidities.  Some of these 
associated diseases such as cardiovascular disease (CVD); depression and the risk 
of infection or malignancy contribute to the increased mortality rate of RA 
sufferers. 
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1.3.1 Cardiovascular mortality and RA 
There is extensive evidence that RA patients with well-established disease have 
increased risk of ischaemic heart disease [67].  In addition, individuals with RA 
are more likely to develop heart failure when compared to the general 
population [68]. Cardiovascular risk may be heightened in RA sufferers due to 
treatment effects.  Of some concern is the use of non-steroidal anti-
inflammatory drugs (NSAIDs) which appear to generate the highest risk of a heart 
attack [69].  It has been demonstrated that chronic inflammatory diseases in 
general have increased rates of cardiovascular disease.  This suggests that it is 
the presence of on-going inflammation that causes mortality and not specifically 
the RA disease process.  
1.3.2 Osteoporosis 
The risk of osteoporosis has been demonstrated in RA patients for many years, 
due to the presence of pro-inflammatory cytokines and activation of osteoclasts 
resulting in reduced bone density [70, 71].  Increased disease activity and 
severity are associated with bone loss, suggesting early treatment may be 
beneficial in patients to prevent bone erosions [72]. 
1.3.3 Lung Disease 
Pulmonary pathology is common during RA and contributes significantly to its 
mortality rate.  Interstitial lung disease (ILD) is the most common and 
potentially most dangerous manifestation of RA within the lung [73].  The risk of 
RA-ILD has been demonstrated to be 10% [74].  The prognosis after being 
diagnosed with RA-ILD is extremely poor with a median survival rate of 
approximately 3 years, with the preferred treatment option being 
immunosuppressive drugs, cyclosporine or cyclophosphamide [75, 76].  The 
biological mechanisms that drive RA-ILD are relatively unclear, and further 
research is required due to the high mortality rate from this co-morbidity.  
Biologic therapy paradoxically is also associated with increased mortality in 
those with RA and lung disease – the cause of this is also unknown. 
Recent studies have also examined the lung as a site of initiation out-with the 
joint, especially in ACPA positive disease, due to the previously discussed link 
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between smoking and RA.  RA related lung disease has been highlighted by the 
use of high resolution CT scanning (HRCT) which has identified the presence of 
ACPAs to be associated with parenchymal lung abnormalities and the 
citrullination of proteins in early RA [77].  In addition, inducible bronchus 
associated lymphoid tissue (iBALT) has been identified in the lungs of RA 
patients in which B cells can produce RF and ACPAs.  This has led to a hypothesis 
that suggests smoking triggers citrullination of proteins within the lung resulting 
in the production of ACPAs by B Cells.  A second injury in the synovium then 
results in citrullination of joint proteins, which results in the development of 
chronic disease [78].  
1.3.4 Malignancy 
RA is also associated with a risk of lymphoma development, which increases 
dependent on the level of on-going inflammation present [79].  There has been 
intense investigation into the risk of malignancy associated with treatment i.e. 
the use of immunosuppressive agents and new biologic therapies.  Small studies 
have reported EBV related lymphomas associated with methotrexate (MTX) 
treatment, however this was not replicated in larger case studies [80, 81].  
Studies have also reported a risk of lymphoma development with MTX and anti-
TNFα therapy, however this risk is relatively low [82]. 
1.4 Clinical Manifestation  
The onset of RA is preceded by an asymptomatic pre-articular phase, marked by 
a breach of self-tolerance and the presence of circulating antibodies, such as 
ACPAs and RF.  These antibodies can be present years prior to clinical 
manifestation of disease [83].  A transition event then occurs which results in 
the disease becoming clinically evident as the synovium is transformed from a 
functional lining two to three cells deep, to a hyperplastic invasive tissue full of 
infiltrating immune and resident joint cells [84].  These cells initiate and 
perpetuate on-going inflammation, tissue damage, and joint destruction.  
It is now widely accepted that RA is a multi-factorial disease that develops from 
a complex interaction of environmental triggers, occurring on a genetically 
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susceptible background.  This results in a breach of tolerance and the 
recruitment of pro-inflammatory cells to the joint [85]. 
1.5 Immunopathology of RA 
The normal joint is composed of two adjacent bony ends that are covered with a 
layer of cartilage, separated by a joint space and surrounded by the synovial 
membrane. The normal synovial membrane is <100 μm thick and the synovial 
lining consists of a thin layer of synoviocytes.  RA is characterised by an influx of 
pro-inflammatory cells into the synovium resulting in the thickening of the joint 
lining and pannus formation.  The pannus contains proliferating synovial cells 
that establish chronic inflammation resulting in destruction of cartilage and 
bone.  It is important to understand which cells are present in this tissue in 
order to development novel treatments which can target either cells or the 
mediators they which produce. 
1.5.1 Synovial Fibroblasts in RA synovitis 
 The intimal lining of the RA synovium demonstrates an increase in both 
macrophage and RA synovial fibroblasts  (RASFs), both of which are critically 
important in the disease process [86] 
RASFs are active drivers of joint destruction through the production of pro-
inflammatory cytokines and matrix degrading enzymes [87].  Activation of RASFs 
occurs in both an autocrine fashion, through their production of fibroblast 
growth factor (FGF) and transforming growth factor β (TGFβ) and also through 
their interaction with pro-inflammatory cytokines such as TNFα, IL-1 and IL-17A, 
produced by other cells within the joint [87].  Activation of these cells promotes 
many aspects of disease pathology such as cartilage invasion and degradation. 
RASFs are described as “tumour like” cells, which can adhere to and invade 
surrounding cartilage [88].  RASFs are primarily responsible for the destruction 
of cartilage observed in RA, through the production of matrix 
metalloproteinase’s (MMPs). These destructive enzymes are constitutively 
expressed at high levels by early passage RASFs and within the synovium, 
especially at the cartilage/pannus junction [84].  MMP production by RASFs can 
be up-regulated by pro-inflammatory cytokines TNFα, IL-1β and growth factors 
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present at high levels in the joint [89].  In healthy individuals MMP production is 
regulated by the production of Tissue Inhibitors of Metalloproteinases (TIMPs) 
produced by chondrocytes, fibroblasts and endothelial cells [90].  In RA this 
balance is disturbed favouring production of high levels of destructive MMPs 
resulting in cartilage invasion and destruction.  Overexpression of TIMP 1 and 3 
in the joint by gene transfer has been shown to reduce RASF invasiveness; with 
TIMP 3 sensitising RASFs to Fas ligand induced apoptosis [91]. 
In addition to driving joint destruction, RASFs interact with other cells within the 
synovium to promote the production of pro-inflammatory cytokines.  RASFs 
contribute to T cell recruitment and retention within the joint through the 
production CXCL12 that recruits T cells into the synovium [92].  In addition, 
RASFs produce IL-6, TGFβ and IL-23, which are essential for the differentiation 
of Th17 cells [93]. These cells also produce molecules required for the formation 
of germinal centres (GCs), CXCL12 and CXCL13, and increase B cell survival 
through the production of B cell activating factor of the TNF family (BAFF) [94]. 
RASFs also act on resident cells within the joint to promote angiogenesis through 
the production of growth factors such as vascular endothelial growth factor 
(VEGF), and promote bone degradation through the production of receptor 
activator of NF-κB ligand (RANKL) and Dickkopf-related protein 1 (DKK)-1 [95]. It 
also has been shown that microparticles within the synovium containing 
inflammatory mediators can be released from RASFs promoting the production of 
pro-inflammatory cytokines and MMPs and contribute to the activation of 
adjacent cells [96] An intriguing recent study has also attributed the spread of 
RA in part to RASFs.  Initially only a small number of joints are affected by RA, 
but this usually spreads.  A study in mice has revealed a role for RASFs in this 
dissemination [97].  
1.5.2  Dendritic Cells in RA synovitis 
Dendritic cells (DCs) are important immune effector cells due to their ability to 
present antigen to cells and mediate the adaptive immune response [98].  DCs 
are immature within the periphery, and are activated in response to pro-
inflammatory mediators, such as pathogen associated molecular patterns 
(PAMPs) during infection.  After activation, DCs migrate to the lymph nodes, 
mature, present antigen to T cells, and secrete cytokines that result in T cell 
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polarisation.   In this way they generate and maintain self-tolerance by 
presenting endogenous self-antigen both in the thymus and periphery resulting in 
the deletion of autoreactive cells [99]. Depletion of DCs in animal models results 
in the induction of a fatal autoimmune disease, emphasising their role in 
maintaining tolerance [100].  Breakdown of self-tolerance is considered to be an 
important initiating factor in RA.   RA SF contains high numbers of both myeloid 
and plasmacytoid (mDC, pDC) and these cells have been shown to both migrate 
into and differentiate within the synovium, dependent on the cytokine and 
chemokine milieu [101, 102].  RA DCs cells in-vivo also appear activated as they 
express high levels of MHC Class II, RANK and RANKL [103].  
Presentation of autoantigen to lymphocytes by DCs can in theory result in the 
evasion of central tolerance and the induction of autoimmunity.  Several auto-
antigens have been described in the context of RA, such as citrullinated type II 
collagen that can be taken up, processed and presented to induce auto-reactive 
T cells by DCs [104].  Additionally, in-vitro synovial DCs have been shown to 
present human glycoprotein 39 to antigen specific T cells [105].  Auto-antigen 
recognising T cells can then produce pro-inflammatory and cytotoxic mediators 
and provide help for autoantibody production by B cells.  Additionally, DCs 
isolated from SF produce high levels of pro-inflammatory IL-1, IL-6 and TNFα 
when stimulated [106].   
In addition to activating the adaptive immune response, DCs have also been 
shown to induce tolerance.  These tolerogenic DCs (tolDCs), mature in an anti-
inflammatory cytokine milieu with high levels of IL-10 and TGF-β, or 
immunosuppressive substances such as corticosteroids.  tolDCs can induce 
peripheral tolerance in many ways such as blocking T cell clonal expansion, 
inducing T cell anergy and inducing the differentiation of Tregs [107].  Studies 
have therefore investigated the clinical use of these cells as therapy for immune 
driven diseases.  To do this, simply, DC precursors are removed from patients, 
isolated and differentiated to a tolDC phenotype, at which point they are 
injected back into the patients.  Human clinical trials are continuing with tolDCs 
in immune related diseases such as Type I diabetes showing positive results 
[108].  This suggests that on-going trials in RA may prove beneficial in the 
future, opening up further treatment options for patients. 
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1.5.3  T cells in Rheumatoid Arthritis 
T cell involvement in RA has been investigated since the identification of the SE.  
In addition, recent advances in the understanding of the genetics of RA have 
demonstrated T cell associated SNPs as risk factors for disease development.  
For example the SNP at PTPN22 locus and the programmed death 1 (PD-1) gene 
that protects auto-reactive T cells from apoptosis, allowing a breakdown in 
tolerance [109].   
Based on studies in rodent models, RA was originally believed to be a CD4+ Th1 
driven disease, however only low levels of Th1 cytokines were detected within 
the joint [1, 110].  However with the description of a new subtype of T cells, 
Th17 cells, which produce the highly inflammatory cytokine IL-17 the rationale 
around T cell and disease progression was changed.    Th17 cells produce a 
distinct set of cytokines including IL-17A, IL-17F, IL-21 and IL-22, resulting in a 
specific immune response [111].  Th17 cells were first described in mice and 
differentiate from precursor cells in the presence of TGFβ, and a combination of 
other pro-inflammatory cytokines, such as IL-1, IL-6, IL-21 and IL-23 [112].  IL-
17A is found at high levels in the T cell rich areas of the synovium, and higher 
concentrations of this cytokine have been identified in both the serum and SF of 
RA patients, when compared to both osteoarthritis (OA) patients and healthy 
controls, where is correlates with disease activity [113].  Levels of IL-17A are 
also higher in ACPA positive disease which has been shown to be more erosive 
[114].  The location of Th17 cell differentiation is unclear, however the presence 
of IL-6, IL-23 and TGFβ in the joint creates conditions where differentiation 
could occur [1].    IL-17 activates both RASFs and macrophages which can then 
promote inflammation and destruction, through the release of further pro-
inflammatory cytokines and destructive enzymes whilst also acting on 
chondrocytes and osteoclasts to promote activation and differentiation, allowing 
cartilage and bone degradation to occur [115].  Experiments demonstrate that 
the severity and incidence of disease is dramatically reduced in mice deficient in 
IL-17 or its receptor in models of CIA [110].  However, Th1 cells, and IFNγ may 
still play a role in disease.  It has been hypothesised that IFNγ, may play a dual 
role in the synovium, initially supporting inflammation, but inhibiting the 
differentiation of Th17 cells [116].  In addition to the production of cytokines T 
cell contact with macrophages within the synovium results in the production of 
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pro-inflammatory TNFα, chemokines and MMPs [117-119].  Among other things, 
this cell contact mediated production of pro-inflammatory cytokines is 
prevented by Abatacept (CTLA-4) therapy discussed in 1.5.5. 
Regulatory T cells (Treg) have also been found in the peripheral blood and 
synovium of RA patients [120].  However it has been hypothesised that the 
regulatory ability of these cells in disease is impaired.  Ehrenstein et al have 
shown that high levels of TNFα in the synovium can affect the ability of Tregs to 
suppress pro-inflammatory cytokine expression of effector T Cells [121].  Further 
studies have shown that indeed, TNFα within the joint has the ability to subvert 
Treg function.  A study by Nie et al has shown that TNFα in the synovium induces 
the expression of the protein phosphatase 1 (PP1) enzyme, which prevents the 
phosphorylation of forkhead box P3 (FOXP3) and its activity.  They also 
demonstrated that treatment with anti-TNFα decreased PP1 expression and 
restored FOXP3 phosphorylation and Treg suppressive function [122].  
Additionally, others have hypothesised that under inflammatory conditions in the 
joint, T cell plasticity, allows Tregs to be polarised towards a pathogenic Th17 
phenotype.  Wang et al have identified IL-17 producing Tregs in the PB and SF of 
RA patients, suggesting that these cells may lose their suppressive function at 
sites of inflammation, under high levels of polarising inflammatory cytokines 
[123].   Other studies have also suggested that effector T cells within the joint 
are resistant to Treg suppression [124]. 
1.5.4 B Cells in Rheumatoid Arthritis 
The involvement of B Cells in the pathogenesis of RA has been highlighted due to 
the success of depletion therapy, such as with Rituximab, and this population 
plays several roles in the context of autoimmunity.  One of the hallmarks of 
disease is the presence of circulating autoantibodies such as RF and ACPAs, with 
the presence of ACPAs being associated with a highly erosive disease [125].  
Patients can be split into subsets depending of the presence of these 
autoantibodies, with 50-80% of patients expressing either RF or ACPAs within 
their sera [126].  Antibody responses take place in B cell areas of secondary 
lymphoid organs, such as germinal centres, where somatic hypermutation (SHM) 
and class switch recombination (CSR) takes place.  Ectopic GCs have been 
identified in around 25% of patients in the RA synovium, where B cells can 
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accumulate [127].  These well maintained structures allow affinity maturation 
and receptor editing of autoantibody producing B cells and Humby et al have 
shown that these structures are functional within the synovium resulting in the 
continued production of pathogenic autoantibodies [127].  The importance of 
autoantibody producing B cells in RA has been demonstrated by Holmdhal et al 
who conducted experiments on µMT mice that lack B cells.  Immunisation of 
these mice with Type II collagen does not induce arthritis, and the T cell 
response to antigen is also disrupted [128].  The most studied of these 
autoantibodies, RF, was discovered in the PB of patients in 1957 and can appear 
years before clinical symptoms are witnessed [129].  Patients seropositive for RF 
have a worse prognosis, correlated with a more severe aggressive disease [130].  
It is believed that RF causes damage through the formation of immune 
complexes and the Fc mediated activation of the complement system.    
In addition to the production of autoantibodies B cells can produce pro-
inflammatory cytokines and are efficient antigen presenting cells that can 
activate T cells through co-stimulation.  The importance of this role has been 
demonstrated using a human synovium/ Severe combined immunodeficiency 
(SCID) model in which it was shown that T cell activation is B cell dependent 
[131, 132]   
1.5.5 Osteoclasts and Osteoimmunology in RA 
Bone destruction by osteoclasts is a hallmark of RA [95].  Osteoclasts are highly 
specialised cells with the ability to remove calcium from, and degrade bone.  In 
a healthy setting osteoclasts, along with osteoblasts maintain bone homeostasis, 
[133].  During inflammation the balance between these 2 cells is disturbed, and 
an accumulation of osteoclasts in the joint results in high levels of bone 
resorption, leading to damage and erosions [134].  Mice deficient in osteoclasts 
do not exhibit bone erosion despite the presence of inflammation [135].   
 Enhanced osteoclastogenesis occurs in the joint due to a combination of 
factors reliant on the influx of monocytic precursors, and their subsequent 
differentiation into osteoclasts within the inflammatory environment.  
Osteoclast differentiation requires the presence of M-CSF and RANKL, both of 
which are present at high levels in the inflamed joint.  These molecules bind to 
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their receptors, RANK and CD115 respectively inducing differentiation [95].  
Th17 cells can also influence osteoclastogenesis through the production of 
RANKL when stimulated with IL-23 and act directly on precursor cells, which has 
been shown to be a co-factor in osteoclast activation [136, 137].   Clinical trials 
using a humanized anti-RANKL antibody (Denosumab) has been shown to be 
protective against joint destruction in RA as osteoclastogenesis is prevented 
[138] 
Inflammation itself can actively suppress bone formation through its effect on 
Wnt signalling within the joint [139].  Wnt signalling enhances osteoblast 
differentiation and downregulates osteoclastogenesis through the expression of 
Osteoprotegerin (OPG) [140]. The high level of inflammatory cytokines in the 
joint interferes with the ability of the osteoblast to differentiate and therefore 
repair bone that has been damaged.  One important pro-inflammatory cytokine, 
TNFα can induce the expression of the proteins DKK-1 and Sclerostin which 
inhibit the Wnt pathway and are found in the synovium of RA patients [136].  
These proteins inhibit osteoblast formation and thus inhibit bone formation and 
repair [139].  This not only blunts bone formation, but also increases bone 
degradation as lower amounts of OPG are produced within the joint.   It is 
important to address the balance in RA that is clearly disturbed, as prevention of 
bone degradation would be of great benefit to the patient in terms of pain and 
functionality of their joints.   
1.5.6 Monocytes/macrophages in RA Synovitis 
The role of monocytes and macrophages has been studied intensively within RA 
due to their ability to produce a large range of inflammatory mediators leading 
to chronic inflammation, tissue damage and remodelling within the joint [141].   
Cells of the mononuclear phagocyte system are ‘plastic’ cells that can 
differentiate into different cell types depending on growth factors and cytokines 
present in their environment.  Monocytes differentiate from a CD34+ stem cell 
via an intermediate monoblast stage in the bone marrow and when they leave 
they are thought to circulate for up to three days.  Monocytes are recruited 
rapidly to the site of injury or infection and it is now clear that more than one 
subtype of these cells exists in humans, and these can be phenotypically 
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separated based on CD14/CD16 expression upon each subtype which in turn 
mediate discrete roles in the immune response (Table 1-3) [142].  CD14 is a cell 
surface protein which acts as a co-receptor for LPS, and CD16 is a receptor 
which has a low affinity for IgG is also known as FcγRIII.   
Table 1.3 Subsets of human monocytes 
Subset Markers Function 
Classical CD14++CD16- Phagocytosis, anti-microbial, wound healing 
[143]  
Intermediate CD14++CD16+ Pro-inflammatory- upregulated in various 
disease states [144] 
Non-Classical CD14+CD16++ Patrolling and anti-viral immunity [145] 
 
CD14+CD16+ monocytes have been shown to express many features of 
inflammatory tissue macrophages such as high expression of MHC Class II 
molecules (allowing antigen presentation), high production of pro-inflammatory 
cytokines, and low production of anti-inflammatory IL-10 [146, 147].  In healthy 
individuals this population forms 10% of circulating monocytes [146].  It is 
thought that the differentiation of monocytes is altered in RA patients as PB 
monocytes express higher levels of adhesion molecules, phagocytic activity and 
production of pro-inflammatory cytokines [148, 149].  Patients with active RA 
show higher frequencies of CD14+CD16+ blood monocytes, with the frequency of 
these cells decreasing in patients that respond well to therapy [144].  The 
increase in this population can be attributed in some part to the expression of 
cytokines within the joint that have been shown to drive CD16 upregulation such 
as TGFβ, M-CSF and IL-10 [150, 151].  These monocytes also express high levels 
of CCR5 that allow the cells to be recruited rapidly to the joint where they can 
differentiate under inflammatory conditions to macrophages.  It has been 
proposed that these CD14++CD16+ are the precursors to pro-inflammatory CD16+ 
macrophages within the joint [146].  In addition, these ‘intermediate’ 
monocytes have been implicated in the generation of the pathogenic Th17 
response within the joint [152].   
In a non-infectious state of chronic inflammation, as witnessed in RA, it is likely 
that cell to cell contact with T cells contributes to monocyte activation.  Rossol 
et al demonstrated that contact of CD14++CD16+ cells with preactivated T cells 
causes the cells to produce high levels of TNFα, IL-1β and IL-23.  IL-23 is 
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required to stabilise the pathogenic Th17 phenotype and the production of this 
cytokine may account for the expansion of the Th17 compartment [153].  Indeed 
the frequency of Th17 cells correlates with the numbers of intermediate 
monocytes in RA patients suggesting a direct role for T cell- monocyte contact in 
the generation of the pathogenic Th17 response in RA [152]. 
Monocytes migrate from the circulation, through the endothelium and 
differentiate into macrophages within tissues under the influence of various 
growth factors such as M-CSF and Granulocyte-macrophage colony-stimulating 
factor (GM-CSF) [154].  Macrophages, like monocytes exist in different subsets, 
with differing functions within the immune response depending on the 
environmental cytokine milieu.  To date at least four subsets of macrophages, 
classified by their immune function and cytokine production have been 
described (Figure 1.1). 
 
 
Figure 1.1 Human macrophage subsets 
To date, 4 subsets of macrophages have been described, characterised by their cytokine 
production and polarisation environments 
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Each subset has a different function, with M2 macrophages being more plastic 
than the classical M1 cells (Table1-4). 
Table 1.4 Subsets of human macrophages 
Subset Name Stimuli Function 
M1 Classically activated LPS/IFNγ Defense/pro-
inflammatory/microbicidal 
[155] 
M2a Alternatively activated IL-4 Anti-inflammatory/wound 
healing [156] 
M2b Type 2 FcγR+LPS Antigen 
presentation/generation 
of Th2 response[157] 
M2c Regulatory IL-10/TGFβ Inhibit immune response 
[158] 
 
The number of macrophages in the RA synovium directly correlates with the 
progression of joint destruction, and response status to a variety of 
therapeutics, demonstrating the importance of these cells in the clinical context 
of RA [159, 160].  Activation of macrophages within the joint may occur through 
the ligation of TLRs PAMPs, or endogenous joint derived particles (DAMPs), 
released as a result of joint damage, such as fibronectin and Tenascin-C [161, 
162].    Similar to monocytes, macrophages can be activated by cell contact 
within the joint.  Macrophage interaction with RASFs results in the production of 
pro-inflammatory cytokines, with significant cartilage degradation occurring in 
in vitro co-cultures of these cells [163].  Interaction with activated T cells also 
results in the production of pro-inflammatory cytokines IL-1α, IL-1β and TNFα, 
and destructive MMPs [164].  As well as influencing immune cells, cell contact 
between macrophages and endothelial cells results in the upregulation of 
specific cell adhesion molecules (CAMs) which are critical for the continued 
recruitment and retention of activated monocytes within the joint [141].  
Macrophages can also be activated in both an autocrine and paracrine way by 
pro-inflammatory cytokines within the joint.   
Once activated macrophages are critical in promoting inflammation and have 
many functions in RA.   
Macrophages are a major phagocytic cell population within the immune system.  
Within the RA synovium damage to the joint and high levels of pro-inflammatory 
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cytokines can result in cell death.  Dead cells are phagocytosed by macrophages 
resulting in their activation and the production of pro-inflammatory cytokines 
such as TNFα, IL-1β and IL-12.  In addition macrophages can process and present 
antigen to T and B cells resulting in the initiation of the adaptive response and 
perpetuation of inflammation [165].  In addition to the production of cytokines, 
macrophages also produce high levels of chemokines such as IL-8, CCL3, CCL4 
and CCL-2 resulting in the recruitment of further inflammatory cells to the joint 
[166].   
1.5.7 Macrophage effector cytokines in RA 
The primary function of macrophages within the RA synovium is the production 
of cytokines and other mediators of inflammation.  Cytokines are a varied group 
of proteins that can be secreted or membrane bound, and regulate immune 
function.  They are released by almost all cells during the effector phase of the 
immune response and alter the environment to regulate growth, differentiation 
and inflammation.  Cytokines appear to be crucial at each stage of the 
pathogenesis of RA and are influential in the establishment of chronic disease.  
Novel treatments for RA have focused on blocking many of these molecules such 
as TNFα, IL-6 and IL-1, which will be discussed below. 
1.5.7.1 TNFα 
TNFα, which is mostly produced by macrophages, is critical in the inflammatory 
cascade within the joint [141].  It is found at high levels in the synovial 
membrane and at the cartilage pannus/junction of RA patients, and in general 
expression correlates with severe disease [167].  Blocking of TNFα has proven 
extremely important in the clinical setting – its blockade using specific molecular 
therapeutics confers a clinical response in 70% of patients, reflecting not only 
it’s importance in primary pathogenesis, but how disease differs between 
individuals and at different stages of clinical manifestation [1].  TNFα is 
important in RA due to its pro-inflammatory effects. It induces the release of 
additional pro-inflammatory cytokines from cells, such as IL-1, IL-6, IL-23 and G-
M-CSF which enhance the inflammatory environment and drive destruction [141].  
It also induces the up-regulation of various chemokines such as CCL5, CCL2 and 
IL-8 resulting in the recruitment and retention of immune cells [141].  TNFα does 
  42 
 
not only contribute to retention of, but also to the activation of cells such as 
osteoclasts, leading to resorption of bone and joint destruction.  Additionally, 
TNFα contributes to angiogenesis and endothelial activation, further aiding the 
infiltration of destructive immune cells [141].  
In addition to TNFα, macrophages also produce a large number of various other 
pro-inflammatory cytokines that are emerging as critical in the establishment of 
chronic inflammation.   
1.5.7.2 IL-1 
IL-1, like TNFα is predominantly produced within the joint by inflammatory 
macrophages and correlates with severe disease progression [168].  Unlike TNFα, 
IL-1 appears to primarily mediate tissue destruction, by regulating proteoglycan 
synthesis and therefore bone and cartilage destruction [169].  IL-1 production by 
macrophages induces the production of MMP-1 and MMP-3, enhancing matrix 
destruction and providing a critical role for macrophages in bone resorption 
[170].  IL-1 can bind 2 surface receptors, 1 activatory and 1 inhibitory.  The 
activatory type I IL-1 receptor (IL-1R1) is found on a variety of cells within the 
RA synovium allowing many cells to respond to the pro-inflammatory cytokine.  
However expression of its counterpart, the decoy IL-1 receptor (IL-1RII), is low in 
the synovium [171].  This suggests that the IL-1R balance in RA is disturbed, 
promoting expression of the pro-inflammatory type I receptor, resulting in 
chronic inflammation and destruction [172].  However therapeutic interference 
in this pathway has elicited only modest responses in patients, suggesting 
problems due to redundancy in IL-1R signalling [173].  In addition to IL-1, 
macrophages also produce an IL-1R antagonist (IL-1RA) that binds to the 
receptor but does not induce an intracellular response.   
As TNFα inhibition does not aid in recovery of all patients, it is important to 
continue developing therapies that focus on other inflammatory mediators 
within the joint.  Inhibition of IL-1R by molecules based on IL-1RA (Anakinra) 
have proven modestly effective in the treatment of RA but has shown some 
efficacy with regards to slowing joint destruction [174].  However the magnitude 
of improvement is insufficient to represent a viable therapeutic intervention. 
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1.5.7.3 IL-6 
IL-6, along with TNFα and IL-1β, drives production of C-reactive protein (CRP) 
from the liver and is expressed at high levels in SF where is correlates with DAS 
[175, 176]. This cytokine plays a central role in the initiation and propagation of 
inflammation observed in RA.  IL-6 exerts its functions through 3 molecules; a 
membrane bound receptor mIL6-R, the signal transducer gp130 and also a 
soluble form of receptor, sIL-6R.  Binding of IL-6 to mIL-6R results in 
homodimerisation with gp130 resulting in the formation of a signalling complex.  
Uniquely IL-6 can also bind to sIL-6R and binding of this complex to membrane 
bound gp130 also results in activation in a process named trans-signalling [177].  
mIL-6R is expressed only on specific cells within the body, whereas gp130 is 
ubiquitously expressed, widening the populations of cells which can be activated 
by IL-6 [178].  IL-6 is multi target cytokine that has wide ranging effects on both 
the innate and adaptive immune system.  It can act on endothelial cells and 
monocytes to induce the up-regulation of adhesion molecules and the production 
of CCL2 and IL-8, increasing cellular invasion into the synovium [179].  It can 
also propagate joint destruction as it induces RANKL production from RASFs, and 
also the production of MMP1, 3 and 13, resulting in increased osteoclastogenesis 
and joint destruction [180, 181].  IL-6 also influences the adaptive immune 
response by driving the induction of pathogenic Th17 cells and the development 
of autoantibody producing plasma cells [182, 183].  The importance of IL-6 in 
joint inflammation is highlighted by the effectiveness of the humanised anti-IL-
6R antibody Tocilizumab (TCZ) which has been shown to improve clinical 
symptoms and prevent damage progression in RA [184]. Recent studies using this 
therapy have implicated IL-6 signalling in lipid metabolism in RA.  TCZ treatment 
across 8 independent clinical trials has shown an increase in serum cholesterol, 
high-density lipoprotein (HDL) and low-density lipoprotein (LDL).  The reason for 
these changes requires more detailed mechanistic studies but likely reflects 
regulation of scavenger receptor expression and thus altered reverse cholesterol 
transport [185]. 
1.5.7.4 IL-23 
IL-23, another member of the IL-12 family promotes and maintains Th17 
differentiation by inducing the production of IL-6, TNFα and IL-1β from synovial 
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macrophages and RASFs [186].  Il-23 is formed of a p19 and p40 subunit (which is 
shared with IL-12).  The p19 subunit, along with IL-17 is significantly increased in 
both SF and synovial tissue of RA patients when compared OA [187].  IL-23 is 
inducible by TLR activation in RASFs and has been shown to play a role in joint 
destruction through the induction of TNFα and IL-1β, which results in the 
production of RANKL from these cells [188-190].  Mouse models have 
demonstrated the importance of IL-23 expression in RA, where transgenic mice 
that overexpress the p19 subunit demonstrate increased expression of TNFα and 
IL-1β resulting in systemic inflammation and premature death [191].  However, 
although the p19 subunit is upregulated within the synovium, levels of the p40 
subunit and active IL-23 are low in both SF and PB of RA patients [187].  Previous 
attempts to block IL-23 in RA have so far failed to prove effective. 
1.5.7.5 IL-18 
A profound dysregulation of the IL-18 system exists within RA.  IL-18 is produced 
by CD68+ macrophages in lymphoid aggregates, and CD14+ monocytes and 
neutrophils from the synovial fluid of patients [141, 192].  It has been a focus of 
interest in RA as levels correlate with the inflammatory marker CRP released by 
the liver [193].  It is thought that IL-18 exerts it’s disease causing effects 
through the induction of TNFα, GM-CSF and Interferon (IFN)-γ, the induction of 
the acute phase response and upregulation of TLR-2 and TLR-4 in synovial cells 
[194].   IL-18 is also involved in joint destruction through the upregulation of 
RANKL production by T cells, resulting in higher levels of osteoclast 
differentiation [87].  Prior studies have shown that IL-18 treatment markedly 
aggravates arthritis in mice and there appears to be a profound dysregulation of 
the IL-18 system in patients with RA [87].     
1.5.7.6 IL-15 
Macrophage produced IL-15 is detectable in RA synovial fluid by ELISA at 
comparable levels to TNFα and has chemoattractant properties for memory T 
cells [195].  Lining layer macrophages are the predominant source of IL-15 within 
the synovium [196].  IL-15 stimulated T cells have been shown to induce TNFα, 
IL-1β and IL-8 production from macrophages in a co-culture system [197]  This 
data suggests a feedback loop in which IL-15 produced by activated macrophages 
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within the synovium can maintain T cells to further perpetuate inflammation.  
Baslund et al have trialled a humanised monoclonal anti-IL-15 antibody (HuMax-
IL15) that demonstrated a substantial improvement in disease activity according 
to ACR criteria [198].  These data suggest targeting of IL-15 may produce 
therapeutic benefit in RA of which phase IIa human studies concurred with. 
1.5.7.7 IL-10 
In addition to pro-inflammatory cytokines, synovial macrophages also produce 
anti-inflammatory cytokines such as IL-1RA (discussed in 1.1.7.2) and IL-10.  IL-
10 produced by macrophages has autocrine effects and causes down-regulation 
of antigen presentation and pro-inflammatory cytokines such as TNFα, IL-1 and 
IL-6 [199].  Despite its anti-inflammatory functions IL-10 is present in the RA 
synovium [200].  Studies have suggested that co-expression of IL-10 with TNFα, 
as witnessed in RA may indicate a failure of IL-10 to sufficiently suppress the 
immune response [201].  Additionally reports have suggested that continual 
expression of TNFα also causes macrophages and synovial fibroblasts to become 
unresponsive to IL-10 and this may explain the lack of clinical effect witnessed 
by IL-10 treatment in RA [202, 203].  
1.5.8 Macrophage effector chemokines in RA 
In addition to cytokines, macrophages also produce high levels of inflammatory 
chemokines within the joint.  Chemokines are chemoattractant cytokines that 
are important in the recruitment and retention of leukocytes at sites of 
inflammation.  Chemokines are classified based on their structures and the 
position of cysteine residues.  Four families of chemokines exist, CXC, CC, C and 
CX3C, each with differing functions in both health and disease.  The previous 
years have seen an increase in studies aimed at targeting chemokines and their 
receptors within RA.  Important chemokines produced by macrophages will be 
discussed below.  
1.5.8.1 IL-8/CXCL8 
CXCL8 is detected at high levels in SF, sera and involved joints of RA patients, 
suggesting it plays a direct role in inflammation within the synovium [204, 205].  
CXCL8 is produced by macrophages, synovial fibroblasts and endothelial cells 
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within the joint and is a potent angiogenic factor [206].  Angiogenesis is a 
hallmark of inflammation and is required for the recruitment of inflammatory 
cells to the joint space, therefore CXCL8 drives joint inflammation both 
indirectly, by creating new blood vessels for leukocytes trafficking and also 
through its direct role as a chemoattractant for neutrophils [207]   
1.5.8.2 IP-10/CXCL10 
Synovial fluid levels of CXCL10 are higher in RA compared to OA [208].  CXCL10 
expression is induced by IFNγ and is a chemoattractant for Th1 cells and is 
present at high levels in T cell rich areas of the synovium.  Immunostaining has 
shown that macrophages in the lining layer and infiltrating synovial fibroblasts 
are the main source of this chemokine, which causes the perpetuation of 
inflammation through its recruitment of pathogenic T cells [209].  Studies have 
shown that treatment of CIA mice with anti-CXCL10 antibodies suppressed 
clinical progression and joint erosion of RA by slowing the recruitment of Th1 
cells [210].  In addition use of a humanised monoclonal antibody against CXCL10 
increased response to methotrexate in patients who previously responded 
inadequately to the drug, suggesting there may be a clinical effect in targeting 
CXCL10 [211]. 
1.5.8.3 CCL2/MCP-1 
CCL2 is expressed at high levels in RA SF when compared to OA, with expression 
induced by TNFα, IFNγ, IL-1β and hypoxia, all of which are found in the RA 
synovium [212, 213].  Expression of high levels of CCL2 exacerbates 
inflammation through the recruitment of pro-inflammatory leukocytes, mainly 
monocytes.  Current therapies for RA such as anti-TNFα have been shown to 
decrease the levels of CCL2 present in the arthritic joint potentially offering a 
mechanism to explain diminished inflammatory monocyte migration [214].  .   
1.5.8.4 CCL5/Rantes 
CCL5 is a chemoattractant for lymphocytes and monocytes among other cells, 
with messenger RNA (mRNA) being detected in both synovial macrophages and T 
cells [215].  CCL5 is present in RA SF and serum at higher levels than OA, where 
expression correlates with number of swollen joint, erythrocyte sedimentation 
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rate (ESR) and CRP [216].  Expression of CCL5 has been shown to induce IL-6 
production from RASFs, and expression of this chemokine is downregulated by 
treatment with disease modifying anti-rheumatic drug (DMARD) therapy [217]. 
1.5.8.5 CCL3/MIP-1α and CCL4/MIP-1β 
Both CCL3 and CCL4 are major chemokines produced by macrophages after 
stimulation with bacterial endotoxins, which have been shown to be present 
within the joint.  Levels of CCL3, a chemoattractant for various cells, including T 
cells, monocytes and neutrophils, are higher in RA SF compared to OA [218-220].  
CCL3 has been shown to directly stimulate osteoclast formation by increasing 
RANKL and IL-6 production from stromal cells in multiple myeloma, suggesting it 
could have a similar effect on these cells in RA [221].  CCL4 is also readily 
detectable in RA SF where it’s expression correlates with disease activity, and is 
thought to be involved in the further recruitment of monocytes to the joint [222, 
223]. 
1.6 Current Therapies for RA 
Recent advances in understanding the pathogenesis of RA have resulted in the 
advancement of treatment, from treating pain to treating the aberrant immune 
response associated with joint inflammation.  The advent of biologic therapies, 
targeting disease propagating molecules has revolutionised prognosis and 
progression of disease. 
1.6.1 cDMARDs 
cDMARDs can be used alone or in combination with each other, or a biologic 
therapy.  The best studied cDMARD, MTX remains the foundation of initial 
therapy, and is used alone and in combination with other treatments.  Other 
cDMARDs which have been shown to be effective in RA treatment both alone and 
in combination are sulfasalazine, hydroxycholoroquine and leflunomide.  The 
exact action of these DMARDs has yet to be clearly understood though 
increasingly they are recognised to modulate a variety of inflammation 
associated signalling pathways e.g. NFκB and Adenosine.  
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1.6.2 Anti-TNFα therapy 
TNFα, as discussed is a potent pro-inflammatory cytokine with a dominant role 
in chronic inflammatory and destructive pathways within the joint.  It causes 
macrophage production of pro-inflammatory cytokines IL-1, IL-6 and IL-8, 
activation of T cells, differentiation of osteoclasts and activation of RASFs to 
produce MMPs [224]. TNFα was the first cytokine to be fully validated as a 
therapeutic target within the joint and molecules that knock down its expression 
have revolutionised the treatment of RA.  To date 5 TNFα targeting agents have 
dominated biological treatment of RA, Etanercept, Infliximab, Adalimumab, 
Golimumab and Certolizumab.   Etanercept is a dimeric fusion protein of human 
extracellular p75 TNFα receptor linked to Fc region of human IgG1.  The others 
are monoclonal antibodies against TNFα [225]. Efficacies of each of the agents in 
RA clinical trials are similar and each has been shown to slow radiographic 
progression.  Each of these biologics is more effective when combined with 
another DMARD, particularly MTX [83, 226-228] 
However not all patients respond to anti-TNFα treatment and therefore other 
treatment options require investigation.  
1.6.3 Rituximab and B Cell depleting therapy 
Rituximab, a mouse/human chimeric IgG1 monoclonal antibody was first 
developed for use in treating B cell malignancies, but was later licensed for 
treatment of RA [229].  Rituximab targets B cell specific cell surface antigen 
CD20 and leads to rapid B cell depletion via antibody dependent cytotoxicity 
(ADCC) [230].  In the phase III REFLEX trial in which Rituximab treatment was 
given to 311 patients, compared to 209 placebo, they found that a single course, 
concomitantly with MTX provided significant and clinically meaningful 
improvement in patients who had already failed anti-TNFα therapy [231].  
Although CD20 is expressed on the majority of circulating B cells it is not 
expressed on lymphoid progenitor cells within the bone marrow that allows 
repopulation of autoreactive B cells after treatment, and can lead to relapse.  
The success of B cell depleting therapy appears dependent on levels of CD27+ 
memory B cells in the periphery, as a high percentage of memory cells as 
baseline is associated with early relapse [232]. 
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The success of Rituximab treatment has led to a variety of therapies which 
target CD20 on the cell surface such as the monoclonal antibodies Ofatumab and 
Ocrelizumab [233].  Phase I clinical trials in RA are also on-going to investigate 
the blocking of the cytokine IL-21 [234].  IL-21 is responsible for the 
differentiation of plasma cells and therefore has a role in autoantibody 
production [235].  
However, not all B cell directed therapies have proven effective and their failure 
for example, Atacicept within RA is still not fully understood.   Atacicept is a 
fusion protein containing the extracellular domain of transmembrane activator 
and calcium modulating ligand interactor, fused to Fc portion of IgG which binds 
to and blocks both BAFF and a proliferation-inducing ligand (APRIL), to inhibit B-
cell maturation [236].  However, studies have shown that APRIL may be required 
for maintenance and generation of IL-10 producing regulatory B cells (Bregs) 
[237], and therefore, it has been hypothesised that atacicept depletes these 
protective Breg cells without sufficiently targeting pathogenic subsets. 
1.6.4 IL-6R blockade 
The central role of IL-6 in joint inflammation highlighted IL-6 as a potential 
target in RA.  There have now been many trials showing the use of TCZ, a 
humanised anti-IL-6R monoclonal antibody, on patients with RA.  One of these 
trials, on patients with established RA, who had previously failed one DMARD, 
found improvements in disease activity within 1 week in patients receiving high 
doses of TCZ [238].  Further trials of TCZ alone, and combined with MTX, 
demonstrated that combination therapy was effective in those patients who 
were previously resistant to anti-TNFα therapy and that TCZ treatment reduced 
radiographic joint damage [239, 240] 
1.6.5 Abatacept and T cell blockade 
Abatacept therapy focuses on targeting the T cell response in RA.  Abatacept is a 
human, soluble fusion protein made up of the extracellular domain of human 
cytotoxic T-lymphocyte-associated protein (CTLA)-4 linked to modified Fc 
portion of human IgG.  It binds CD80/86 on the surface of the antigen presenting 
cell (APC) preventing co-stimulation and activation of T cells, whilst reducing 
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their ability to activate macrophages by cell contact [241].  Clinical trials have 
demonstrated effectiveness of abatacept therapy in patients with inadequate 
responses to both MTX and anti-TNFα therapy, offering an alternative treatment 
option for those patients who are currently failing “gold standard” treatments 
[242, 243].  
1.6.6 Chemokine inhibition in RA 
Chemokines are important in recruiting inflammatory cells to the RA joint to 
perpetuate inflammation.  Although indirect effects on chemokine expression 
appear beneficial in disease, direct targeting of chemokines and their receptors 
in RA has so far, proved disappointing.  Despite promising pre-clinical studies in 
animal models of disease, chemokine inhibition has largely proved a failure 
[244].  For example, use of a CCR1 antagonist (MLN3897) provided similar ACR20 
response criteria as methotrexate alone in a Phase IIa trial [245].  Additionally, 
an anti-CCR2 monoclonal antibody also failed to show efficacy in Phase II trials 
[246].  Chemokine inhibition in RA has proven difficult due to redundancy in the 
system, and levels required to saturate receptors.  However, combination 
therapy may help to improve the efficacy of these drugs in the future. 
1.6.7 Other Therapies 
Tofacitinib, a Jak 1/3 inhibitor has been trialled in the context of RA.  JAK1 and 
3 are Janus kinases (Jak) that mediate signal transduction of cell surface 
receptors after interaction with cytokines in RA.  Tofacitinib, which can be 
taken orally, has been shown to improve disease in patients with active RA, in 
combination with MTX [247]. 
1.6.8 Unmet Need 
TNFα blockade shows a response in around 60-70% of patients regardless of 
DMARD status [248].  It is therefore important to identify patients who will 
respond to these expensive and potentially toxic therapies, prior to 
administration.  Bacterial infections including sepsis and pneumonia have been 
reported with the use of anti-TNFα treatment.  There is also a risk of the 
reactivation of latent TB associated with the use of these drugs [249].  It is not 
only anti-TNFα therapy which comes with a risk of adverse side effects, but 
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reports of psoriasis and psoriatic arthritis have been witnessed after Rituximab 
treatment and infection, decreased neutrophil and increased lipids in TCZ 
treated patients [240, 250]. 
 The success of biologic interventions has revolutionized RA therapy – however 
considerable unmet needs remain including the need for remission inducing 
therapeutics, identification of new therapeutic targets and biomarker based 
prediction of response and toxicity.  In this context I elected to study the biology 
of epigenetic mechanisms, specifically the relevant biology of microRNAs in the 
context of RA monocyte biology.  
1.7 MicroRNA 
miRs are conserved short, non-coding RNA molecules approximately 21-23 
nucleotides in length which act to post transcriptionally regulate gene 
expression.  Regulation occurs through binding of the miR to complementary 
sequences, typically in the 3’ UTR of target mRNA resulting in repression of 
translation [251]   Almost 2,500 human miRs are now predicted to exist, 
although possibly not all are functional, that regulate ~60% of human protein 
coding genes [252].  Due to their key role in regulation of gene expression miRs 
have been shown to impact various aspects of mammalian biology including cell 
proliferation, differentiation and the development of the immune response.  
Aberrant expression of miRs has been implicated in many human diseases 
including cancer, cardiovascular disease and autoimmunity.  
1.7.1 Biogenesis of microRNA 
miRs can be located within exons and introns of both coding and non-coding 
transcripts with studies demonstrating more than 50% are expressed 
intronically[253].  Intronic miRs can be dually regulated both by their own 
intronic and host gene promoters, and can also have their own gene [254]  
Current models of miR biogenesis suggest a compartmentalised process 
beginning in the nucleus and ending in the cytoplasm.  However as more 
information emerges concerning this process it is becoming clear that one 
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pathway of processing does not apply to all miRs.  A canonical pathway of 
consecutive cleavage of precursor miR has been proposed. 
Typically, miRs are transcribed by either RNA polymerase II or III into long 
primary transcripts that contain either 1 or more hairpin structures, forming the 
pri-miRNA.  Processing of the pri-miR into the final mature miR occurs in several 
steps [255, 256].  
Firstly pri-miRs are processed in the nucleus by a multiprotein complex 
composed of the RNAse III enzyme Drosha and the RNA binding protein DGR8 
(DiGeorge syndrome critical region gene 8), dubbed the Microprocessor. [257] 
Drosha recognises specific sequences at both 5’ and 3’ ends of the hairpin 
structure, whilst DRG8 recognises structural features of the pri-miRNA  ensuring 
Drosha cleavage occurs at the precise correct location [258].  Cleavage releases 
the hairpin structure of the pre-miRNA.  This pre-miRNA contains a 5’ phosphate 
and a 3’ overhang which is recognized by the transportin protein Exportin 5.  
Exportin 5 coupled to Ran-GTP enables active transport of the pre-miR from the 
nucleus to the cytoplasm, where processing continues [259].  
It is at this step of processing an alternative pathway can also occur.  In addition 
to processing by Drosha, intron derived transcripts can be released by splicing.  
These hairpins or mitrons are already the correct size of pre-miRs and can 
therefore bypass Drosha processing and be transported immediately to the 
cytoplasm by Exportin 5 [260] 
Once in the cytoplasm the hairpin pre-miRNA is further processed by the RNAse 
III enzyme Dicer.  Dicer cleaves the hairpin loop of the pre-miR resulting in an 
unstable ~22 nucleotide miRNA-miRNA* duplex.  The importance of Dicer 
processing is further illustrated by the lethal phenotype of dicer knock out mice 
[261].  One strand of the duplex, dependent on base pair stability at the 5’end, 
is then incorporated into the RNA induced silencing complex (RISC) which is 
guided to the seed sequence in the 3’ UTR of its target mRNA for silencing [262].  
The function of the passenger strand (miRNA*), is so far unknown, however there 
is some suggestion that this is not simply discarded and degraded, but also plays 
a biological role [263]. 
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Figure 1.2 Canonical processing of microRNA 
miRs are transcribed within the nucleus, cleaved and exported to the cytoplasm where further 
processing takes place.  The functional miR stand is loaded onto the RISC complex and is then 
able to regulate its targets 
 
1.7.2 Function of microRNA 
MicroRNAs recognize their target mRNA through the principle of Watson-Crick 
base pairing.  Typically miRs recognize complementary base pairs located in the 
3’ UTR of the target mRNA [264].   
Requirements at this ‘seed region’ (miR nucleotides 2-8) are stringent, as this is 
the location where the miR recognizes its target mRNA.  Nucleotides 2-8 of the 
seed region must bind complementarily to the 5’ tail of the microRNA for target 
recognition to occur.  The requirements at the 3’ end of the microRNA are more 
relaxed and the miR: mRNA duplexes typically contain imperfect mismatches 
and bulge out with the seed regions [265].  In addition, miRs have now been 
shown to also bind to sequences in the 5’ UTR and coding sequence of target 
genes opening up alternative mechanisms of regulation [266] 
Initial evidence suggested that miRNA mediated regulation of gene expression 
occurred through repression of mRNA resulting in reduced transcription without 
altering mRNA levels.  However it is now clear that miRNAs function in at least 
two basic ways, through repression or degradation of mRNA [267].  Which of 
these methods dominates in mediating microRNA function is still under debate.  
mRNA degradation has been clearly demonstrated.  Many studies have shown 
that upon transfection with a microRNA mimic or antagomir, levels of mRNA 
targets containing the miRNA seed region are altered [268].  It is thought that 
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miRNA regulated degradation occurs under perfect binding conditions and that 
miRNAs target mRNA to the 5’-3’ mRNA decay pathway where they are 
deadenylated and decapped resulting in endonucleolytic digestion [269] 
However as the majority of binding is not perfect, translational repression is also 
important.  Evidence suggests that miRs can repress translation at both pre and 
post initiation stages.  Argonaute (Ago) proteins of the miRISC complex have 
been shown to compete with the translation initiation factor eIF to inhibit 
translation initiation [270] In addition it has been demonstrated that the miRISC 
complex can inhibit translation by interfering with ribosome elongation and 
increasing proteolysis [271]. 
 
1.7.3 Prediction of microRNA targets 
Prediction of reliable microRNA targets is essential.  The most used approach 
currently for identifying miR targets is to use computer-based algorithms that 
scan for complementary microRNA response elements (MREs) within messenger 
RNA.  Target prediction occurs based on a 3-step protocol.  Firstly the miR seed 
region is identified, next 3’ UTRs are searched for matching aligning regions.  
Lastly the site is examined for conservation throughout species.  The hypothesis 
being that evolutionary conserved targets will have been under selective 
pressure to remain in the genome[272]  
Not all algorithms return identical predicted targets for miR, but there is a large 
amount of overlap and so it is important that many are used simultaneously to 
determine predicted miR targets. 
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Table 1.5 Tools for microRNA target prediction 
Tool Mechanism of 
Prediction 
URL Targeting 
confined to 
3’UTR 
TargetScan Stringent seed 
pairing, site 
conservation, 
context score 
http://targetscan.org Yes 
MiRanda Moderate seed 
pairing, 
conservation, 
number of sites 
http://www.microrna.org Yes 
PicTar Stringent seed 
pairing, site 
conservation, 
pairing stability 
http://pictar.mdc-berlin.de Yes 
RNA.22 Moderate seed 
pairing, pairing 
stability, no site 
conservation  
http://cbcsrv.watson.ibm.co
m/rna22 
No 
 
 
 
 
The majority of algorithms are built around seed pairing of miR to mRNA.  The 
seed region, nucleotides 2-8 at the 5’ end of the miR, has particular importance 
in miR targeting, and is the most evolutionary conserved region of the miR [273].  
Frequently, this region is most complementary to the mRNA, and studies have 
shown complementarity in this region alone can confer target recognition [265].  
However, new data are emerging that suggest that other areas of the miR are 
also important, and that miR recognition can also occur in both the DNA coding 
sequence and open reading frame (ORF) [274-276].    As accepted targeting 
methods are expanded it is important to recognise that computer algorithms, 
which confine targeting to the 3’ UTR may miss genuine targets (Table 1.5).  
However these algorithms are still widely used, and are an essential part of the 
beginning of many studies.   
Due to the potential of algorithms to generate false positive data, and also miss 
certain targets depending on their location, it is essential that experimental 
validation of target interactions is confirmed.  This validation is usually carried 
out using luciferase reporter assays, which can demonstrate the potential of a 
miR to target its MRE sequence within a reporter plasmid.   
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In addition, degradation of target mRNAs can be visible by transcriptomic 
analysis, such as microarrays following ectopic miR expression.  The first of 
these transcriptomic profiles was demonstrated in 2005, where a downregulation 
of over 100 genes was witnessed after transfection of HeLa cells with either a 
miR-1 or miR-124 mimic.  These downregulated genes were found to contain a 
consensus sequence, to either miR-1 or miR-124 seed regions, suggesting these 
mRNAs were targets of these miRs [277].  Since this study, many other groups 
have employed this method to identify miR targets [278].  Limitations of this 
method remain problematic, as some miRs exhibit only modest effects on 
degradation of targets, while others function only at a level of translational 
repression [277].  
As technology advances, new methods of identifying miR targets are continually 
being introduced, such as immunoprecipitation of RISC components.  This is a 
method by which target mRNAs undergoing direct miR regulation are 
immunoprecipitated along with Argonaut proteins, which makes up part of the 
RISC complex.  A basic outline of the process involves expression of an epitope 
tagged Argonaute protein, along with a miR mimic.  Lysate is 
immunoprecipitated with an antibody against the epitope tag, and mRNAs in the 
sample can then be sequenced [279].  Further modifications have been added to 
this method, whereby crosslinking of RNA to RNA binding proteins prior to IP, 
allows deep sequencing of transcripts bound in real time.  This method is known 
as crosslinking IP-Seq or CLIP-seq [280]. 
As a single miR can target multiple mRNAs, research is progressing to the 
examination of miR:mRNA networks, and studies will continually evolve to make 
use of multiple strategies for target identification simultaneously –this comprises 
the RNA-RNA interactome. 
1.8 MicroRNA in immune cell development 
Haematopoiesis is a lifelong, highly regulated process wherein pluripotent 
haematopoietic stem cells (HSCs) give rise to all blood cell lineages.  Expression 
of lineage specific genes is required for differentiation and miR silencing of 
these cell specific genes is key for correct differentiation.  Loss of Dicer in mice 
leads to lethality in early development as the mice are depleted of stem cells 
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[261].  Similarly conditional Dicer deletion in HSCs renders these cells unable to 
reconstitute the haematopoietic system [281].  In lymphoid cells Dicer deletion 
results in fewer T cells in the thymus and periphery and fewer surviving B cells 
with a diminished antibody repertoire [282, 283].  Studies have shown a miR 
expression profile in haematopoietic tissues.  For example miR-181 is strongly 
expressed in the thymus, miR-223 in the bone marrow and miR-142 in all 
haematopoietic tissues [284].  This expression pattern is consistent with the 
cellular expression of these miRs after lineage commitment.  miR-181 is highly 
involved in lymphopoesis, enforced expression of miR-181 both in-vitro and in- 
vivo results in a doubling of B cell numbers present in the periphery [284].  In 
addition to B cell development, miR-181 plays a role in positive and negative 
selection of thymocytes in the thymus [285], and modulates TCR signalling by 
altering TCR sensitivity in immature T cells [286].  In contrast, miR-223 appears 
to be involved in granulopoesis, as it is not detected in the spleen or thymus 
[284].  In addition, miR-223 knockout mice exhibit increased numbers of 
activated neutrophils, resulting in spontaneous development of inflammatory 
lung pathology [287].  This evidence demonstrates expression of lineage specific 
miR can regulate and alter haematopoetic differentiation and therefore impact 
on immune cell generation.  
1.9 microRNA in immune responses 
1.9.1 Innate Immunity 
Innate immunity is the critical first line of defence against infection.  The innate 
immune system is constituted by cells such as macrophages, neutrophils and 
dendritic cells that sense infection, or damage through highly conserved pattern 
recognition receptors (PRRs) triggering an inflammatory response [288].  TLRs 
are an important family of PRRs that are restricted to certain cell lineages that 
tailor particular responses from specific cells depending on the inflammatory 
stimuli [289].  It is important that TLR activation and signalling pathways are 
tightly regulated to ensure an effective immune response, but also that the 
inflammatory response is resolved when the threat has been dealt with.  It has 
been demonstrated that miRs can regulate the strength and resolution of TLR 
signalling and therefore a major contributor to the innate immune response.  In 
addition to TLR signalling, miRs can also regulate formation of the innate 
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inflammasome.  The inflammasome is a multi-protein complex that contains a 
PRR domain, and can therefore be activated by intracellular infection and 
damage.  The function of the inflammasome is to cleave pro forms of IL-1 family 
cytokines, resulting in the release of their mature forms [290].   
miRs can be both induced and downregulated by TLR activation.  Three of the 
most highly studied miRs, miR-146a, miR-21 and miR-155 are induced at high 
levels after TLR stimulation and act to negatively regulate inflammation in 
monocytes and THP1 cells.   
miR-146a is mainly expressed in immune tissues and is induced in response to 
LPS, TNFα and IL-1β stimulation in an NFκB dependent manner [291].  This miR is 
part of a sophisticated negative feedback loop by which TLR ligation activates 
NFκB that in turn induces the expression of miR-146a.  miR-146a has been shown 
to directly target pro-inflammatory members of the MyD88 signalling pathway 
TRAF6 and IL-1R-associated kinase 1 (IRAK1) thereby dampening inflammation by 
regulating pro-inflammatory cytokines and aiding in resolution.   Knockout of 
miR-146a in mice results in an exaggerated immune response and hyper 
responsiveness to LPS leading to an excessive production of TNFα and IL-6 and 
increased sensitivity to septic shock.  Aging mice also develop spontaneous 
autoimmunity and tumours in secondary lymphoid organs [292].  These data 
demonstrate that miR-146a is an important negative regulator of inflammation.  
Like miR-146a, miR-21 is also induced by LPS stimulation in monocytes and 
macrophages in an NFκB dependent manner and similarly negatively regulates 
TLR activation [293].  miR-21 directly targets programmed cell death protein 4 
(PDCD4) and downregulates its expression.  This protein is upregulated 8 hours 
post LPS stimulation and can bind to and inhibit the translation of anti-
inflammatory IL-10, thereby promoting an inflammatory state [294].  Mice 
deficient for PDCD4 are resistant to LPS induced death. PDCD4 expression is 
downregulated 24 hours post LPS stimulation, due to binding by miR-21, allowing 
production of IL-10 and resolution of inflammation [295].  PDCD4 thus acts as a 
switch between pro-inflammatory NFκB activation and anti-inflammatory IL-10 
activation through the action of miR-21.   
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miR-155 has been shown to mediate a central role in regulation of responses to 
infection by exerting both positive and negative effects on the immune system.  
Tili et al demonstrated an increase in miR-155 expression following LPS 
stimulation and increased production of TNFα after overexpression of miR-155.  
This pro-inflammatory phenotype is mirrored in miR-155 transgenic mice that 
show increased serum TNFα and increased susceptibility to endotoxin shock 
[296].  This inflammatory phenotype is likely a consequence of miR-155 targeting 
of negative regulators of inflammation Phosphatidylinositol-3,4,5-trisphosphate 
5-phosphatase 1 (SHIP-1) and suppressor of cytokine signalling 1 (SOCS1) [297, 
298].  miR-155 directly targets SHIP1 resulting in increased activation of Akt 
kinase after LPS stimulation terminating in increased pro-inflammatory cytokine 
production.  Knock down of SHIP1 in mice results in a myeloproliferative disorder 
similar to that observed in miR-155 transgenic mice, suggesting miR-155 
targeting of SHIP1 is important for the differentiation of immune cells [297].  
miR-155 also acts as a positive feedback regulator of antiviral responses by 
promoting type I interferon signalling through the targeting of SOCS1 in 
macrophages [298].   
Conversely, miR-155 has been shown to negatively regulate the immune 
response in innate cells by applying a “brake” in the response to infection.  
Ceppi et al have demonstrated an increase of miR-155 levels in response to LPS 
in human dendritic cells.  This study suggests that miR-155 acts to control the 
intensity and duration of the immune response after activation through targeting 
of TAK1-binding protein 2 (TAB2), a signalling molecule downstream of TRAF6 
that activates NFκB [299].  miR-155 targeting of TAB2 inhibits the activation of 
the MAPK signalling pathway, preventing the production of IL-1β and other pro-
inflammatory cytokines.  However, this only been reported once, and therefore 
requires more investigation.  
In addition to these well studied miR interactions, novel miR that negatively 
regulate the innate immune response are being described.  miR-132 is induced in 
the monocytic cell line THP1 cells by LPS and also in primary human cells by 
infection with two separate viruses, the herpes simplex virus (HSV) and the 
human cytomegalovirus (CMV).  This miR negatively regulates the response to 
these infections by directly targeting the p300 transcriptional co-activator.  P300 
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has also been shown to regulate miR-132 expression itself, forming a feedback 
loop by which p300 silencing results in a downregulation of pro-inflammatory 
signalling whilst downregulating its own expression [300].  Furthermore miR-9 is 
upregulated in both monocytes and neutrophils after activation with LPS and the 
pro-inflammatory cytokines TNFα and IL-1β.  This miR controls NFκB activation 
by targeting its p50 subunit preventing dimerization with the p65 subunit and 
the activation of pro-inflammatory cytokines [301].    
1.9.2 Adaptive Immunity  
T Cell activation is a tightly regulated process and recent studies have 
demonstrated the involvement of miR in the regulation of the T cell response.  
The regulation of IL-2 production appears to be critical to the function of miRs in 
regulating T cell activation.  Various miRs have been identified which function in 
this way.  miR-155 is upregulated in response to T cell activation where it 
enhances proliferation through targeting of SOCS1 and allows costimulation 
through targeting CTLA-4 [302].  In addition miR-181c directly targets IL-2, and 
miR-9, upregulated after TCR ligation targets PR domain zinc finger protein 1 
(BLIMP) and B-cell lymphoma protein (BCL) 6 resulting in increased IL-6 and IFNγ 
production [303, 304].  
miR-155 appears to be important in generation of Th17 cells, both in-vitro and 
in-vivo.  Escobar et al have demonstrated that there is defective Th17 cytokine 
expression in miR-155 deficient CD4+ T cells.  Their study showed that these T 
cells express elevated levels of a DNA binding protein, jumonji, AT rich 
interactive domain 2 (Jarid2).  Jarid2 recruits Polycomb Repressive Complex 2 
(PRC2) to chromatin, which binds and results in higher levels of H3K27 
methylation.  H3K27 methylation is involved in the repression of translation, 
resulting in low IL-22, IL-10, and IL-9 and thereby generates an indirect effect on 
the production of IL-17A and IL-17F.  This study demonstrates miR-155 regulation 
of chromatin structure, and global changes in gene expression [305]. 
Additionally, miR-155 seems to play an important role in regulating the 
interferon response to viral infection in both CD8+ and natural killer (NK) cells 
[306, 307].  Recent studies have shown miR mediated gene regulation as critical 
also for B cell responses.  miR-155 is required for normal B cell function and GC 
formation.  This miR is expressed at high levels in mature B cells [308].  miR-155 
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plays a role in production of antibodies and class switching through targeting of 
Spi-1 proto-oncogene( PU.1) and Activation-induced cytidine deaminase (AID) 
[309].  In addition miR-181b also contributes to regulation of antibody class 
switching, again through targeting of AID [310].  
1.10 microRNA in Rheumatoid arthritis 
The majority of miR studied in the context of inflammation have been 
investigated in the context of inflammatory diseases, including RA. Dysregulated 
expression of miRs has been well documented in RA (Table 1-6).  Investigation of 
these miRs has highlighted novel pathways involved in inflammation and 
identified new potential biomarkers or targets for treatment.  However, 
although many dysregulated miRs have been identified, in various cell types, the 
pathogenic function of several within RA still remains to be elucidated.  The 
majority of miR observations are made in primary human cells, with target 
interactions validated in cell lines, and primary human cells. 
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Table 1.6 Dysregulated miR in RA or animal models of RA  
miR Tissue Target Function Species Reference 
miR-16   PBMCs   Human [311] 
miR-18a  RASFs TNFAIP3 Allows 
constitutive 
NFκB signalling 
Human [312] 
miR-19   LPS RASFs TLR2 Regulation of 
IL-6 and MMP 
production 
Human [313] 
miR-23b   RASFs TAB2/3 
IKKα 
Drives 
inflammation 
Human [314] 
miR-34a*   RASFs XIAP Resistance to 
apoptosis 
Human [263] 
miR-124a   RASFs CDK-2 MCP-
1 
 Human [315] 
miR-132   PBMCs   Human [311] 
miR-146a   PBMCs 
  RASFs 
  CD4+ T cells 
TRAF6/ 
IRAK1 
 
FAF1 
Failed 
regulation 
Suppresses T 
cell apoptosis 
Human [311, 316, 
317] 
miR-155  RASFs 
 PBMCs 
 CD14+  
MMP 1+3 
SOCS1 
SHIP1 
 
Drive 
inflammation 
and joint 
destruction 
Human [318-320] 
miR-203  RASFs  Increased IL-6 
and MMP-1 
Human [321] 
miR-
221/222 
 RASFs   Human/TNFα  
Transgenic 
mouse 
[322] 
miR-223   CD4+ T 
Cells 
IGF1-R Impairs IL-10 
production 
Human 
 
 
[323] 
miR-346  LPS RASFs TTP TNFα release Human [324] 
miR-363   CD4+ T cells   Human [317] 
miR-451   Neutrophils Rab5a 
CPNE3 
Allows 
neutrophil 
recruitment 
Human [325] 
miR-498   CD4+ T cells   Human [317] 
TNFAIP3, Tumour necrosis alpha inducible protein 3; TLR2, Toll like receptor 2; TAB2/3. 
Transforming growth factor beta activated protein 2/3; IKKα, IKappa B kinase; CDK-2, Cyclin 
dependent kinase 2; MCP-1, monocyte chemotactic protein 1; TRAF6, TNFα receptor associated 
kinase factor 6; IRAK1, Interleukin-1 receptor associated kinase 1; FAF1, Fas associated factor 1; 
MMP-1, metalloproteinase 1; SOCS1, suppressor of cytokine signalling 1; SHIP1 
phosphatidylinositol 3,4,5 triphosphate 1; IGF1-R, Insulin like growth factor 1; TTP, Tristraprolin; 
Rab5a, Ras related protein 5a; CPNE3, Copeine III 
Three of the most well studied miR; both in the context of inflammation and RA 
are discussed below 
1.10.1 miR-155 
miR-155 is up regulated in PBMCs and SF CD14+ cells of RA patients.  Exposure of 
healthy CD14+ cells to RA SF triggers the up-regulation of miR-155, resulting in 
the production of pro-inflammatory TNFα, IL-6, IL-1β and IL-8, whilst inhibition 
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results in a downregulation of TNFα production [320].  Although many targets 
have been identified for miR-155, currently only 1 inflammatory pathway has 
been validated in the context of RA CD14+ cells and inflammation.  miR-155 
directly targets SHIP-1 in these cells, allowing constitutive expression of pro-
inflammatory cytokines.  The contribution of miR-155 to the pathogenesis of 
arthritis has been investigated by 2 groups using miR-155 knockout mice.  These 
mice were found to be protected against CIA development compared to wild 
types, with no evidence of bone erosions or inflammatory infiltrate.  Additionally 
miR-155 knockout mice exhibited lower anti-collagen autoantibodies and 
defective IL-17 polarisation.  Interestingly these mice exhibited higher levels of 
SHIP-1 and lower levels of pro-inflammatory mediators [320, 326].   
However, in a K/BxN serum transfer model of arthritis both WT and KO mice 
develop comparable arthritis, suggesting miR-155 is not involved in antibody 
mediated effector responses in this disease state.  However in this arthritis 
model KO demonstrated fewer bone erosions, whilst in-vitro KO CD14+ cells 
demonstrated impaired osteoclastogenesis.  In addition, S Bluml et al (Abstract 
presented at “Be the Cure” conference 2014) demonstrated that TNFα 
transgenic mice on miR-155 KO background do not differ in arthritis severity 
from WT littermates, suggesting that miR-155, although crucial for TNFα 
production, is dispensable for its action on bone.  
1.10.2 miR-146a 
miR-146a expression has been found to be increased in various cell and tissue 
types within the RA joint, including peripheral blood mononuclear cells (PBMCs), 
RASFs, CD4+ T cells and SF itself (extracellular), where its expression positively 
correlates with DAS scores [311, 317, 318, 327].  It has been hypothesised that 
the inflammatory environment within RA causes the up-regulation of this miR, as 
in-vitro miR-146a expression is induced in both RASFs and CD4+ T cells by 
stimulation with LPS [316, 318].  It has been demonstrated that miR-146a can 
directly target members of the TLR signalling pathway TRAF6 and IRAK1.  
However, although miR-146a expression is upregulated in many compartments in 
RA, levels of TRAF6 and IRAK1 are similar between RA patients and healthy 
controls, suggesting miR-146a is defective in its regulation of these molecules in 
RA [311].  Alternatively as one miR can target many different mRNAs it may 
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highlight that these genes are not targeted by miR-146a in these cells under 
these specific conditions.  Interestingly, along with this role in regulation of 
inflammation overexpression of miR-146a suppresses osteoclastogenesis.  Thus, 
the miR-146a targets TRAF6 and IRAK1 are also regulators of osteoclastogenesis.  
This observation was supported in-vivo since the injection of double stranded 
miR-146a in a murine model of arthritis resulted in a downregulation of joint 
destruction and TRAP positive cells, whilst marginally affecting immune cell 
infiltration and inflammation [328]. Additionally miR-146a has been implicated in 
contributing to the “pro-inflammatory phenotype” of T regs in RA.  Zhou et al 
demonstrated diminished upregulation of miR-146a in response to stimulation in 
RA Treg cells, with lower miR146a in patients with active disease.  They 
hypothesise that this miR-146a defect results in enhanced Signal transducer and 
activator of transcription (STAT) 1 expression and increased production of pro-
inflammatory cytokines by Tregs, contributing to RA pathogenesis [329].   
It is therefore interesting to note, that although miR expression may be 
increased in certain cellular compartments within RA, that their regulation of 
validated targets can appear defective, underlying the fact that one miR may 
exert a major effect on different targets in different cells, under different 
environmental conditions.  It also hints at the possibility that although 
expression of a miR is altered in disease states, its upregulation may not be 
enough to counteract high levels of chronic inflammation. 
1.10.3 miR-223  
miR-223 is dysregulated in many cell types within the RA joint.  It is one of the 
most abundantly detectable miRs in RA blood and plasma, where its expression 
negatively correlates with tender joint count [327].  It is up regulated in RASFs 
and CD4+ T cells within the synovium, and can have a pro or anti-inflammatory 
role, depending on the cell type.  In T cells, miR-223 has both pro and anti- 
inflammatory functions, increasing LPS induced IFNγ, but modulating IL-17A 
production through the targeting of the Roquin ubiquitin ligase that reduces IL-
17 synthesis [330, 331].  Conversely, miR-223 functions in an alternative manner 
in monocytes and macrophages, where it enhances anti-inflammatory responses 
and regulates macrophage polarisation to an M2 phenotype [332].  Unpublished 
data from this lab group has shown that miR-223 is downregulated in SF CD14+ 
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cells.  In these cells it is hypothesised that miR-223 would target the NLRP3 
inflammasome, therefore regulating IL-1β production [290]. Thus, its down-
regulation in myeloid cells may lead to high production of IL-1 family members 
in the joints.   
On the other hand miR-223 seems to support osteoclast differentiation [333]. 
Commensurate with this, knockdown of miR-223 in a murine CIA model using a 
miR-223 lentiviral sponge vector results in reduction of arthritis score and 
incidence of disease, in addition to a downregulation of erosions and Tartrate-
resistant acid phosphatase (TRAP) positive cells within the joint space, 
suggesting a dominant pathogenic role for miR-223 in animal model of arthritis 
[334]. However, it is difficult at this moment to say how this will translate to 
human disease, given the anti-inflammatory role of miR-223 in human 
macrophages. 
1.11 microRNA as therapy 
The role of miRs as powerful regulators of inflammation and disease has led to 
the possibility of using them as therapeutics being explored.  As with any novel 
therapy safety is of paramount importance, therefore currently tissue specific 
miRs are preferred.  Using miRs as therapy will involve either miR replacement, 
or knockdown of overexpressed miRs in a disease state.  Use of synthetic 
duplexes to mimic miR activity is difficult as there is a risk of off target effects 
if the mimic is not delivered to the correct cell/tissue.  Investigators are trying 
to overcome this issue to a certain extent by the use of adenoviral vectors for 
delivery, which can allow for potential tissue specificity.  This method is 
currently in clinical trials for gene therapy.  The most widely used approach 
currently is the use of modified anti-miRs.   
The first miR to be considered to have therapeutic potential was miR-122 in 
Hepatitis C viral infection.  miR-122 is the most abundant miR in the liver and is 
tissue specific.  It is also required for replication of the Hep C virus, and 
inhibition of this miR reduces viral replication [335].  Inhibition of miR-122 using 
an anti-miR, Miravirsen, is currently in clinical trials.  Data from Phase IIa trials 
suggests that Miravirsen provides continuous anti-viral activity and is well 
tolerated by patients, demonstrating the clinical utility of target miRs [336].  In 
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addition to Miravirsen, a clinical trial of MRX34, as a mimic of miR-34a is on-
going in primary and metastatic liver cancer.  The rationale behind this being 
that miR-34a is decreased in many cancers allowing the p53 pathway to be 
activated and facilitate tumour growth [337].  The phase I trial for this 
treatment began in May 2013 carried out by Mirna Therapeutics.  
Due to the success of Miravirsen research into the role of novel miRs in health 
and disease has increased. 
1.12 The microRNA 125 family 
MicroRNA profiling in the lab revealed that miR-125a is up regulated in RA 
synovial CD14+ cells compared to PB CD14+ cells  
1.12.1 Introduction 
The miR-125 family is highly conserved across species, and is composed of three 
homologues, hsa-miR-125a, hsa-miR-125b1 and hsa-miR-125b2 encoded on 3 
different chromosomes.  These miRs are expressed in clusters along with 
members of the miR-99 and Let 7 families (Figure 1.2).  Members of the miR-
125a cluster are separated by only 1kb, suggesting a single promoter for the 
whole cluster.  However, this has not yet been proven, and the cellular 
expression pattern of these 3 miRs would suggest that this is not the case.  The 
distance between miR-125b and the other members of the cluster suggest that 
miR-125b may have a second promoter which allows its expression regardless of 
other members of the cluster [338]. 
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Figure 1.3 Genomic organisation of the miR-125 clusters 
The different miR-125 homologues are encoded on different chromosomes.  The distance between 
each family member suggests additional promoters which allow the transcription of miR-125 alone 
 
miR-125a shares the same seed region as miR-125b and it is therefore possible 
that these miRs may share a similar function.  It has been demonstrated 
however, that these 2 miRs have different cellular expression profiles.  In both 
monocytes and macrophages miR-125a has been shown to be upregulated in 
response to the TLR4 ligand LPS [301, 339], whereas, in these same cells, LPS 
has been shown to downregulate miR-125b expression [340, 341].  It is not only 
in myeloid cells that the difference in expression is demonstrated, miR-125a has 
been shown to play a role in activated T cells, whereas miR-125b plays a role in 
naïve T cells [342, 343] This suggests that although homologues, these miRs, and 
their clustered miRs may play different roles in fine tuning of gene expression, 
at different stages of the immune response. 
1.12.2 miR-125 in cancer 
Much of the literature surrounding the functional role of miR-125, both a and b, 
has concentrated on their role in the initiation and maintenance of many 
different cancer types, acting both as an oncogene, and tumour suppressors. 
1.12.2.1 miR-125a   
miR-125a is downregulated in a number of different cancers, where it would by 
inference play a tumour suppressor role, such as in oral squamous cell carcinoma 
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[344], medulloblastoma [345] and chronic lymphocytic leukaemia, where it’s 
underexpression is linked to an inferior disease outcome [346].   
The most intensely studied role for miR-125a is as a tumour suppressor through 
the targeting of the growth receptor, Receptor tyrosine-protein kinase erbB-2 
(ERRB2).  It has been demonstrated that miR-125a is downregulated in breast 
cancer tumours overexpressing the Her2 receptor, encoded by the ERBB2 gene.  
Overexpression of miR-125a in these cells can reduce protein and transcript 
levels of ERBB2, and in addition, diminish the invasive and migratory potential of 
these cells [347].  A single nucleotide polymorphism discovered in the miR-125a 
gene which prevents processing of the pri-miR-125a into a mature miR-125a has 
also been demonstrated [348].  This variant of miR-125a correlates with low 
expression of miR-125a, and high Her2 expression in breast cancer tumours, 
suggesting miR-125a may be used as a prognostic marker of Her2 expression in 
breast cancer [349].  The role of miR-125a in this growth factor pathway has also 
been implicated in the aggressive phenotype of acute myeloid leukaemia [350], 
lung carcinoma [351] and gastric cancer [352].  In addition miR-125a has been 
shown to inhibit the malignant phenotype of hepatocarcinoma cells through the 
targeting of MMP11 and VEGFA [353].  Additionally, miR-125a has also been 
described as an oncogene due to its ability to enhance the invasiveness of 
urothelial carcinoma[354].  
1.12.2.2 miR-125b 
Compared with miR-125a, many more studies have been conducted to determine 
the role played by miR-125b in cancer.  One might speculate that this is due to 
the clear role it plays as a result of many translocation abnormalities.  Increased 
miR-125b expression can be seen in many myeloid malignancies, where studies 
have shown it plays a major pro-proliferative role. A direct role for miR-125b in 
acute myeloid leukaemia (AML) and myelodysplastic syndrome has been 
suggested, due to the rare chromosomal translocation t (2:11)(p21q23), which 
results in up to 90 fold increased expression of miR-125b.  Upregulation resulted 
in inhibited terminal monocytic and granulocytic differentiation in HL60 and NB4 
leukemic cell lines [355].  In addition, miR-125b has also been implicated in the 
initiation of acute lymphoblastic leukaemia (ALL), as upregulation of miR-125b 
occurs through the insertion of this gene into the immunoglobulin heavy chain 
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locus (IgH,) in all ALL harbouring the t (11:14) q (24:32) translocation.  Bousquet 
and colleagues also demonstrated the causative potential of miR-125b in ALL 
through the transplant of foetal liver cells that ectopically expressed miR-125b 
into nude mice.  In this study, they found that higher expression of miR-125b 
increased white blood cell counts in mice, and half of these mice died of diverse 
leukaemias, such as B-cell and T-cell ALL [356].  Another recent study, carried 
out by So et al has also demonstrated that miR-125b plays a causative role in 
leukaemia initiation.  They demonstrated that miR-125b overexpression results 
in enhanced myeloid progenitor output from stem cells, as well as inducing 
immortality, self-renewal, and tumourigenesis in myeloid progenitors. This 
occurs through the miR-125b mediated repression of interferon regulatory factor 
4 (IRF4), deletion of which results in the development of B cell leukaemia in 
mice [357, 358]. 
The role of miR-125b in solid tumours is less clear, like miR-125a, miR-125b can 
play the role of either a tumour suppressor or oncomir depending on different 
cell context.  Dysregulation of miR-125b has been reported in multiple cancer 
types, including, but not limited to stomach, colonic, pancreatic, bladder, 
breast and prostate cancer [347, 359-363].  Upregulation in prostate cancer cells 
promotes tumour growth by targeting the p53 apoptosis pathway member’s p53 
upregulated modulator of apoptosis (PUMA) and BAK1 (Bcl-2 homologous 
antagonist/killer), preventing death of cancer cells by apoptosis.  Conversely 
miR-125b is downregulated in breast cancer, where its expression could inhibit 
growth of these cells through targeting of Muc1, ERBB2 and ERBB3 [347, 364]. 
Tumourigenesis has often affected myeloid and lymphoid lineages, and as 
previously discussed, GWAS studies have shown that RA risk associated genes, 
significantly overlap with genes associated with haematological cancers [24].  
Therefore we were interested to investigate the role of miR-125, in myeloid 
cells, in inflammatory disease.   
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1.12.3 miR-125 and the immune response 
1.12.3.1 miR-125a  
miR-125a appears to play a broad role in activating and modulating the immune 
response, and plays a crucial role in the inflammatory response of macrophages 
to a variety of stimuli.  miR-125a is upregulated in myeloid cells by the 
recognition of PAMPs by PRRs.  Studies have demonstrated that the cluster of 
miR-125a/99b/Let-7e is upregulated in response to heat killed Candida albicans, 
and the TLR4 ligand LPS in human monocytes [301, 365].  In addition, miR-125a 
is upregulated in response to TLR2 stimulation by Listeria monocytogenes [366].  
In each of these conditions, upregulation of the miR is dependent on NFκB 
activation, suggesting miR-125a is regulated by NFκB expression.  Furthermore, 
miR-125a is upregulated in macrophages that phagocytose oxidised low-density 
lipoprotein (OxLDL).  A direct interaction between oxysterol binding protein 9 
(ORP-9) and miR-125a has been demonstrated by luciferase reporter assay.  This 
protein binds both cholesterol and phospholipids, and is downregulated by miR-
125a.  By inhibiting miR-125a using antagomirs in the presence of OxLDL, Chen 
et al were able to demonstrate increased level of both ORP-9 mRNA and protein.  
Additionally, they showed and increased uptake of lipids, increased pro-
inflammatory cytokine production, TNFα, IL-6 and IL-2, and also increased 
expression of the scavenger receptor CD68 from OxLDL stimulated, PMA 
differentiated THP-1 cells, suggesting a protective role for this miR in 
atherosclerosis [367]. 
In addition, miR-125a has been implicated in the control of macrophage 
polarisation although with conflicting results.  In the first study, using murine 
macrophages, miR-125a has been shown to promote and maintain an M2 
phenotype whilst suppressing an M1 phenotype.  This study used GM-CSF 
cultured bone marrow derived macrophages to represent an M1 phenotype and 
MCSF derived macrophages as an M2 phenotype.   Transfection of M1 cells with a 
miR-125a mimic resulted in lower TNF, IL-12 and iNOS production, whilst 
increasing IL-4 induced Arg1 expression, a marker of M2 macrophages.  This is 
mirrored in M1 macrophages, where transfection with a miR-125a inhibitor 
results in higher TNF, IL-12, iNOS, MHC Class II, CD40 and a decrease in IL-4 
induced Arg1 expression.  This suggests an inhibitory role for miR-125a in M1 
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macrophage polarisation, commensurate with anti-inflammatory role seen in 
OxLDL stimulated macrophages. This may be explained in part through the direct 
targeting of the transcription factor Kruppel-like factor 13 (KLF13) by miR-125a 
[339].   
These studies are contradicted by an additional study investigating the role of 
miR 125a in the polarisation of human macrophages.  Graff et al demonstrated 
that miR-125a is upregulated in M1 macrophages, stimulated with LPS and IFNγ 
and also in M2b polarised macrophages, stimulated with IgG and LPS, again as a 
result of LPS stimulation.  In addition, they demonstrated that transfection of 
these cells with a miR-125a mimic, results in a slight increase in TNFα and IL-6 
production, in addition to the chemokine CXCL9 that is a marker of the M1 
macrophage phenotype.  The authors attributed the pro-inflammatory effect of 
miR-125a to its ability to target the deubiquitin ligase TNFAIP3 demonstrated by 
Kim et al [368, 369].  Targeting of TNFAIP3 has been shown in this study to allow 
the constitutive activation of NFκB contributing to the aggressiveness of diffuse 
large B cell lymphoma (DLBCL), where both of these miRs are overexpressed 
[369].  It is intriguing that TNFAIP3 is an RA risk associated allele in GWAS 
studies. 
Studies have shown that although macrophages express high levels of miR-125a, 
the downregulation of this miR is required for osteoclastogenesis.  
Overexpression of miR-125a prevents osteoclastogenesis through the silencing of 
TRAF6, a molecule essential for their formation [370].  TRAF6 is also involved in 
the response to TLR activation, and therefore it is possible that miR-125a 
silencing of TRAF6 may also aid in resolving the inflammatory response. 
In addition to macrophages and osteoclasts, miR-125a plays a role in regulating 
the activation and effector function of T cells.  This miR is downregulated in T 
cells from Systemic lupus erythematosus (SLE) patients resulting in an 
overexpression of the transcription factor KLF13 and the chemokine CCL5 [343].  
This downregulation results in a missing regulatory feedback loop, which allows 
the overproduction of CCL5 from terminally differentiated T cells in SLE. 
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1.12.3.2 miR-125b 
Due to the intense focus of investigating miR-125b in cancer, fewer studies have 
concentrated on the role of miR-125b in regulating the immune response.  
However it has been demonstrated that miR-125b is expressed in macrophages, 
where it is downregulated in response to LPS in human, mouse and RAW .267 
cells [296, 371].  Chaudhuri et al have hypothesised that the role of miR-125b in 
macrophages is to amplify the innate and adaptive immune response to 
infection.  Overexpression of miR-125b in macrophages results in an increase in 
MHC Class II, CD40, CD80 and CD86.  Additionally, overexpression of miR-125b 
results in increased apoptosis in these cells.  This study hypothesises that miR-
125b regulates the activation of macrophages through targeting of IRF4, which is 
also an inhibitor of the macrophage response [372].  In addition to IRF4, miR-
125b can target TNFα itself, and represses expression under homeostatic 
conditions [296].  Additionally, miR-125b has a role in chondrocyte destruction in 
OA.  This miR is downregulated in OA cartilage when compared with healthy 
control.  It has been demonstrated that miR-125b targets metallopeptidase with 
thrombospondin type 1 motif (ADAMTS-4), which possesses aggrecanase activity, 
which can result in degradation of cartilage [373]. Recent studies have also 
suggested that miR-125b may be used as a biomarker for response to Rituximab 
therapy in RA.  High serum levels of miR-125b associated with good clinical 
response to Rituximab 3 months after disease flare [374]. 
The study of miR-125 in various different cancers and immune disorders, has 
demonstrated a critical regulatory role of this family in various cellular 
processes, including apoptosis, proliferation, metastasis and the immune 
response.  It has also identified targets of this family that can be viewed in more 
than 1 of these categories and may aid in the understanding of various disease 
processes (Figure 1.4). 
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Figure 1.4 Validated targets of miR-125 adapted from [375] 
Validated miR125 targets in different cellular processes.  Red are validated only for miR-125a, blue 
are validated only for miR-125b and purple are validated for both miR-125 members 
 
These studies demonstrate the potential multifunctional roles played by the 
miR-125 family in regulating activation and maintenance of the immune 
response.  Studies in inflammatory disease have so far focused on the expression 
pattern of these miRs whilst the targets and inflammatory pathways that they 
regulate still require identification.  Thus, I was interested in clarifying the role 
of miR-125a in human macrophage biology and dissecting the role of increased 
levels of miR-125a in the activation of RA synovial macrophages. 
1.13 Aims 
We hypothesised that miR expression can differentially influence differentiation 
and effector functions of macrophages in RA, resulting in pathogenic disease 
progression.  Therefore, the aims of this study were 
1. To identify miR species which are dysregulated in RA macrophages 
2. Once identified, to determine the regulation of novel miR, and identify 
their expression levels in different subgroups of RA patients 
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3. Identify functional targets of these novel miR expressed in macrophages, 
and determine how they regulate macrophage activation. 
4. Identify if dysregulation of these miR plays a role in maintaining the pro-
inflammatory nature of macrophages in RA 
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Chapter 2 Materials and Methods 
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2.1 General Buffers and Reagents 
Complete RPMI – RPMI 1640 media supplemented with 10% foetal calf serum 
(FCS), 2mM L-Glutamine, 100IU/ml penicillin, 100µg/ml streptomycin (all 
Invitrogen). 
Complete DMEM- DMEM media supplemented with 10% FCS 2mM L-Glutamine, 
100IU/ml penicillin, 100µg/ml streptomycin (All Invitrogen). 
Wash media- RPMI 1640 medium supplemented with 100IU/ml penicillin, 
100µg/ml streptomycin (All Invitrogen) 
MACs/FACs Buffer- Phosphate Buffered Saline (PBS) supplemented with 2% FCS 
and 100IU/ml penicillin, 100µg/ml streptomycin (All Invitrogen)  
ELISA wash buffer- PBS (Invitrogen) with 0.05% Tween (Sigma) 
ELISA assay buffer- PBS (Invitrogen) with 0.5% Bovine Serum Albumin (BSA) 
(Sigma) 
Tris-acetate EDTA (TAE) buffer- To make a concentrated 50x stock solution of 
TAE dissolve 242 g Tris base 750 mL deionized water.   Add 57.1 ml glacial acetic 
acid and 100 mL of 0.5 M EDTA (pH 8.0).  Adjust the solution to a final volume of 
1 L.  
2.2 Cell Culture  
All tissue culture experiments were carried out in laminar flow hoods.  Cells 
were cultured under normal culture conditions, in 5% CO2 at 37°C unless 
otherwise stated. 
2.2.1 Culture of Cell Lines 
Cell lines were obtained from ATCC (www.atcc.org), a repository for cell lines. 
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2.2.1.1 THP1 Cells 
Cells from the THP-1 cell line were cultured in 25mls of complete RPMI in T75 
tissue culture flasks (Corning).  Cells were passaged twice a week.  Briefly, cells 
were centrifuged at 200g for 5 minutes to wash and then counted.  Cells were 
seeded at a density of 2x106 in 25mls of complete RPMI and cultured under 
normal culture conditions.  
2.2.1.2 miR-125a Sponge THP-1 cells 
Cells from the THP-1 cell line, which were stably transfected with either the 
miR-125a sponge or reporter control vectors were maintained by the same 
method as normal THP-1 cells (Described in Chapter 4).  However these cells 
were also cultured along with 250mg/ml of the antibiotic G418 to allow for 
selection (Life Technologies).   
2.2.1.3 Culture of Adherent Human HEK293 Cells 
HEK293 cells were cultured in complete DMEM in T75 tissue culture flasks.  Cells 
were passaged twice a week.  Briefly, media was removed from the cells which 
were then incubated for 3 minutes at 37°C with 5ml 0.05% Trypsin EDTA 
(Invitrogen) to dissociate cells from the flask.  After the cells had detached 7mls 
of complete DMEM was added to the flask to inactivate trypsin and cells were 
centrifuged at 200g for 5 minutes at room temperature.  Cells were then seeded 
in a fresh T75 Flask in 15mls complete DMEM and cultured under normal culture 
conditions.    
2.2.1.4 PMA differentiation of THP-1 Cells 
The optimum concentration of PMA (Sigma) was experimentally validated and 
cells were differentiated as follows:  THP-1 cells were washed with wash media 
and counted, after which cells were seeded at a density of 0.25x106 cells per 
well in a 24 well plate along with 5ng/ml of PMA.  Cells were cultured overnight 
in PMA, after which media was removed, with fresh RPMI added.  Culture media 
was changed on day 3 and cells were cultured until day 7. 
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2.2.1.5 Freezing Down Cell Lines  
Cell lines, when not in use were stored in liquid nitrogen.  Cells were frozen in 
cryovials at a concentration of 1x106 in 10% DMSO in complete RPMI. Cells were 
stored at -80°C overnight and then transferred to liquid nitrogen. 
2.2.2 Primary Human Cell Culture 
2.2.2.1 Patient Samples 
All samples were obtained from buffy coats, healthy volunteers and RA patients 
who fulfilled the 2010 ACR/EULAR criteria for RA.  Samples were obtained after 
obtaining written consent, with the appropriate ethical approvals in place 
(Research Ethics Committee 11/S0704/7, Internal Ethics Committee 2012073). 
All human cells were cultured in complete RPMI, unless otherwise stated  
2.2.2.2 Separation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were separated using density 
centrifugation.  Blood samples were obtained from buffy coat packs provided by 
the Scottish National Blood Transfusion Service (SNBTS) or from healthy donors.  
Briefly, blood was diluted 1:1 in wash media, layered over room temperature 
Histopaque®-1077 (Sigma) and centrifuged at 350g for 20 minutes at room 
temperature.  The mononuclear layer of cells was transferred to a new 50ml 
falcon tube and washed in wash media by centrifugation at 200g for 10 minutes 
at 4°C.  The cell pellet was resuspended in 20mls of ice-cold MACs buffer and 
cells were counted using trypan blue (Sigma).       
2.2.2.3 Separation of mononuclear cells from synovial fluid 
Prior to separation cells were pelleted from synovial fluid by centrifugation at 
350g for 20 minutes at room temperature.  Aliquots of cell free synovial fluid 
were then stored at -80°C for subsequent experiments.  Pelleted cells were 
resuspended in wash media and layered over room temperature Histopaque®-‐
1077.  Cells were centrifuged at 350g for 20 minutes at room temperature.  
Mononuclear cells were then treated as described in 2.2.2.3 
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2.2.2.4 Purification of CD14+ monocytes from mononuclear cells 
CD14+ monocytes were purified from mononuclear cells using positive selection 
by AutoMacs according to manufacturer’s instructions.  Briefly, cells were 
counted and resuspended in 80µl MACs buffer per 1x107 cells.  A chosen volume 
of cells, depending on experiment size, was then filtered into 15ml tubes using 
70µm filters (BD Falcon).  Samples were placed on the AutoMacs rack along with 
anti-CD14+ conjugated magnetic microbeads (Miltenyi Biotec 130-050-201).  
Monocytes were isolated from samples using the PosselD programme; this 
programme ensures maximum cell purity by running the sample over two 
columns.  Purity of the monocyte population was assessed by flow cytometry and 
was typically >90% 
2.2.2.5 Culture of human macrophages 
Human macrophages were differentiated from separated CD14+ cells.  These 
cells were cultured under normal conditions at a density of 0.25x106 cells per 
well in a 24 well plate.  Cells were cultured in complete RPMI with the addition 
of 50ng/ml M-CSF or GM-CSF (Peprotech).  Cells were cultured for 7 days with 
the media being replaced on day 3.   
2.2.2.6 Culture in Synovial Fluid 
To mimic the synovial microenvironment monocytes were also cultured in 10% 
synovial fluid. Previous experiments within this lab group, by Dr Mariola 
Kurowska-Stolarska have shown that 10% SF is the lowest amount of SF which 
could be used to alter the expression of miR-155, another miR altered in the 
synovial microenvironment, in CD14+ cells.  Monocytes were separated and 
plated at a density of 0.25x106 per well in complete RPMI.  After plating, 25µl of 
synovial fluid was pipetted into each well and the plate was gently swirled.  The 
cells were then cultured under normal conditions for 24 hours, after which they 
were stored for analysis of miR expression. 
2.2.3 Cell Stimulation 
THP-1, PMA differentiated THP-1, primary human monocytes and M-CSF 
differentiated macrophages were stimulated with various TLR ligands to 
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determine their effect on microRNA expression and cytokine production.  The 
concentration of these stimuli is detailed in Table 2.1.  These concentrations 
were chosen based on previous work concerning the regulation of miR-155 within 
this lab group [320].  Macrophage cells were stimulated with 10ng/ml of LPS due 
to the extremely high levels of TNFα production if stimulated with 100ng/ml. 
Table 2.1 TLR Cell Stimulations 
Stimuli Concentration 
LPS –TLR4  
(Sigma: L2630) 
 100ng/ml (monocyte) or 10ng/ml 
(macrophage) 
Pam3CSK4 –TLR 1/2             
(Invivogen: 112208-00-1) 
 300ng/ml 
Poly I:C -TLR3   
(Sigma: P9582) 
 50µg/ml 
CL097 -TLR 7/8  
(Invivogen: tlrl-c97) 
 5µg/ml 
 
Cells and supernatants were stored for further experiments. 
2.3 Flow Cytometry 
2.3.1 Assessment of cell purity 
Purity of samples collected by AutoMACS isolation was verified by flow 
cytometry.  Cells were washed twice in 500μl of MACs buffer, and resuspended 
at 1x106 cells per ml. 100μl of cells was then added to two clean FACS tubes.  
One tube was used for isotype control and the other for antibody staining.  Both 
tubes were incubated for 20 minutes at room temperature with 10μl of Human 
Fc block (Miltenyi Biotech: 130-059-901) to prevent non-specific binding.  For 
the purity check antibodies detailed in Table 2.2 were used (all Miltenyi 
Biotech): 
Table 2.2 Antibodies used to determine purity of CD14 cells 
Antibody Isotype Amount (in 100 μl) Source/Cat No. 
PE anti-human CD14 IgG2A 10 μl 130-091-835 
Mouse IgG2A isotype 
control 
IgG2A 10 μl 130-091-242 
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10μl of each antibody was added to 100 μl of cells in each tube and incubated in 
the dark for 30 minutes at 4oC.  Cells were washed in 500μl of MACs buffer with 
the supernatant discarded.  Cells to be analysed immediately were resuspended 
in 400μl of MACs buffer.  Cells to be analysed the next day were resuspended in 
200μl of MACs buffer and 200μl FACS FIX (4% paraformaldehyde in PBS).  Analysis 
was performed on a FACS Calibur (BD bioscience) and using Cell Quest software.  
Cells were compared to isotype control to determine purity. 
2.3.2 Assessment of Transfection Efficiency 
One method of measuring transfection efficiency was by flow cytometry.  In 
addition to transfection with a targeting miR mimic/inhibitor, cells were 
transfected with Dy547-labeled mimic based on C. elegans miRNA #1: cel-miR-67 
(Dharmcon: CP-004500-01).  This mimic was labelled with Dy547 that has an 
absorbance/emission of 557/570 allowing transfection to be monitored and 
visualised.  Briefly, cells were transfected with both a control mimic 
(Dharmacon: CN-002000-01) and labelled control.  Cells were then removed from 
the culture plate and washed twice in 500μl of MACs buffer.  Cells were then 
resuspended in 400μl of MACs buffer or 200μl of MACs buffer and 200μl FACS FIX 
and analysed using a FACS Calibur with emission on the FL2 channel.  Samples 
transfected with the labelled mimic were compared to those transfected with 
control mimic to determine transfection efficiency.  
2.3.3 TLR4 expression 
TLR4 surface expression was measured on human macrophages and THP-1 cells.  
Adherent cells were removed from plates using a non-enzymatic dissociation 
solution (Sigma- C5914-100ML), to minimise cell death.  Briefly, reagents were 
warmed to room temperature and media was removed from cells which were 
then washed in PBS.  After this, 200μl of dissociation reagent was added to each 
well and the plate was incubated at 37°C for 3 minutes.  Cells were then washed 
in PBS, re-suspended and incubated with Fc block as described previously.   
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Cells were split into 100μl in 2 tubes to stain:   
Table 2.3 Antibodies used to determine TLR4 expression 
Antibody Isotype Amount (in 100 μl) Source/Cat No. 
PE anti-human TLR4 Mouse IgG2A 5 μl Biolegend 312805 
Mouse IgG2A isotype 
control 
Mouse IgG2A 5 μl Biolegend 400211 
 
Non-adherent THP-1 cells were washed in PBS and incubated with Fc block as 
previously described.  
5µl of each antibody (Table 2.3) was added to the tubes and incubated in the 
dark for 30 minutes at 4°C.  Cells were washed in 500μl of MACs buffer with the 
supernatant discarded.  Cells were resuspended in 400μl of MACs buffer or 200μl 
of MACs buffer and 200μl FACS FIX, and analysed on the FACSCalibur. 
2.4 Real Time Polymerase Chain Reaction (q-PCR) 
2.4.1 RNA Isolation from Cells 
Total RNA was isolated from cells using miRnEasy kit (Qiagen).  Cultured cells 
were lysed using 700µl Qiazol (Qiagen) per 3x106 cells, samples were either 
stored at -20°C or RNA extraction was continued according to manufacturer’s 
protocol.   
Briefly, 140µl of chloroform was added to each sample and shaken vigorously.  
Samples were centrifuged at 12,000g for 15 minutes at 4°C.  All subsequent 
centrifugation steps were carried out at room temperature.  The upper aqueous 
phase of the solution was transferred to a clean 1.5ml Eppendorf tube and mixed 
with 525µl 100% alcohol.  The solution was transferred to an RNeasy mini spin 
column provided with the kit and centrifuged for 15 seconds at 8,000g, with the 
flow through discarded.  Next, samples were washed with 350µl of RWT buffer 
with the flow through discarded.  In some cases samples were subject to a 
DNAse digestion step.  For this reaction an RNAse free DNAse kit was used 
(Qiagen).  The reaction consisted of 10µl of DNAse I stock solution added to 70µl 
of RDD buffer, this 80µl solution was added to the column and incubated at room 
temperature for 15minutes.  Subsequently, columns were washed with 350µl of 
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RWT buffer followed by 500µl RPE buffer (x2) by centrifugation at 8000g for 1 
minute with the flow through discarded.  Columns were centrifuged one final 
time to remove excess buffer and the spin column was transferred to a clean, 
labelled 1.5ml Eppendorf tube.  RNA was eluted in 50µl RNAse free water 
(Qiagen) by centrifugation at 8000g for 1 minute.   
RNA was stored at -20°C before being measured and at -80°C for longer term 
storage.  
2.4.2 Measuring Nucleic Acid Concentration 
Nucleic acid concentrations were determined using a Nanodrop ND-1000 
spectrophotometer (ThermoScientific).  Before each set of samples the 
equipment was blanked using 1µl of water and then initialised with the same 
volume.  Ratios of absorbance at 260 nm and 280 nm were used to indicate 
purity of samples.  The value of 2.0 for each of these measurements was 
recommended by the manufacturer as standard to indicate samples free of 
contaminates.  Ratios obtained in these experiments were close to 2, indicating 
good quality RNA. 
2.4.3 SYBR green protocol 
To measure miR expression miScript primer assays, detailed in Table 2.4 were 
used (all Qiagen).   
Table 2.4 Qiagen miScript primers used to measure microRNA 
Assay Name Cat No. 
U6 snRNA MS00033740 
Hsa-miR-99a MS00032158 
Hsa-miR-99b MS00032165 
Hsa-miR-125a MS00033423 
Hsa-miR-125b MS00036629 
Hsa-miR-193b MS00031549 
Hsa-miR-511 MS00006993 
Hsa-miR-642a MS00023835 
Hsa-miR-642b MS00023828 
 
To measure mRNA levels primers detailed in Table 2.5 were used 
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Additionally primers were designed to measure TLR4 variants, and purchased 
from IDT.  The sequences are detailed below: 
TLR4-Total 
Forward: ACACTCTGTCACTTTGTCACTC 
Reverse: AAGTGGGATGACCTCAGGA 
 
TLR4-001 Long 
Forward:  AAGGCAGGGAGTATACATTGC 
Reverse: CAATCAGGATGTCATCAGGGAA 
 
Table 2.5 Primers used to measure mRNA using SYBR green qPCR method 
Assay Name Supplier Cat No./Assay Name 
GAPDH IDT Hs.PT.39a.22214836 
TNFα IDT Hs.PT.58.45380900 
TRAF6 Qiagen QT00062888 
CCL4 Qiagen QT01008070 
TNFAIP3 Qiagen QT00041853 
2.4.3.1 cDNA preparation 
cDNA was prepared from RNA samples according to protocol using two separate 
kits.  The first was a miScript II reverse transcription kit (Qiagen).  The kit 
supplies two buffers which can be used depending on species being amplified.  
HiFlex buffer can be used for interrogation of both mRNA and microRNA.  HiSpec 
buffer can be used to study only microRNA expression.  All steps were performed 
on ice.  Briefly, 100-500ng of RNA was added in 10μl to reaction detailed below 
in Table 2.6 
Table 2.6 miScriptSYBR green cDNA reaction 
Kit Component Per Reaction (μl) 
5x HiFlex/HiSpec buffer 4 
10x Nucleics mix 2 
RNAse free water 2 
Reverse transcriptase 2 
Template RNA 10 
 
The reaction was placed in a thermocycler for cDNA synthesis.  The cycling 
conditions were as follows: 60 min at 37°C and then 95°C for 5 min. 
Subsequently cDNA was diluted 1 in 10 by adding 180μl of RNAse free water to 
the 20μl cDNA sample.  cDNA not used immediately was stored at -20°C. 
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cDNA was also prepared using a High Capacity cDNA kit (Life Technologies).  
Briefly, RNA was standardised to a concentration of 2ng/µl before beginning.  Kit 
components were thawed on ice and a master mix was made up as detailed in 
Table 2.7  
 
 
Table 2.7 High Capacity cDNA reaction 
Kit Component  Per Reaction (μl) 
10xRT Buffer  2 
25 x dNTP Mix (100 
mM) 
0.8 
RT Random Primers  2 
MultiScribe Reverse 
Transcriptase 
1 
RNase Inhibitor 1 
RNAse free water 4.2 
 
10µl of reaction was mixed with 10µl of RNA sample and placed in the 
thermocycler.  The cycle conditions for the cDNA reaction are as follows: 25°C 
for 10 minutes, 37°C for 120 minutes and then 85°C for 5 minutes.  cDNA was 
then used for further analysis, or stored at -20°C 
2.4.3.2 SYBR green PCR for mRNA detection 
Reactions were ran in triplicate in 10µl volume using a 384 well PCR plate and 
Power SYBR® green master mix (Life Technologies), detailed in Table 2.8 
Table 2.8 SYBR green mRNA PCR reaction 
Kit Component  Per Reaction (μl) 
Power SYBR green  5 
Primer mix 1 
cDNA  1 
RNAse free water 3 
 
A no template control (1 µl of water) was also added to ensure no contamination 
of master mix. 
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The plate was covered with a MicroAmp optical adhesive cover (Life 
Technologies) centrifuged at 250g for 1 minute, and placed in an ABI 7900HT 
real-time PCR machine (Life Technologies) where it was read on cycling 
conditions detailed in Table 2.9 
Table 2.9 SYBR green mRNA PCR cycling conditions 
 UNG 
incubation 
Polymerase 
activation 
PCR – (40 cycles) 
Temperature (°C) 50 95 95 60 
Time (mm:ss) 2:00 10:00 00:15 1:00 
 
A dissociation/melt curve was measured after the run to ensure specificity of 
primers as follows: Incubate for 15 seconds at 95°C, Incubate for 15 seconds at 
60°C and Incubate for 15 seconds at 95°C 
2.4.3.3 SYBR green PCR for microRNA detection 
cDNA was prepared as described in 2.4.3.1 
The miScript SYBR green PCR kit (Qiagen) was used to measure miR expression 
using SYBR green technology.  Reactions were in 10µl volumes as detailed in 
Table 2.10 
Table 2.10 SYBR green miRNA PCR reaction 
Kit Component  Per Reaction (μl) 
QuantiTect SYBR green master mix  5 
10x miScript universal primer 1 
10x miScript primer assay 1 
RNAse free water 2 
cDNA template 1 
 
The plate was run under the cycling conditions detailed in Table 2.11 
Table 2.11 Cycling conditions SYBR green miRNA PCR 
 Polymerase 
activation 
PCR – (40 cycles) 
Temperature (°C) 95 94 55 70 
Time (mm:ss) 15:00 00:15 00:30 :30 
 
  87 
 
2.4.4 Taqman Protocol 
cDNA was prepared for microRNA analysis using the microRNA reverse 
transcription kit (Life Technologies).  RNA was standardized to 2ng/µl by diluting 
in RNAse free water and specific cDNA reactions were made for each miR.  
Assays used are detailed in Table 2.12 (Life Technologies) 
 
 
Table 2.12 Taqman primers used to measure microRNA 
Assay Name Cat No. Assay ID 
snRNU6 4440887 001973 
Hsa-Let7-a 4440887 000377 
Hsa-miR-99b 4440887 000436 
Hsa-miR-125a-5p 4440887 002198 
Hsa-miR-125a-3p 4427975 002199 
Hsa-miR-125b 4427975 000449 
Hsa-Let-7e 4440887 002406 
 
The cDNA reaction was made up as detailed in Table 2.13 
Table 2.13 Taqman miRNA cDNA reaction 
Kit Component  Per Reaction (μl) 
10xRT Buffer  1.5 
25 x dNTP Mix (100 
mM) 
0.15 
MultiScribe Reverse 
Transcriptase 
1 
RNase Inhibitor 0.19 
RNAse free water 4.16 
Specific RT primer 3 
     
10µl of RNA was added to 10µl of master mix and cycled under the following 
conditions 16°C for 30 minutes, 30°C for 30 minutes and 85°C for 5 minutes, 
cDNA not used immediately was stored at -20°C. 
2.4.4.1 Taqman PCR for microRNA detection 
The PCR protocol was altered for use of universal master mix, no UNG (Life 
Technologies).  Briefly a master mix was made as detailed in Table 2.14  
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Table 2.14 Taqman miRNA RT-PCR reaction 
Kit Component  Per Triplicate (μl) 
Universal master mix  16.5 
Taqman miR assay 1.65 
RNAse free water 12.655 
cDNA 2.2 
 
Samples were analysed in 10 μl volumes.   
The plate was run in an ABI 7900HT real-time PCR machine where it was read 
under the cycling conditions detailed in Table 2.15: 
Table 2.15 Taqman miRNA RT-PCR cycling conditions 
  
Stage 1 
  
Stage 2- 40 Cycles 
 
Temperature (°C) 95 95 60 
Time (mm:ss) 15:00 00:15 1:00 
 
2.4.5 Analysis of PCR 
Results were then analysed using SDS 2.4 software provided by Life 
Technologies. 
2.4.5.1  Generation of microRNA standards for RT-PCR 
In order to measure absolute copy number of miR, we generated specific miR 
standards.  To do this, we took the miR mimic and denatured at 95°C for 5 
minutes.  From this reaction we generated cDNA from a known amount of miR 
and created a standard curve through serial dilutions.  This allowed us to relate 
a Ct value to a copy number of miR through the absolute quantification method.  
For example shown in Figure 2.1A is a standard curve for Let-7a and the Ct 
values in Figure 2.1B 
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Figure 2.1 Generation of miR q-PCR Standard for copy number calculation 
PCR standards were generated for each miR studied.  A) Standard curve of Let-7a showing 
quantity of miR present and cycle number detected. B) Ct curves showing amplification of known 
amounts of Let-7a miR, allowing calculation of copies of miR expressed in a sample  
 
2.5 Cloning Techniques: Preparation of reporter plasmids 
To determine direct interaction between miR-125a and it’s predicted target 
gene, reporter plasmids were generated.  Fragments of 3’ UTR of predicted 
target were inserted downstream of a luciferase reporter gene in the cloning 
sites of modified pmirGLO Dual-Luciferase miRNA Target Expression Vector 
(Figure2.2)(Promega) 
 
Figure 2.2 pmirGLO vector 
Schematic of pmiRGLO vector purchased from Promega which was used in luciferase reporter 
assays. 
 
A) B)
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The cloning strategy described in Figure 2.3 was followed to generate reporter 
plasmids for validating of miR-125a targets 
 
Figure 2.3 Overview of cloning strategy used to generate reporter plasmids for luciferase 
assays.  
Inserts were resuspended and ligated into the pmiRGLO vector.  This was then transformed into 
E.coli and DNA was extracted.  This DNA was verified and sequenced. 
 
2.5.1 Designing target G-Block Fragments®  
To functionally validate miR-125a targets we used G-Block gene fragments®.  G-
block fragments are DNA molecules which are synthesised, and are compatible 
with the Gibson Assembly® Method of cloning.  Firstly, 3’ UTR sequences 
containing the potential target site were identified using the ensembl genome 
browser, and the resulting miR binding site of the target gene was determined 
using the TargetScan website.  This sequence was sent to IDT for synthesis.  Ends 
compatible with the Gibson Assembly® Method were also added to these 
sequences to allow cloning to take place (GTCTGCAGAGATCTGTTT at beginning 
of sequence and GTCTAGAGTCGACCTGCAG at the end).  Additionally the miR-
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125a target site was also mutated to validate miR-125a targeting.  The insert 
was ligated into pmiRGLO vector as follows: 10 µl Gibson Assembly Master Mix, 5 
µl pmiRGLO, 5µl G-Block insert.  This reaction was then placed in the 
thermocycler under the following programme: Incubate at 50°C for 60 minutes.  
The reaction was then transformed into competent E.Coli, or frozen for future 
use.  Table 2.16 shows the sequences of G-Blocks generated, with the miR-125a 
binding site according to either the TargetScan or RNA22 prediction algorithms 
underlined. 
Table 2.16 Sequences of potential miR-125a targets used for reporter assay 
Name Sequence 
TLR4 GAGAACTACGTGTGAAGGTATTCAAGGCAGGGAGTATACATTGC
TGTTTCCTGTTGGGCAATGCTCCTTGACCACATTTTGGGAAGAG
TGGATGTTATCATTGAGAAAACAATGTGTCTGGAATTAATGGGGT
TCTTATAAAGAAGGTTCCCAGAAAAGAATGTTCATCCAGCCTCCT
CAGAAACAGAACATTCAAGAAAAGGACAATCAGGATGTCATCAG
GGAAATGAAAATAAAAACCACAATGAGATATCACCTTATACCAGG
TAGAATGGCTACTATAAAAAAATGAAGTGTCATCAAGGATATAGA
GAAATTGGAACCCTTCTTCACTGCTGGAGGGAATGGAAAATGGT
GTAGCCGTTATGAAAAACAGTACGGAGGTTTCTCAAAAATTAAAA
ATAGAACTGCTATATGATCCAGCAATCTCACTTCTGTATATATAC
CCAAAATAATTGAAATCAGAATTTCAAGAAAATATTTACACTCCCA
TGTTCATTGTGGCACTCTTCACAATCACTGTTTCCAAAGTTATGG
AAACAACCCAAATTTCCATTGAAAAATAAATGGACAAAGAAAATG
TGCATATACGTACAATGGGATATTATTCAGCCTAAAAAAAGGGG
GAATCCTGTTATTTATGACAACATGAATAAACCCGGAGGCCATTA
TGCTATGTAAAATGAGCAAGTAACAGAAAGACAAATACTGCCTG
ATTTCATTTATATGAGGTTCTAAAATAGTCAAACTCATAGAAGCA
GAGAATAGAACAGTGGTTCCTAGGGAAAAGGAGGAAGGGAGAA
ATGAGGAAATAGGGAGTTGTCTA 
 
mTLR4 GAGAACTACGTGGATCCGTATGGATCCAAGGATCCAGTATACAT
TGCTGTTTCCTGTGGGCAATGCTCCTTGACCACATTTTGGGAAG
AGTGGATGTTATCATTGAGAAAACAATGTGTCTGGAATTAATGGG
GTTCTTATAAAGAAGGTTCCCAGAAAAGAATGTTCATCCAGCCTC
CTCAGAAACAGAACATTCAAGAAAAGGATCCTCAGGATCCATCA
GGAATCCGAAAATAAAAACCACAATGAGATATCACCTTATACCAG
GTGAATGGCTACTATAAAAAAATGAAGTGTCATCAAGGATATAGA
GAAATTGGAACCCTTCTTCACTGCTGGAGGGAATGGAAAATGGT
GTAGCCGTTATGAAAAACAGACGGAGGTTTCTCAAAAATTAAAAA
TAGAACTGCTATATGATCCAGCAATCTCACTTCTGTATATATACC
CAAAATAATTGAAATCAGAATTTCAAGAAAATATTTACACTCCCAT
GTTCATTGTGGCACTCTTCACAATCACTGTTTCCAAAGTTATGGA
AACAACCCAAATTTCCATTGAAAAATAAATGGACAAAGAAAATGT
GCATATACGTACAATGGGATATTATTCAGCCTAAAAAAAGGGGG
AATCCTGTTATTTATGACAACATGAATAAACCCGGAGGCCATTAT
GCTATGTAAAATGAGCAAGTAACAGAAAGACAAATACTGCCTGA
TTTCATTTATATGAGGTTCTAAAATAGTCAAACTCATAGAAGCAG
AGAATAGAACAGTGGTTCCTAGGGAAAAGGAGGATCCGAGGAT
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CGAGGATCCAGGGAGTTGTCTA 
 
 
TNFAIP3 GTAACTGGCAAGGGATGATGTCAGATTCAGCCCAAGGTTCCTCCTCTCCT
ACCAAGCAGGAGGCCAGGAACTTCTTTGGACTTGGAAGGTGTGCGGGGA
CTGGCCGAGGCCCCTGCACCCTGCGCATCAGGACTGCTTCATCGTCTTGG
CTGAGAAAGGGAAAAGACACACAAGTCGCGTGGGTTGGAGAAGCCAGAG
CCATTCCACCTCCCCTCCCCCAGCATCTCTCAGAGATGTGAAGCCAGATCC
TCATGGCAGCGAGGCCCTCTGCAAGAAGCTCAAGGAAGCTCAGGGAAAAT
GGACGTATTCAGAGAGTGTTTGTAGTTCATGGTTTTTCCCTACCTGCCCG
GTTCCTTTCCTGAGGACCCGGCA 
 
mTNFAIP3 GTAACTGGCAAGGGATGATGTCAGATTCAGCCCAAGGTTCCTCCTCTCCT
ACCAAGCAGGAGGCCAGGAACTTCTTTGGACTTGGAAGGTGTGCGGGGA
CTGGCCGAGGCCCCTGCACCCTGCGCATCAGGACTGCTTCATCGTCTTGG
CTGAGAAAGGGAAAAGACACACAAGTCGCGTGGGTTGGAGAAGCCAGAG
CCATTCCACCTCCCCTCCCCCAGCATCTCTCAGAGATGTGAAGCCAGATCC
TCATGGCAGCGAGGCCCTCTGCAAGAAGCTCAAGATCCGAAAATGGACGT
ATTCAGAGAGTGTTTGTAGTTCATGGTTTTTCCCTACCTGCCCGGTTCCT
TTCCTGAGGACCCGGCA 
 
CCL4 AAAAAGCAGATGTAAATATATGATATCAACAAAAAAGCAGATGTA
AATATATGCATTCAAACAGCTGCTCAGAGACAGGAAGTCTTCAG
GGAAGGTCACCTGAGCCCGGATGCTTCTCCATGAGACACATCTC
CTCCATACTCAGGACTCCTCTCCGCAGTTCCTGTCCCTTCTCTTA
ATTTAATCTTTTTTATGTGCCGTGTTATTGTATTAGGTGTCATTTC
CATTATTTATATTAGTTTAGCCAAAGGATAAGTGTCCCCTATGGG
GATGGTCCACTGTCACTGTTTCTCTGCTGTTGCAAATACATGGAT
AACACATTTGATTCTGTGTGTTTTCATAATAAAACTTTAAAATAAA
ATGCAGACAGTT 
 
mCCL4 AAAAAGCAGATGTAAATATATGATCCAACAAAAAAGCAGATGTAA
ATATATGCATTCAAACAGCTGCTCAGAGACAGGAAGTCTTCAGG
GAAGGTCACCTGAGCCCGGATGCTTCTCCATGAGACACATCTCC
TCCATACTCAGGACTCCTCTCCGCAGTTCCTGTCCCTTCTCTTAA
TTTAATCTTTTTTATGTGCCGTGTTATTGTATTAGGTGTCATTTCC
ATTATTTATATTAGTTTAGCCAAAGGATAAGTGTCCCCTATGGGG
ATGGTCCACTGTCACTGTTTCTCTGCTGTTGCAAATACATGGATA
ACACATTTGATTCTGTGTGTTTTCATAATAAAACTTTAAAATAAAA
TGCAGACAGTT 
 
TRAF6 GAAGGATCCTGTAGAATCCTGGAAGTAACCAGATTTTCCTAATAGGGAGA
TGATTTTTTTGTGTGCCATCATGTATTTGTTAAAGGCCTATATATAGATAT
AAAATATCGTGGAATCTAGTTCTCAGGGAGACCCGCAACTAGTATAAGCT
TATAAAGGATCTAAAGATCCATCCACCATTTAAAGTTGTCTGGTAATGAGA
GATGACATTGTATCCCCCAGAGAGGCCAAATCAGAGTCGCCAGCCAGCGT 
 
mTRAF6 GAAGGATCCTGTAGAATCCTGGAAGTAACCAGATTTTCCTAATAGGGAGA
TGATTTTTTTGTGTGCCATCATGTATTTGTTAAAGGCCTATATATAGATAT
AAAATATCGTGGAATCTAGTTCAGATCCGACCCGCAACTAGTATAAGCTTA
TAAAGGATCTAAAGATCCATCCACCATTTAAAGTTGTCTGGTAATGAGAG
ATGACATTGTATCCCCCAGAGAGGCCAAATCAGAGTCGCCAGCCAGCGT 
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TNFα CTTCGAAACCTGGGATTCAGGAATGTGTGGCCTGCACAGTGAAG
TGCTGGCAACCACTAAGAATTCAAACTGGGGCCTCCAGAACTCA
CTGGGGCCTACAGCTTTGATCCCTGACATCTGGAATCTGGAGAC
CAGGGAGCCTTTGGTTCTGGCCAGAATGCTGCAGGACTTGAGA
AGACCTCACCTAGAAATTGACACAAGTGGACCTTAGGCCTTCCT
CTCTCCAGATGTTTCCAGACTTCCTTGAGACACGGAGCCCAGCC
CTCCCCATGGAGCCAGCTCCCTCTATTTATGTTTGCA 
 
 
mTNFα CTTCGAAACCTGGGATTCAGGAATGTGTGGCCTGCACAGTGAAG
TGCTGGCAACCACTAAGAATTCAAACTGGGGCCTCCAGAACTCA
CTGGGGCCTACAGCTTTGATCCCTGACAGATATCATCTGGATAT
CAGGGAGCCTTTGGTTCTGGCCAGAATGCTGCAGGACTTGAGA
AGACCTCACCTAGAAATTGACACAAGTGGACCTTAGGCCTTCCT
CTCTCCAGATGTTTCCAGACTTCCTTGAGACACGGAGCCCAGCC
CTCCCCATGGAGCCAGCTCCCTCTATTTATGTTTGCA 
 
m; mutated, underlined sequences are areas of predicted miR-125a binding, which were then 
mutated 
 
2.5.2 Transformation 
3µl of the reaction was pipetted into aliquots of One Shot® TOP10 Chemically 
Competent E.coli, incubated on ice for 30 minutes and heat shocked at 42°C for 
30 seconds.  The cells were then spread on agar plates containing 1µg/ml 
ampicillin and cultured overnight in an incubator at 37°C.  Ampicillin resistance 
was used to select for those colonies which contained the PCR 2.1® plasmid.  
The next day colonies were picked from plates and cultured overnight in 5mls of 
LB broth with 1µg/ml at 37°C on a shaker at 225rpm. 
2.5.3 DNA Extraction 
Depending on amount of DNA required, DNA was purified from cultures using a 
number of different commercially available kits.  
For up to 20µg of DNA a QIAprep Spin Miniprep Kit (Qiagen) was used according 
to manufacturer’s instruction. Briefly, 1.5ml of culture was centrifuged at 
17,900g for 3 minutes at room temperature.  The bacterial pellet was 
resuspended in 250µl of buffer P1.  Next 250µl of buffer P2 was added to lyse 
cells (solution will turn blue) with the tube inverted 4-6 times.  The reaction was 
neutralized by addition of 350µ buffer N3 with the tube inverted 4-6 times.  The 
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solution was centrifuged at 17,900g for 10 minutes with the supernatant 
transferred to a spin column.  The column was centrifuged at 8000g for 1 minute 
and then washed with 750µl of PE buffer.  The column was dried by 
centrifugation at 8000g for 1 minute with DNA then eluted in 50µl of water. 
For up to 500µg DNA a QIAprep Spin Maxiprep Kit (Qiagen) was used according to 
manufacturer’s instructions.  Overnight cultures (50-100mls) were centrifuged at 
2000g for 30 minutes with the pellets resuspended in 10mls of buffer P1.  Next 
10mls of buffer P2 was added and the tube was inverted 4-6 times and incubated 
for 5 minutes at room temperature. To stop the lysis 10mls of buffer N3 was 
added to the tube which was inverted 4-6 times and incubated on ice for 20 
minutes.  The solution was then centrifuged at 2000g for 30 minutes.  In the 
meantime a Qiagen-tip was equilibrated with 10mls buffer QBT.  The 
supernatant was then applied to the Qiagen-tip column and allowed to flow 
through.  The column was washed twice with 30mls of buffer QC and DNA was 
eluted into a clean 50ml tube by adding 15mls of buffer QF.  DNA was 
precipitated by adding 10.5mls of isopropanol to the eluted DNA and centrifuged 
at 2000g for 30 minutes at 4oC.  The supernatant was carefully decanted and the 
pellet was washed in 5mls of 70% ethanol and centrifuged at 2000g for 10 
minutes at room temperature.  The supernatant was then decanted and the 
pellet was allowed to air dry.  DNA was then dissolved in 500µl sterile water.   
2.5.4 Verification Digest 
To confirm presence of the insert, plasmid DNA was digested with restriction 
enzymes, sites of which were present in the vector.  10µl of plasmid was 
digested in 2µl appropriate buffer (NES), 7µl sterile water and 0.5µl of enzyme.  
The reaction was incubated at 37oC for 1 hour and then ran on a 1% agarose gel.  
The insert and vector were then cut out and gel purified. 
2.5.5 Agarose Gel Electrophoresis 
UltraPure agarose (Invitrogen) was used for agarose gel electrophoresis at 
concentrations of 1% (w/v) in 1xTAE buffer with addition of ethidium bromide to 
allow visualisation of DNA under UV light (Sigma). Prior to gel loading, samples 
were mixed with 1X BlueJuice (Qiagen). Samples were ran alongside 5µl of 1kb 
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plus DNA ladder (Invitrogen). Gels were placed into an electrophoresis tank filled 
with running buffer (1x TAE) and ran at 150V for 20-30 minutes, depending on 
size of expected fragment.  
2.5.6 Sequencing of Reporter plasmids 
After purification, samples were sent to Source Bioscience for sequencing.  
2.5.7 Co -Transfection of cells with luciferase reporter plasmid 
and microRNA 
Transient transfection of HEK 293 cells was accomplished using Attractene 
transfection reagent (Qiagen) according to manufacturer’s instructions.   
Shortly before transfection 12x104 cells were seeded per well of a 24-well plate 
in 500μl of complete DMEM and incubated for the short time until transfection. 
DNA concentration of the reporter plasmid were measured and adjusted to a 
working concentration of 200ng/µl by diluting in sterile water.  microRNA mimics 
were adjusted to a working concentration of 5µM.  To prepare the transfection 
master mix 0.4 μg DNA was diluted in 60μl OptiMem media (Invitrogen).  
Subsequently 6pmol of miRNA was added to the DNA and the solution was mixed 
vortexing.  This gives a final concentration of 10nM added to cells.  Finally 1.5μl 
Attractene Transfection Reagent was added to the diluted DNA and the solution 
was again mixed by vortexing.  The transfection master mix was incubated for 
10−15 min at room temperature (15−25°C) to allow the formation of transfection 
complexes.  The transfection complexes were added drop−wise onto the cells 
with the plate gently swirled to ensure uniform distribution of transfection 
complexes.  The cells were then incubated along with the transfection 
complexes for 24 hours under normal growth conditions. 
2.5.8 Dual Luciferase reporter assay 
Validation of the interaction of microRNA with 3’UTR target sequence is 
achieved using a dual luciferase reporter assay (Promega).  This assay allows the 
measurement of 2 different “glow type” luciferase signals sequentially in the 
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same sample, one from Firefly Luciferase and one from Sea Pansy luciferase, 
referred to as Renilla.   
After 24 hours OptiMem media was removed and cells were washed twice with 
PBS and lysed by the addition of 200µl of 1X passive lysis buffer to each well.  
The reaction was incubated at room temperature for 15 minutes on a shaker.  
Next, 50µl of cell lysate was added in triplicate to a microtitre plate along with 
50µl of luciferase substrate and incubated for 10 minutes on a shaker at room 
temperature, after which the values for luciferase were measured. The renilla 
reaction was initiated by the addition of 50µl Stop & Glo® Reagent provided with 
the kit, and incubated for 10 minutes on a shaker at room temperature after 
which renilla values were measured.   
2.6 Generation of miR sponge 
Generation of the miR-125a sponge, which was designed, created and stably 
inserted into THP-1 cells and will be discussed in Chapter 4. 
2.7 Transfection Experiments 
Alteration of expression is the basis to determine miR function.  All transfection 
experiments were carried out using miRIDIAN miR mimics and hairpin inhibitors, 
detailed in Table 2.17, purchased from Dharmacon.  Both controls are based on 
c.elegans miR-67, which is confirmed to have minimal sequence identity with 
miRNAs in human, mouse, and rat.  In addition, to validate transfection 
efficiency, cells were also transfected with a control labelled with Dye 547 
described in 2.3.2 
Table 2.17 miR mimics and inhibitors used for transfection 
Name Cat No. 
Control mimic CN-002000-01 
miR-125a mimic C-300624-05-0005 
Control inhibitor IN-002005-01 
miR-125a inhibitor IH-300624-06-0005 
Control mimic Dy547 CP-004500-01 
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2.7.1 Transfection of macrophages 
In order to validate transfection of human macrophages, a number of different 
transfection reagents were tested. 
The best transfection of adherent cells was achieved using TransIT-TKO® 
Transfection Reagent according to manufacturer’s instructions (MirusBio).  In all 
cases the final concentration of miR was 25nM.  The TransIT-TKO® reagent was 
warmed to room temperature and vortexed before use.  A transfection master 
mix was made for each miR/control miR by adding - 7.5 µl 1µM miR, 50µl 
OptiMem media, and 2.5µl TransIT-TKO® Reagent per well to a tube.  This 
reaction was incubated at room temperature for 30 minutes to allow 
transfection complexes to form.  Before addition to cells, half the media (250µl) 
was removed from each well and 60µl of transfection complexes was added.  
Cells were then cultured for 24 hours under normal culture conditons.  
2.8 Protein measurement 
2.8.1 Enzyme-Linked-immunosorbent assay (ELISA)  
A human ELISA kit (Invitrogen) was used to determine the concentration of this 
cytokine in cell supernatants.  96 well microtitre plates were coated with 
capture antibody in PBS, covered and incubated overnight at 4°C. The plates 
were washed with ELISA wash buffer and blocked by the addition of 200µl of 
assay buffer, to prevent non-specific binding and incubated at room temperature 
for 1 hour.  Next, a standard curve was generated using recombinant human 
cytokine standards dissolved in blocking buffer.  A top standard of 2000pg/ml 
was serially diluted 1:2 across eight samples.  100µl of each standard was added 
in duplicate to the plate along with two wells containing only blocking buffer. 
Samples were ran neat or diluted with blocking buffer, depending on 
experimental set up, with 100µl being added to each well in duplicate.  The 
plates were covered and incubated for 2 hours at room temperature.  Next, the 
plates were washed x2 with ELISA wash buffer and the secondary antibody was 
added.  This step was then incubated for 1 hour at room temperature.  The 
plates were washed as previously and 100µl of streptavidin was added to each 
well.  This reaction was incubated for 20 minutes at room temperature, after 
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which the streptavidin was washed off and 100µl of TMB chromagen (Biosource) 
was added to each well. The reaction was then stopped by addition of 100µl stop 
solution (Biosource) to each well the signal was read at 450 nm on a microplate 
reader. 
Table 2.18 ELISA antibody concentrations 
Cytokine Cat No. Concentration of 
primary antibody 
Concentration of 
secondary 
antibody 
Streptavidin 
dilution 
TNF-α CHC1753 0.250mg/0.125mL 0.025mg/0.125mL 1:625 
IL-6 CHC1263 0.125mg/0.125ml 0.0025mg/0.125ml 1:2500 
IL-12  CHC1563 0.125mg/0.125ml 0.0025mg/0.125ml 1:5000 
IL-10 CHC1323 25μg/0.125ml 125μg/0.125ml 1:1250 
CCL4 CHC2293 0.125mg/0.125ml 25μg/0.125ml 1:2500 
 
2.8.2 Luminex Assay  
A cytokine human 25-plex assay (Invitrogen - LHC0009) was used to determine 
the concentration of 25 cytokines and chemokines simultaneously within 
differentiated miR-125a sponge cell supernatants.  The assay was carried out in 
accordance with the manufacturer’s instructions.  Briefly, the plate was pre-wet 
by washing with wash buffer provided.  Next, beads were vortexed and 
sonicated, then pipetted into each well and washed.  Next standards and 
samples were added with incubation buffer, covered with foil and incubated on 
a shaker at 500-600 rpm for 2 hours, at room temperature.  After 2 hours the 
plate was washed and the biotinylated antibody added, and incubated on the 
shaker for 1 hour at room temperature.  Finally, the plate was washed, 
streptavidin added, incubated for 30 minutes and read on the luminex reader.   
2.8.3 Western Blot  
Human CD14+ cells were separated as described in 2.2.2, and seeded at a 
density of 3x106 per well of a 6 well plate.  Cells were cultured in M-CSF and 
transfected on day 6.  Cells were cultured overnight and then left unstimulated 
or stimulated with LPS (10ng/ml) for 6 hours.   
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2.8.3.1 Protein extraction 
Protein was extracted from cells using M-PER reagent (Thermo Scientific) 
according to protocol.  Briefly, media was removed from cells which were 
washed with PBS.  Next, 400µl of M-PER was added to each well and shaken 
gently for 5 minutes.  The sample was then pelleted by centrifugation at 14,000g 
for 10 minutes, with HALT protease inhibitors (Thermo Scientific) added at a 
concentration of 10μl/ml.  Supernatants were then frozen for further analysis. 
2.8.3.2 Measurement of protein concentration 
Protein concentration was measured using the BCA protein assay kit (Thermo 
Scientific) according to protocol.  Briefly, albumin standards were prepared 
along with BCA working reagent.  Next, 25μl of standard, or sample was pipetted 
into well of a 96 well plate, along with 200μl of working reagent.  The plate was 
then incubated at 37oC for 30 minutes, before the colour change was measured 
around 562nm on a plate reader. 
Samples were then standardised to 20mg for loading onto gel and denatured in 
llameli buffer (Biorad) at 95oC for 10 minutes. 
2.8.3.3 Gel Electrophoresis 
Samples were loaded onto a 10 well 10-12% gel (Invitrogen) which was then 
placed in a gel tank along with 1xMOPS running buffer (Invitrogen).  To allow 
visualisation of size, a ladder was also added at the same time (Invitrogen).  The 
gel was then ran at 150V for around 1 hour, after which proteins were 
transferred to a PVDF membrane. 
2.8.3.4 Transfer and staining 
Proteins were transferred from the gel using the iBLOT dry transfer system 
according to protocol (Invitrogen).  TNFAIP3 expression was then visualised by 
staining with a TNFAIP3 antibody (Invitrogen –A14028), compared to β-actin 
(Santa Cruz-SC47778), using the Azure c Series western blot machine.  Briefly, 
the membrane was blocked for 30 minutes and incubated overnight with primary 
antibody (TNFAIP3 1 in 200, β-actin 1 in 2000) at 4oC.  The next day, blots were 
washed (x3) in TBS-t and incubated for 30 minutes at room temperature with 
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secondary antibodies (TNFAIP3- Donkey anti rabbit antibody labelled with IRDye 
680 RD, and β-actin, donkey anti mouse antibody labelled with IRDye 800CW).  
Protein expression was quantified using Digital Odyssey Imaging software (Li-
Cor).   
2.9 Statistical Analysis 
Values in this thesis were presented as mean ± SEM.  Statistical analysis used 
were indicated in the figure legend and depended on the distribution of results.  
Parametric tests were used in experiments in which the sample size allowed the 
identification of a normally distributed population (determined using a 
Pearson/D’Agostino normalcy test).  These tests were used in experiments were 
the sample size (n) was greater than 6.  Additionally parametric tests were used 
in experiments in which data was normalised (For example in luciferase 
experiments were control data was normalised to 100%).  For small sample sizes, 
or data in which Gaussian distribution could not be determined, non-parametric 
tests were used.  All statistical analysis was carried out using Graphpad version 6 
software.  A p value of <0.05 was deemed significant.  
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Chapter 3 – Dysregulated expression of 
microRNA in Rheumatoid Arthritis 
  
3.1 Introduction and aims 
Rheumatoid Arthritis (RA) is an inflammatory, autoimmune disease, 
characterised by immune cell infiltration into the synovium.  This results in 
chronic inflammation and destruction of the synovial membrane, cartilage and 
bone.  The cause of RA is currently unknown, with both genetic and 
environmental factors thought to contribute to disease susceptibility and 
progression [40, 376].  Monocytes and macrophages play a pivotal role in 
initiating and perpetuating the inflammation evident in RA.  They produce 
pathogenic pro-inflammatory cytokines and chemokines such as TNFα, IL-6, 
CCL3, CCL4, and activate other cells such as T cells through cell contact [167, 
377, 378].  Although treatment of RA has improved since the introduction of 
biologic therapies, which target these pro-inflammatory mediators, there are 
still many patients who do not respond to these interventions. One of the 
underlying mechanisms mediating this refractory state may be the fact that only 
a single end product of macrophage activation is targeted, leaving other 
mediators still bioactive.  Therefore looking at the level of integration of 
activation signals in macrophages may reveal better candidates for therapy. Also 
to date, there is no clear biomarker for response to therapy.  Therefore, many 
studies are now investigating the existence and characterisation of novel 
inflammatory mediators, in an attempt to identify new biomarkers, which may 
aid in identifying responders or non- responders to medication.  In addition, 
studies are on-going to identify novel inflammatory pathways that may lead to 
new therapeutic interventions. 
MicroRNAs (miRs) are a class of post transcriptional regulators that have been 
the subject of intense interest due to their ability to integrate the regulation of 
many pathways in response to environment.  Recently, these molecules have 
also they emerged as useful biomarkers in cancer and cardiovascular field.  As 
miR expression varies between cell types, prior studies have determined the miR 
profile of specific cell subsets, such as regulatory T cells and polarised 
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macrophages [368, 379].  miR expression can be altered by the cellular 
microenvironment.  Thus, the expression of specific miRs can be changed by 
various stimuli of relevance to macrophage activation, such as infection, 
hypoxia, TLR activation and also through maturation signals [301, 380, 381].  
Therefore, it has been hypothesised that miRs play a major role in fine-tuning 
the inflammatory response of a cell by regulating it’s activation, and the 
resultant production of cytokines and chemokines. 
Determining the “normal” miR profile of a cell allows the identification of an 
aberrant miR profile under disease conditions.  Altered miR expression has been 
demonstrated in various cell types in RA, contributing to the molecular 
mechanism of disease.  For instance, miR-155 is up-regulated in RA PBMCs, 
RASFs and CD14+ cells, where in the latter, its targeting of SHIP1, results in over 
production of the pro-inflammatory cytokines, TNFα and IL-6 [318, 320].  These 
data suggest that altered expression of miRs may play a major role in the 
pathogenesis of RA.  Further studies have also identified the potential of miRs to 
be used as biomarkers of response to therapy, such as miR-125b indicating a 
positive response to Rituximab therapy [374].  
To our knowledge there have been no miR profiling studies of monocytes or 
macrophages performed within the RA synovium.  As these cells are a critical 
driving force behind inflammation, and their activation can be regulated by miR, 
a study within this lab generated a distinguished miR profile of RA synovial fluid 
CD14+. Therefore, the aim of this chapter was to verify miR dysregulation in RA 
SF CD14+ cells, and to identify the environmental stimuli that may be 
responsible for the unique miR signature of RA monocyte/macrophages within 
the synovium.  
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3.2 Results 
3.2.1 microRNA dysregulation in the synovial CD14+ 
compartment of RA patients 
To understand the mechanisms regulating activation of a monocyte upon 
entering the synovial compartment from circulation, a recent study within this 
lab group created a differential miR expression profile of RA SF CD14+ cells 
compared with circulating monocyte populations.  This was achieved by 
comparing paired SF samples to PB samples from the same patient.  The 
experimental set up is summarised in Figure 3.1.  PB and SF samples were taken 
from 3 RA patients and CD14+ cells were separated from each donor using 
magnetic bead selection.  Total RNA was extracted from these cells, reverse 
transcribed and the microRNA expression profile was generated using a Taqman 
Low Density Array (TLDA) assay.  This technique allow analysis on a PCR plate 
preloaded with 365 human miR species, allowing the quantification of these 
miRs simultaneously within the same sample, creating a miR expression profile. 
 
Figure 3.1 Experimental setup of RA CD14+ microRNA expression analysis   
CD14+ cells were separated from 3 RA PB and SF samples.  A miR expression profile of these 
cells was then created by TLDA analysis. 
1. 3 x RA Patients
2.SF2.PB
3. CD14+ Selection 
4. TLDA miR analysis
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This study identified a number of miRs that are differentially expressed by 
CD14+ cells that have entered the synovial microenvironment. One of these 
miRs, miR-155 has been studied in depth by my lab group, and its contribution to 
the pathogenesis of RA has been well demonstrated [320].  However, miR-155 is 
not the only miR to show dysregulated expression within RA SF CD14+ cells; 
Table 3.1 shows the fold change of twenty-two miRs that were upregulated by 
more than 1.5 fold in the SF CD14+ compartment of three RA patients, when 
compared with PB CD14+ cells. Based on the results of this array I focused on 
validating the expression of candidate miRNAs that had not been previously 
investigated within the context of RA, shown in red in Table 3.1. 
Table 3.1 The dysregulation of microRNA expression in SF CD14+ cells from RA patients 
compared to matched PB CD14+ cells based on mean fold change between both 
compartments 
 
Data provided from a previous study by Dr Mariola Kurowska-Stolarska at the GBRC 
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For my study, I wanted to investigate miRs which were differentially expressed 
in SF cells, when compared to PB, as this suggests an effect of the synovial 
microenvironment on miR expression.  The previous TLDA analysis (Table 3.1) 
identified miR, which were indeed increased in the synovial miR environment.  
Analysis by Dr Mariola Kurowska-Stolarska at the GBRC compared the fold change 
of expression in SF compared to PB and showed that differences between these 
compartments exist.  I selected miR-125a-5p and miR-99b, because they come 
from the same miR cluster thereby suggesting coordinated expression.  
Additionally, searching the literature surrounding this cluster, it appeared that 
at least miR-125a plays a role in regulating the activation and inflammatory 
response of macrophages.  In addition, I selected miR-511 and miR-642 because 
they were consistently and strongly up-regulated (more than 5 fold) in SF CD14+ 
cells of all 3 donors, and had yet to be described within the context of RA, 
highlighting the novel nature of these observations.  Their expression was 
validated in PB and SF CD14+ cells from six additional RA patients by 
quantitative PCR analysis.  Difference of expression between PB and SF was 
calculated using a relative expression method.  This was calculated by 
subtracting the housekeeping Ct value, from the Ct value of the miR target and 
presented as 2-ΔCt as amount of product doubled with every cycle. Compared 
with CD14+ cells from PB, miR-125a and miR-511 expression were significantly 
increased in SF CD14+ cells from RA patients (p<0.05) (Figure 3.2 D and E), while 
expression of the other miRs investigated were not significantly altered in the 
validation cohort (Fig 3.2 A-C). 
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Figure 3.2 Expression of dysregulated miR in RA SF CD14+ cells 
CD14+ cells were separated from the PB and SF of RA patients. Relative miR expression was 
measured using Taqman qPCR reagents A-C) Expression of miR-99a, miR-642a and miR-642b 
are not significantly altered in SF CD14+ cells D and E) mir-125a and miR-511 expression is 
significantly up-regulated in SF CD14+ cells when compared to PB CD14+ cells.  Values presented 
as mean ± SEM of 6 patient samples and marked bars are statistically different between groups 
using Wilcoxon signed rank test *= p <0.05. 
 
3.2.2 miR-511 is up-regulated in RA CD14+ cells 
miR-511 was found to be the miR with the highest increase in expression in the 
original array analysis and was verified to be upregulated in additional RA 
patient samples.  Based on these data, it was decided to further investigate the 
function of miR-511 in the biology of monocytes and macrophages.  To examine 
the role of miR-511 in these cells, CD14+ cells were isolated as described in 
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section 2.3.1 of materials and methods, and the purity of this population was 
verified. 
3.2.2.1 Purity of CD14+ monocytes 
Both PB and SF monocytes express the CD14 molecule on their surface.  This 
molecule is required for signalling through TLR4 and can also be used as a 
marker for human monocytes.  Therefore these cells can be separated on the 
basis of CD14 expression using magnetic beads.  These beads bind to CD14 on the 
cell surface, and through a process of positive selection allow these cells to be 
specifically sorted.  Purity of the population is confirmed by flow cytometry, 
comparing the percentage of CD14+ cells with an isotype control.  The purity of 
cells was >90% in all experiments tested.  The dot plot in figure 3.3A shows 
gating of live cells based on size and granularity (forward scatter, FSC and side 
scatter, SSC).  Figure 3.3B is representative of CD14+ cells from healthy blood 
samples.  Figure 3.3C shows a representative histogram demonstrating positive 
CD14 expression when compared to an isotype control.   
Thus CD14+ cells purified as defined above were then used for all future 
experiments involving human monocytes and macrophages. 
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Figure 3.3 Purity of CD14+ monocytes 
Purity of CD14+ cells was checked by FACs analysis. A) Live cells were gated on based on FSC 
and SSC.  B) Staining of CD14 was measured on live cells, this is a representative dot plot of 
CD14 expression. C) Representative histogram showing the percentage of CD14+ cells (red) 
separated when compared to and isotype control (blue). 
 
3.2.2.2 miR-511 is expressed at low copy number in healthy monocytes 
and macrophages and is not induced by TLR stimulation 
Previous studies have demonstrated the induction of various miR in response to 
cellular activation, either by infection or environmental signals. These miR can 
then function, to both enhance the inflammatory response, or prevent 
overactive inflammation, by regulating signalling molecules and their inhibitors.  
Pro-inflammatory mediators such as endogenous TLR ligands, including tenascin-
C and fibronectin, that can bind to TLR4, and free nucleic acid that can activate 
TLR3 are also present within the RA joint, where miR-511 is upregulated in 
CD14+ cells [162, 382, 383].  I therefore wanted to investigate the effect of TLR 
stimulation on the expression of miR-511 in healthy monocytes and 
macrophages.  To investigate expression in monocytes, CD14+ cells were 
A. B.
C.
CD14
CD14
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separated from healthy blood, and cultured in 24 well plates, after which cells 
were stimulated with a broad spectrum of TLR ligands for a further 24 hours.  
Total RNA was extracted from these cells to allow transcript levels of miR-511 to 
be determined.  For the initial q-PCR experiments absolute copy number of miR 
was calculated.  This was achieved by engineering miR standards as described in 
the materials and methods section for both miR-511 and Let-7a as a 
housekeeping control.  To be able to perform relative quantification of miR-511, 
we normalized copy number of miR-511 to 10,000 copies of the abundant 
housekeeping control, Let-7a. The baseline copy number of miR-511 is low in 
healthy PB CD14+ cells (3 per 10,000 let7a) and expression does not appear to be 
increased following challenge of these cells with a wide range of TLR ligands 
(Figure 3.4A).   
Along with response to inflammatory mediators, miR expression has also been 
demonstrated to broadly increase during differentiation from monocyte to 
macrophage [368].  Again, growth factors such as M-CSF are present in the 
synovial microenvironment where miR-511 expression is significantly increased 
[384].  Therefore, I wanted to determine if the low copy number of miR-511 
seen in monocytes is increased by culture in M-CSF and differentiation towards a 
macrophage phenotype.  To investigate this, CD14+ cells were separated from 
‘buffy coat’ packs and cultured for 7 days in M-CSF (50 ng/ml), after which RNA 
was extracted and transcript levels of miR-511 were determined by RT-PCR.  
Results demonstrated that copy number of miR-511 is increased during 
macrophage differentiation (Figure 3.4 B).  However this increase did not reach 
statistical significance, and miR-511 continued to be expressed at relatively low 
copy number; there are less than 500 copies per 10,000 Let-7a in these cells.  
Additionally, activation of M-CSF driven macrophages through stimulation with 
TLR ligands (as with monocytes), also does not increase miR-511 expression 
(Figure 3.4 C).   
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Figure 3.4 miR-511 expression in M-CSF differentiated macrophages and TLR stimulated 
monocytes and macrophages  
Copy number of miR-511 was measured in cultured and CD14+ cells stimulated with 100ng/ml 
LPS, 300ng/ml Pam3, 50μg poly I:C and 5μg/ml CL097 using Taqman q-PCR A) Baseline copy 
number of miR-511 in monocytes is low and is not induced by TLR stimulation.  B) Copy number of 
miR-511 increases during M-CSF differentiation, however there are still low numbers present by 
day 7.  C) Copy number of miR-511in macrophages is not affected by stimulation with TLR ligands. 
Values presented as mean ± SEM of 3 healthy donors for stimulation experiments (A & C) and 
mean ± SEM of 4 healthy donors for differentiation experiment.  No significance was detected 
using a Friedman Test. 
3.2.2.3 miR-511 is encoded within the mannose receptor gene   
Due to non-response of miR-511 to pro-inflammatory stimulation, we used 
sequence analysis to examine precisely where the miR-511 is encoded to aid 
identification of potential transcription activators.  We found that miR-511 is 
encoded within the mannose receptor gene (CD206). It is well described that 
miRs encoded within the introns of protein coding genes can be transcribed 
together with the host gene from the same promoter [254].  Expression of CD206 
identifies the M2, or alternatively (anti-inflammatory) activated subset of 
macrophages, and also tumour associated macrophages (TAMs) [385].  This 
suggested that this miR is potentially induced upon alternative activation of the 
cell. Therefore, due to the interest of this study in pro-inflammatory monocytes 
and macrophages, and the apparent low level of expression of miR-511 in these 
cells, it was decided to concentrate further investigation on another family of 
miRs that were upregulated in RA SF CD14+ cells.  Nevertheless future studies 
will be required to follow up the observation and enumerate the copy number in 
RA SF CD14+ cells and RA synovial macrophages. 
3.2.3 miR-125a is up-regulated in SF CD14+ Cells 
In addition to miR-511, two members of the miR-125a cluster were also found to 
be upregulated in the original array analysis (Table 3.1).  Additionally the 
original analysis also identified miR-125b, a homologue of miR-125a, to be 
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upregulated in SF CD14+ cells. Both miR-125a and miR-125b have been shown 
previously to be important in regulating the activation of monocytes and 
macrophages [301, 339].  Accordingly, we decided to concentrate our 
investigation on this family of miRs to elaborate their potential role in 
pathogenesis.  
As we previously demonstrated, not all miRs identified in the initial TLDA 
analysis were verified to be dysregulated in further RA samples.  Therefore, we 
firstly confirmed the original array data with regards to the miR-125 family.   
Peripheral blood and SF CD14+ cells were separated from ten further RA patients, 
and miR expression was analysed by quantitative RT-PCR.  Compared with CD14+ 
cells from PB, miR-125a (p<0.005) and miR-99b (p<0.05), but not Let-7e, were 
significantly upregulated in the SF derived cells (Figure 3.5 A) confirming the 
TLDA expression data (Table 3.1).  The opposite strand of miR-125a, miR-125a-
3p is listed as a conserved miR in its own right, with its own set of specific 
predicted targets.  miR-125a-3p is expressed at low levels in RA SF CD14+ cells 
(Table 3.2), suggesting that miR-125a-5p is the functional strand within these 
cells.  I therefore decided to make my primary investigations into miR-125a-5p. 
(Figure 3.5 B).  Additionally, although upregulated expression of miR-125b was 
detected in SF CD14+ cells, this difference was not significant when compared to 
PB CD14+ cells (Figure 3.5 C) 
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Figure 3.5 Expression of the miR-125 family in RA CD14+ Cells  
Expression of the miR-125a family in CD14+ cells from paired RA PB and SF samples were 
measured by q-PCR A) miR-125a and miR-99b are significantly up-regulated in synovial fluid 
CD14+ cells.  However Let-7e expression is not altered by the synovial microenvironment.  B)  
miR-125a-3p is expressed at low levels in CD14+ cells, and is marginally increased in SF cells C) 
Expression of miR-125b is not significantly increased in SF CD14+ cells.  PB values have been 
normalised to 1, with SF represented as fold change compared to PB.  Values presented as mean 
± SEM of 10 patient samples and marked bars are statistically different from PB using a Paired T 
Test  **= p <0.005  *=p <0.05. 
Next, we thought it was important to examine the relative abundance of the 
expression of the members of this cluster in monocytes. Alternative to the copy 
number test, a simple inspection of q-PCR Ct values can inform the relative 
abundance of the expression of gene of interest. Abundance of the transcript 
decreases with an increasing value of Ct (cycle threshold).  The housekeeping 
RNU6 in these patients’ samples remained relatively stable, allowing a 
comparison of Ct values within these samples.  It is generally accepted that a Ct 
value of 35 represents a single molecule template detection, therefore Ct values 
above 35 are considered ‘noise’ from the system [386]. From this we could see 
that Let-7e is the most abundantly expressed miR in CD14+ cells, and its 
expression is not increased in SF CD14+ cells.  The Ct values also show that 
although both miR-125a and miR-99b are significantly increased in SF CD14+, 
miR-125a appears to be more abundant in these samples when compared to miR-
99b.  Additionally, based on Ct values, we can also speculate that miR-125a is 
expressed at higher levels in both PB and SF CD14+ when compared to it’s 
homologue miR-125b (Table 3.2).  RNU6 levels are included in this table in 
brackets to demonstrate that the housekeeping gene remained relatively stable 
across conditions and allow a comparison between Ct Values. 
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Table 3.2 Average Ct values of miR-125 family members in RA CD14+ cells between PB and 
SF compartments.   
Average Ct Values  
 PB (RNU6) SF (RNU6) 
miR-125a 29.37 (23.44) 
 
27.24 (23.12) 
miR-99b 32.61 (23.25) 
 
29.84 (23.55) 
Let-7e 24.71 (22.22) 24.35  (22.12) 
miR-125a-3p 34.84 (23.44) 34.23 (23.12) 
miR-125b 33.25 (22.22) 31.90 (22.12) 
 Average Ct values of RNU6 are shown in brackets to demonstrate relative stability of the housekeeping 
gene  
Because of this expression pattern we decided to concentrate our investigation 
on both miR-125a and miR-99b as they are expressed in PB CD14+ cells and their 
expression is significantly increased in RA SF CD14+ cells. 
3.2.4 miR-125a is up-regulated in peripheral blood CD14+ cells of 
RA patients who respond well to conventional DMARD 
therapy 
Previous studies have suggested that PB monocytes of RA patients are in an 
abnormal, ‘primed’, pro-inflammatory state before they enter the synovium.  
Therefore, a study was undertaken to determine if the miR profile of PB CD14+ 
was altered as a result of treatment experience and response characteristics in 
patients with RA.  The experimental setup of this study is summarised in Figure 
3.6.   
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Figure 3.6 Experimental setup of PB CD14+ analysis from healthy volunteers, patients 
responding well to cDMARD treatment (Good Responders), and those resistant to biologic 
therapies (Biologic Resistant). 
Patients and healthy control subjects were recruited to this study and classified into groups based 
on their response to different therapies.  From these samples miR and mRNA studies were 
performed on separated CD14+ cells from each group.  Additionally, cytokine analysis was 
performed on the serum of these blood samples 
Patients and healthy control subjects were recruited to the study by Dr Derek 
Baxter, Glasgow Royal Infirmary.  This cross-sectional cohort was recruited 
comprising two groups, namely those who responded well to conventional 
DMARD therapy from the outset and who were therefore judged to be ‘good 
responders’, and those who had failed DMARD therapy but were also proving to 
be resistant to biologic treatment – i.e. those who apparently present a therapy 
resistant phenotype.  These groups were gathered to determine if there was a 
difference in the state of patients, who had distinct clinical response histories 
over time.   Blood samples were taken and CD14+ cells were separated by Miss 
Lynn Stewart of the Glasgow Biomedical Research Centre (GBRC).  RNA was 
extracted from these cells and miR expression was measured by q-PCR.  This 
allowed the generation of a miR profile of RA PB CD14+ cells, from patients 
1.Healthy
3. CD14+ Selection 
2. Good 
Resonders
3. Biologic 
Resistant
1.miR 
analysis
2.mRNA 
analysis
3. Cytokine 
analysis
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under different treatment regimes and with this distinct therapy response 
phenotype. 
As miR-125a and miR-99b were significantly up-regulated in RA SF CD14+ cells, I 
wished to determine if a change in these miRs could also be demonstrated in PB 
CD14+ of RA patients, by carrying out q-PCR on the RNA which had been isolated 
from these RA samples.  Interestingly, the results demonstrated that miR-125a 
expression did not differ between healthy and biologics resistant patients. 
However, its expression was significantly upregulated in the RA good responders 
group, when compared to both healthy controls and biologic resistant patients 
with a p value of p<0.005 (Figure 3.7A). This could suggest a specific activation 
of miR-125a in those RA patients in whom treatments have been successful – this 
could either reflect direct effects of the drugs (methotrexate or sulphasalazine) 
that patients were receiving, or could be an indicator of a disease activity state 
that is low, or even ‘held’ in a state of low activation status.  Expression of miR-
99b did not appear affected by treatment status (Figure 3.7B). 
 
Figure 3.7  miR-125a and miR-99b expression in PB CD14+ cells of RA patients 
miR expression was measured in PB CD14+ cells of 3 different groups of subjects. A) miR-125a is 
upregulated in good responders compared to healthy control and biologic resistant patients B) 
Expression of miR-99b is not altered between groups.  Values presented as mean ± SEM and 
marked bars are statistically different from other groups using Kruskal-Walis H test  **= p <0.005. 
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3.2.4.1 miR-125a expression correlates with clinical measures of 
disease 
As miR-125a is increased in good responders (low disease score, DAS28-CRP 
below 3.0), suggesting a protective role for this miR in response to therapy, we 
wished to investigate if miR-125a expression correlates with clinical variables of 
disease.  Demographic data, as evaluated at the baseline time-point of PB 
collection, from subjects are listed in Table 3.3.  Available data included age, 
disease duration, sex, smoking status, swollen joint count (SJC), tender joint 
count (TJC), simple disease activity index (SDAI), clinical disease activity index 
(CDAI) erythrocyte sedimentation rate (ESR), C-Reactive protein (CRP), disease 
activity score 28-ESR (DAS28) and DAS28-CRP 
Table 3.3 Demographics and disease characteristics of study patients 
  Healthy 
Controls 
Good 
Responders 
Biologic Resistant 
n=15 n=15 n=24 
Age (years) 32-60 (48) 54-81 (63) 36-78 (59) 
Disease duration (months) N/A 78-367 (242) 72-346 (183) 
Female 80% 66% 88% 
Smoking status N/A Current: 21% 
Ex:          21% 
Never:    58% 
Current: 25% 
Ex:          13% 
Never:    62% 
SJC n/a 1.88 11.13 
TJC n/a 1.59 11.20 
SDAI n/a 9.16 35.92 
CDAI n/a 7.92 33.12 
ESR mm/hr. 9.76 22.82 28.96 
CRP mg/dl 0.34 1.24 2.48 
DAS28-ESR n/a 3.23 5.86 
DAS28-CRP n/a 2.98 5.44 
 SJC: swollen joint count, TJC: tender joint count, ESR: erythrocyte sedimentation rate, CRP: C-
reactive protein, DAS28: disease activity score 28 
SDAI, CDAI and DAS 28 values generate a disease score which as a continuous 
variable indicates a level of on-going disease activity (Table 3.4).  We can 
therefore see that based on these scores, good responders appear to be 
experiencing low to moderate disease activity, whereas biologic resistant 
patients are experiencing higher disease activity.  
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Table 3.4 Scoring of disease activity in RA patients 
 SDAI CDAI DAS28 
Score based on SJC, TJC, patient 
questionnaire, 
evaluator 
questionnaire, 
CRP value 
SJC, TJC, patient 
questionnaire, 
evaluator 
questionnaire 
SJC, TJC, patient 
questionnaire, 
either CRP or ESR 
value 
Remission 0-3.3 ≤ 2.8 ≤ 2.6 
Low 3.4-11 >2.8 - ≤10 >2.6-<3.6 
Moderate 11.1 - 26 >10 - ≤ 22 >3.6-<5.1 
High >26 ≥ 22 >5.1 
 
My data demonstrates that miR-125a expression negatively and significantly 
correlates with TJC and SJC of RA patients (Figure 3.8 A and B).  Additionally, 
miR-125a expression negatively and significantly correlates with SDAI, CDAI and 
DAS28 ESR of patients (Figure 3.8 C, D and E).  Although this association would 
suggest a relationship between miR-125a expression and disease activity, a 
correlation was not demonstrated between miR-125a and the indicators of 
inflammation, CRP and ESR (Figure 3.8 F and G). 
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Figure 3.8 miR-125a expression negatively correlates with clinical variables of disease 
A-E) miR-125a expression significantly and negatively correlates with patient SJC, TJC, SDAI, 
CDAI and DAS28 ESR levels F-G) miR-125a does not correlate with either clinical measures of 
disease activity CRP or ESR.   
The R-value and correlation coefficient for miR-125a and clinical variables of 
disease are shown in Table 3.5 
Table 3.5 miR-125a correlates with clinical variables of disease 
Clinical Variable MicroRNA-125a relative expression (Correlation 
coefficient (p value)) 
SJC -0.420   (0.0052) 
TJC -0.425   (0.0056) 
SDAI -0.442   (0.0043) 
CDAI -0.448   (0.003) 
DAS28-ESR -0.409   (0.0079) 
ESR mm/hr -0.038   (0.8162) 
CRP mg/dl -0.034   (0.833) 
 Pearson Coefficient 
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3.2.4.2 miR-125a expression positively correlates with serum IL-10 
expression 
During the study serum samples were also taken from patients, and a Luminex 
assay for cytokine expression was carried out by Miss Lynn Stewart and Dr Donna 
McIntyre, both part of my lab group at the GBRC.  As these foregoing data 
suggested a protective role for miR-125a in CD14+ cells, we wanted to determine 
if cellular miR-125a expression correlates with serum cytokine and chemokine 
levels in RA patients.  I therefore took my own dataset and co-analysed it with 
the cytokine/chemokine dataset provided by my colleagues. 
The results suggest that miR-125a expression positively correlates (weakly but 
nevertheless significantly) with serum levels of the anti-inflammatory cytokine 
IL-10 (R=0.3307, P=0.0213) but did not correlate with other pro-inflammatory 
cytokines such as TNFα and IL-6 (Figure 3.9A).  In addition cellular expression of 
miR-125a did not correlate with soluble pro-inflammatory chemokines such as 
CCL3, CCL4 and CCL5 (Figure 3.9B).    
 
Figure 3.9 miR-125a expression and cytokine and chemokine production from RA PB CD14+ 
cells 
Serum cytokine and chemokine expression was measured using a Luminex assay. A) miR-125a 
positively correlates with IL-10 serum levels.  However miR-125a expression does not correlate 
with other important disease cytokines such as TNFα and IL-6.  Each dot represents miR-125a 
expression versus cytokine expression.  B) miR-125a expression does not correlate with serum 
chemokine expression from RA patients. Each dot represents miR-125a expression versus 
chemokine expression. 
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3.2.5 miR-125a is up-regulated in response to LPS stimulation in 
healthy monocytes 
As miR-125a and miR-99b are upregulated in SF CD14+ cells, I next set out to 
examine the regulation of these miRs, and the cluster member, Let-7e, in 
healthy CD14+ monocytes in order to try to reconstruct the pathway that leads 
to the synovial ‘miR125a phenotype’.  Firstly, I decided to examine the effect of 
TLR stimulation. SF contains many endogenous TLR ligands such as fibronectin 
and Tenascin-C.  In addition, it has been shown that expression of various TLR2 
and TLR4 ligands are upregulated in RA synovium along with their receptors on 
macrophages and other cell lineages [387, 388].   To investigate this, CD14+ cells 
were separated from healthy buffy coat samples and cultured for 24 hours in 
varying concentrations of different TLR ligands.  The expression of the miR-125a 
cluster was then measured by Taqman RT-PCR.  The results demonstrated that 
baseline copy number of miR-125a and miR-99b was similar in monocytes.  
However, copy number of miR-125a alone was significantly upregulated 
(p<0.005) by culture for 24 hours with LPS (100ng/ml) (Figure 3.10A). The 
expression of miR-99b mirrored that of miR-125a, but did not demonstrate 
statistical significance between experimental conditions (Figure 3.10 B).  Let-7e 
appears to be regulated in an alternative manner in activated monocytes.  It is 
expressed at a higher basal copy number and its expression does not appear to 
be altered by stimulation with TLR ligands (Figure 3.10C).  Activation of these 
cells was verified by measurement of the pro-inflammatory cytokine TNFα, 
which is produced by monocytes in response to TLR stimulation.  This was 
measured using an ELISA assay (Figure 3.10D). 
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Figure 3.10 miR-125a cluster expression in TLR stimulated monocytes  
Expression of miRs in human CD14+ monocytes were measured using Taqman q-PCR  A) miR-
125a is significantly up-regulated in monocytes by stimulation with LPS B) miR-99b expression also 
increases after stimulation, but this is not significant.  C) Let-7e expression does not appear to be 
affected by TLR stimulation in monocytes. D) TNFα ELISA demonstrates that cells are activated 
and producing TNFα after TLR stimulation.  Values are represented as copies per 10,000 Let-7a as 
mean ± SEM of 3 healthy donors and marked bars are statistically different from other groups using 
a Freidman Test with Dunn’s multiple comparison test. *p<0.05 
 
3.2.5.1 miR-125a can be up-regulated by culture in synovial fluid 
miR-125a and miR-99b are expressed at low levels in healthy PB CD14+ 
monocytes (Ct values of around 30 for miR-125a and 32 for miR-99b), however  
the miR-125a cluster is upregulated in SF CD14+ cells and also by TLR4 
activation.  I therefore set out to investigate if culture in RA patient derived SF 
itself can cause upregulation of the miR-125a cluster.  Healthy CD14+ cells were 
separated as before, but were cultured overnight in 10% synovial fluid from 5 
different RA patients.  The results demonstrated that culture in SF has differing 
effects on miR expression across different donors.  As previously observed, miR-
125a and miR-99b appear to follow the same expression pattern, with miR-99b 
being expressed at a lower level, when compared to miR-125a.  Their expression 
was increased by RA3 and RA4 SF and not by RA 1 and RA 5 SF, however this 
change in expression did not reach statistical significance and appeared donor 
variable (Figure 3.11 A and B). This suggests that synovial environment is 
capable of inducing miR-125a expression in monocytes. Further studies are 
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required with increase number of donors and SFs.  It would also be important to 
look at a wider time course and range of SFs.  
 
Figure 3.11 miR-125a family expression in CD14+ cells cultured in RA SF 
Culture of cells in 10% RA synovial fluid has the potential to upregulate both A) miR-125a and B) 
miR-99b C) Let-7e expression appears variable in culture with 10% synovial fluid.  Values are 
represented as mean ± SEM of 3 healthy donors cultured in 5 different RA synovial fluids   
Although part of the same cluster, Let-7e does not appear to be regulated in the 
same way as miR-125a and miR-99b.  Its expression is not altered between PB 
and SF CD14+ cells, it does not appear inducible by activation of TLRs in 
monocytes, by culture in SF or differentiation into macrophages.  For these 
reasons I decided to focus on the other members of the miR-125a cluster which 
are inducible by inflammation in the monocyte/macrophage lineage, and are 
overexpressed in RA macrophages.  These miR may prove more relevant in 
regulating of these cells in the pathogenesis of RA. 
3.2.6   miR-125a and miR-99b are up-regulated in response to M-
CSF 
It has been reported that the miR profile of monocytes changes broadly upon 
differentiation to macrophages, reflecting the different biological functions of 
these two cell types. [368]. Macrophage differentiation factor M-CSF is abundant 
in RA SF thus I decided to test whether M-CSF maturation signals affect 
expression of miR-125a and miR-99b [384, 389].  Healthy CD14+ cells were 
separated, as previously described, and differentiated into macrophages by 
culture for 7 days in M-CSF with the media replaced on day 3.  RNA was 
extracted from cells and miR expression was measured by Taqman RT-PCR.  
Copies of miR-125a significantly increased by day 3 in culture with M-CSF and 
although the copy number was lower on day 7 it was still higher than in resting 
monocytes (Figure 3.12 A). Copies of miR-99b also increase by day 3 in culture 
with M-CSF, with this increase becoming significant by day 7, but expression of 
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miR-99b appears up to 10 times lower than that of miR-125a on day 3 (Figure 
3.12 B). These data suggest that both miR-99b and miR-125a may play a role in 
macrophage biology. Particularly high copy number of miR-125a points to 
potential dominant role of this miR in the regulation of the activation of 
macrophages. 
 
Figure 3.12 miR-125a and miR-99b expression in M-CSF macrophages  
CD14+ cells were differentiated towards a macrophage phenotype over 7 days with M-CSF and 
miR expression was measured using Taqman PCR. A) miR-125a expression significantly 
increases by day 3 in culture and remains highly expressed at day 7 B) miR-99b expression 
significantly increases by day 3 and continue to rise by day 7.  Values are represented as copies 
per 10,000 Let-7a of 5 healthy donors as mean ± SEM and marked bars are statistically different 
from other groups using a Friedman multiple comparison test. *p<0.05.  
 
miR-99b is expressed at low levels in resting and activated monocytes but 
increases upon macrophage differentiation indicating that it may be involved in 
activation of these cells.  Previous studies carried out in HSPCs which examine 
this cluster of miR have also demonstrated higher expression of miR-125a 
compared to miR-99b expression, suggesting miR-125a plays a dominant function 
within this cluster of miR.  Published literature on the function of miR-99b alone 
is scarce, and studies appear to concentrate on descriptive, expression level 
investigation.  Concurrent with our data set, which shows significantly increased 
levels of miR-99b in macrophages, validated targets of miR-99b such as mTOR 
and TRAF2 are important in macrophage biology [390, 391].  However, due to 
the higher expression levels of miR-125a, and it’s interesting expression pattern 
in RA PB CD14+ cells, we decided to concentrate the rest of our investigations on 
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this miR, given the time scale of the project.  However further investigations 
will need to be undertaken to examine the role of miR-99b within these cells. 
As cells can be exposed to both M-CSF and GM-CSF within the synovium, with 
potentially important effects on subset generation, or at least some degree of 
functional polarisation, next we wanted to examine the expression levels of miR-
125a after differentiation with GM-CSF [389].  As described previously, CD14+ 
cells were separated from human buffy coat packs and differentiated towards a 
macrophage phenotype using the growth factor GM-CSF, with media changed on 
day 3.  miR-125a expression was measured by q-PCR on day 0, day 3 and day 7.   
3.2.6.1 miR-125a is up-regulated in response to GM-CSF 
-  
Figure 3.13 miR-125a expression in GM-CSF derived macrophages 
CD14+ cells were cultured for the indicated time-points with the growth factor GM-CSF.  
Expression of miR-125a was significantly increased by day 3 in culture.  Values are represented as 
copies per 10,000 Let-7a of 4 healthy donors as mean ± SEM and marked bars are statistically 
different from other groups using a Friedman multiple comparison test. *p<0.05. 
Results demonstrated that as with M-CSF, miR-125a expression is significantly 
increased by day 3 in culture with GM-CSF.   Again, the level of miR-125a 
decreases by day 7 but is still over 5 times higher than levels in monocytes.  Also 
it is clear from miR-125a copy number that expression of miR-125a is up to 10 
times higher in M-CSF derived macrophages than GM-CSF derived macrophages 
(Figure 3.13) suggesting that the biology of this miR may have discrete impact in 
different macrophage lineages. 
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3.2.7 miR-125a expression is not altered in response to TLR 
activation in macrophages 
As previously shown, miR-125a is induced by LPS stimulation in monocytes 
(Figure 3.10 A) and differentiation towards a macrophage phenotype with both 
M-CSF and GM-CSF (Figures 3.12 A and 3.13).  As miR-125a is expressed at its 
highest levels in M-CSF driven macrophages, indicating an important functional 
role in these cells, I wanted to determine if expression can be further regulated 
in response to TLR stimulation.  CD14+ cells were separated, as described 
previously from healthy buffy coat packs, and cultured for 6 days in M-CSF.  On 
day 6 various TLR ligands were added and cells were stimulated for an additional 
24 hours.  For this analysis I decided to determine the fold change in miR-125a 
expression compared to cells alone.  I considered relative expression sufficient 
as I had already demonstrated the high basal copy number of miR-125a in these 
cells (Figure 3.12 A).  Results showed that TLR stimulation did not affect miR-
125a expression in these cells (Figure 3.14 A), suggesting a different functional 
role in macrophages, compared to monocytes.  Activation of cells was verified 
by measuring the amount of TNFα produced by the cells by ELISA.  It appears the 
stimulation was effective as all stimulated samples produced TNFα (Figure 3.14 
B).   
 
Figure 3.14 miR-125a expression in TLR stimulated macrophages 
CD14+ cells were separated from healthy blood and differentiated for 7 days in M-CSF.  After 
which cells were stimulated for 24 hours with varying TLR ligands, and miR-125a expression was 
measured using RT-PCR. A) miR-125a expression in macrophages is not affected by TLR 
stimulation.  B) Cells were activated as demonstrated by TNFα production. Unstimulated is 
normalised to 1 with other conditions being expressed as fold change compared to unstimulated  
Values are presented as mean ± SEM of 3 donors.  Values are not significantly different using a 
Repeated measures ANOVA. 
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3.2.8 miR-125b is regulated in an alternative manner to miR-125a 
in monocytes and macrophages  
miR-125b is a homologue of miR-125a, and although it is expressed on a different 
chromosome, it contains an identical seed region (Figure 3.15).  This identical 
seed region suggests that these two miRs have the potential to regulate the 
same genes.  Reports in the literature have demonstrated that their co-
expression differs depending on cell type and environmental stimuli.  However, 
as miR-125b is present in RA SF CD14+ cells, it was important that we validate its 
expression pattern in monocytes and macrophages to ensure we attribute 
functional effects to the correct miR. 
 
Figure 3.15 The mature miR-125a and miR-125b sequences 
miR-125a and miR-125b have identical seed regions shown in blue, suggesting they may have 
identical targets.  The only nucleotide difference between these miRs are indicated in red. 
 
3.2.8.1 miR-125a RT-PCR assay is specific for miR-125a and does not 
detect miR-125b 
As both miR-125a and miR-125b have an identical seed region, and the whole 
sequence differs in only one nucleotide, it is important that reagents employed 
in my studies were specific for miR-125a.  To analyse miR-125a expression I 
performed q-PCR using two different systems, Taqman, and SYBR green 
technology.  Taqman q-PCR was useful for samples from which the RNA yield was 
low as it required minimal RNA amounts (1-10 ng per sample).  According to the 
manufacturers, this technology is also highly specific and can distinguish 
between highly homologous sequences, with only a single nucleotide mismatch.  
However as this technology is expensive, I also used SYBR green technology.  
Therefore, I wanted to ensure that miR-125a PCR primers would not detect miR-
125b within samples and vice versa. 
I designed an experiment to test the specificity of the miR-125a SYBR green 
primers.  miR-125a and miR-125b mimics were denatured and a standard curve 
Mature miR-125a UCCCUGAGACCCUUUAACCUGUGA
Mature miR-125b UCCCUGAGACCCUAACUUGUGA
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of known amounts of microRNA was generated, and  replicated to a cDNA 
template (as with PCR standards described in materials and methods).  A q-PCR 
reaction was then performed using this standard curve with miR-125a SYBR green 
primers.  This was to determine if miR-125a primers could amplify miR-125b 
cDNA within a sample.  Table 3.6 shows that miR-125a primers can amplify cDNA 
from a miR-125a standard from around 105 copies and above.  However, these 
primers cannot detect miR-125b expression at the same level, for example, 
instead of detecting 109 copies at cycle 13, it is detected at cycle 30.  The miR-
125a assay cannot detect miR-125b at less than 107 copies.  This demonstrates 
that miR-125a SYBR primers can be used to confidently detect miR-125a 
expression within macrophages without detecting miR-125b.   
Table 3.6 miR-125a SYBR green assay specificity 
miR-125a RT-PCR Primers 
Copy Number of 
miR standard 
miR-125a cDNA 
(Avg Ct Value) 
miR-125b cDNA 
(Avg Ct Value) 
109 13 30 
108 19 34 
107 25 36 
106 29 Undetermined 
105 32 Undetermined 
Standards of miR-125a and miR-125b were generated.  A q-PCR assay was then performed with 
miR-125a SYBR green primers to determine if these primers would amplify miR-125b cDNA from 
the generated standard.  This assay amplifies miR-125a cDNA from 10
5 
copies and above, 
whereas it does not detect miR-125b expression at less than 10
7
 copies, demonstrating the 
specificity of the primers for only miR-125a. 
 
3.2.8.2 miR-125b is regulated in an alternative manner to miR-125a in 
monocytes and macrophages 
Next, I wanted to investigate whether miR-125b is regulated in the same way as 
miR-125a in human monocytes. As before, healthy CD14+ cells were separated 
and cultured for 24 hours in various TLR ligands, after which miR-125b 
expression was measured by RT-PCR.  Results showed that miR-125b is 
downregulated in monocytes after stimulation with LPS, Poly I:C and CLO97, 
although this difference reached significance only after LPS stimulation (Figure 
3.17 A).  Additionally, unlike miR-125a, miR-125b expression also does not 
appear to be inducible by differentiation from monocyte to macrophage with M-
CSF, or by stimulation with TLR ligands in these differentiated cells.  
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Figure 3.16 miR-125b expression in monocytes and macrophages 
A) miR-125b expression is significantly downregulated by LPS stimulation in human monocytes.  B) 
miR-125a expression is not increased during M-CSF driven differentiation C) miR-125b increases 
across GM-CSF differentiation D) miR-125b expression is not altered by TLR activation in human 
macrophages.  Values are represented as mean ± SEM of A) 3 and B and C) 4 healthy donors and 
marked bars are statistically different from other groups using repeated measures one- way 
ANOVA and Tukeys multiple comparison test. *p<0.05. 
These data demonstrate that miR-125a and miR-125b are regulated differently in 
monocyte and macrophages suggesting a different function for these miR within 
these cell types.  Levels of miR-125b were not measured using copy number and 
instead a fold change calculation was demonstrated.  Therefore we cannot 
directly compare expression levels of miR-125a and miR-125b within these cells.  
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3.3 Discussion 
I am interested in the understanding of the regulation of RA macrophage 
activation. My laboratory showed that RA synovial monocytes potentially possess 
a unique microRNA profile that could in turn shed light on the pathogenic 
mechanisms operating therein. The aim of this chapter was to identify and 
validate miRs that were dysregulated in synovial CD14+ cells when compared to 
PB CD14+ cells.  As these samples were matched, the expression profile 
identified alterations in miR expression likely caused by exposure to the synovial 
microenvironment.   
Firstly, we identified miR-511 as being highly upregulated in SF CD14+ cells. 
However, miR-511 was expressed at low copy number in both healthy monocytes 
and M-CSF differentiated macrophages, and did not appear inducible by 
inflammatory stimuli.  These data contradict a previous study by Tserel et al, 
which suggests that miR-511 is highly upregulated in response to TLR4 
stimulation in macrophages [392].  However, in this study, CD14+ cells were 
differentiated towards a macrophage phenotype using the GM-CSF growth factor 
as opposed to M-CSF.  Additionally, the concentration of LPS used for 
stimulation, 1µg/ml, was 10 times higher than the 100ng/ml used in present 
experiments.  These differences in experimental set-up, may account for the 
differences witnessed between results.  
We identified miR-511 as an intronic miR, encoded within the mannose receptor 
gene (Figure 3.18).  Intronic miRs can be transcribed either from their host 
gene, or by an independent promoter.  A study by Squadrito et al, demonstrates 
that miR-511 is transcriptionally co-regulated along with the CD206 gene.  Up-
regulation of CD206 will therefore be accompanied by an increase in the 
expression of miR-511 and vice versa.  This study also suggested that 
overexpression of miR-511, does not alter the pro-inflammatory response of 
macrophages, and suggests that the activity of miR-511 is specific to TAMs [385].      
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Figure 3.17 miR-511 location within the genome 
A screenshot from the ensembl database demonstrates that miR-511 is an intronic miR encoded 
within the CD206 gene 
 
This tightly controlled expression pattern may explain the low copy number of 
miR-511 witnessed in both resting and activated macrophages in the present 
study.  As TLR 4 activation is also a method of inducing M1 macrophages, which 
do not express CD206, this could also account for low levels of miR-511.  Thus, 
although we observed a substantial increase in fold change expression of miR-
511 in RA CD14+ cells, this was associated with low absolute copy number in 
both monocytes and macrophages when I explored expression ex vivo.  
Therefore, we decided to no longer investigate miR-511 in the context of pro-
inflammatory RA macrophage activation.  However, it may prove important in 
the future to determine the consequence of the high level of upregulation of this 
miR.  It is possible that this miR is highly upregulated in CD206+ macrophages 
within the synovium, which function to repair damage.  A novel diagnosis 
technique for RA has recently been proposed by the company Navidea, in which 
a labelled CD206 compound (manocept) can identify a population of CD206 
macrophages in early RA affected joints, which are not present in unaffected 
joints (source: Navidea website).  Therefore this population of macrophages may 
prove important in future studies and expression of miR-511 should be explored, 
particularly in early RA biopsies. 
Next, I turned my attention to the miR-125a cluster, of which 2 members, miR-
125a and miR-99b are significantly increased within SF CD14+ cells.  miR-125a, 
miR-99b and Let-7e form a miR cluster located on human chromosome 19.  The 
close proximity of these miRs suggests that there is a single promoter for this 
cluster, and that all members should be expressed under the same conditions.  
However, from my own, and other studies, it does not appear that these miRs 
are regulated in the same manner [393, 394].  Only miR-125a and miR-99b are 
significantly increased in RA SF CD14+ cells and expression of miR-99b appears to 
mirror that of miR-125a, albeit at lower levels.  Both miR-125a and 99b are 
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inducible by LPS, culture in RA derived SF, and expressed at high levels in 
macrophages, although miR-125a is up to 10 times higher when the two are 
compared.  Considerably higher levels of miR-125a in SF CD14+ cells, and human 
macrophages suggest that during its biogenesis, it undergoes alternative 
methods of regulation that allow it to accumulate at higher levels than other 
members of the cluster, such as higher transcript stability and reduced decay.  
We can therefore hypothesise that miR-125a can be independently, or 
preferentially expressed under certain conditions and in certain cell types, 
including macrophages.  Moreover, we can hypothesise from expression values 
that miR-125a is the dominant miR in this cluster, and previous studies have also 
suggested that miR-125a is solely responsible for the function of this cluster, at 
least with respect to stem cell differentiation.  Overexpression of miR-125a 
alone in these cells is enough to cause haematopoietic expansion [395].  
We therefore decided to concentrate continued investigation on miR-125a.  My 
first key observation is that miR-125a is expressed in, and upregulated in PB 
CD14+ cells of RA patients who respond well to cDMARD therapy.  Expression of 
miR-125a in these cells negatively correlates with RA disease activity scores, 
DAS28 ESR, SDAI and CDAI, along with the number of tender and swollen joints, 
hinting at protective role for this miR in these cells.  Additionally miR-125a 
cellular expression positively correlates with serum levels of anti-inflammatory 
IL-10, again suggesting a positive role for this miR in the circulation, in terms of 
primed circulating monocytes, and potentially thereafter at sites of 
inflammation.  These data suggest that detection of miR-125a in PB CD14+ cells 
could be used to identify response to DMARD therapy, in line with a recent study 
by Murata et al that has also suggested that serum levels of miR-125a may be 
used as a biomarker for diagnosis of RA [396].  Therefore it may be important to 
examine miR-125a expression in PB cells of other diseases with an inflammatory 
component, such as OA and SLE, where in the latter, downregulation of miR-
125a has already been detected in CD4+ T cells [343] 
An increase in miR-125a expression in LPS stimulated monocytes, and healthy 
cells cultured in SF suggests that exposure to inflammatory stimuli may induce 
miR-125a expression.  It has been previously shown, in a study by Bazzoni et al, 
that miR-125a is LPS inducible in monocytes [301].  Additionally, a study by Monk 
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et al demonstrated up-regulation of miR-125a-3p, after exposure to LPS in 
murine BMDMs, demonstrating the difference between human and murine 
myeloid cells [365]. Personal communication from the Loctati group suggests 
that miR-125a-3p is indeed the active strand in murine macrophages, whilst 5p is 
the active strand in human cells.  To further elucidate the role played by SF in 
increasing miR-125a expression, it would be important in the future to increase 
the amount of donors in this experiment.  Additionally the components of the SF 
should be phenotyped for example through Luminex, to identify factors that may 
cause upregulation.  We have shown that miR-125a is upregulated in response to 
both LPS, and the growth factors M-CSF and GM-CSF, which are present in SF.  
However we cannot say for certain that these factors are present in our cultures 
without phenotyping the SF.  In addition, miR-125a expression could also be 
investigated after culture in other SF, such as from OA patients to determine if 
this is a RA specific association.   
Extremely high copy number of miR-125a in M-CSF macrophages suggests that 
this miR may play an important role within these cells.  Expression of miR-125a 
is lower in GM-CSF derived macrophages, in line with a study by Banerjee et al 
which also showed higher levels of miR-125a in M-CSF v GM-CSF derived 
macrophages [339].  Unlike monocytes, miR-125a is not further inducible in 
macrophages stimulated with LPS, suggesting an alternative role for this miR 
between these cells, reflecting the differing functions of monocytes and 
macrophages.   
miR-125b, a homologue of miR-125a is expressed as 2 identical forms on 
chromosome 11 and chromosome 21, in clusters with Let-7 and miR99 family 
members.  This miR is also expressed in RA PB and SF CD14+ cells, where its 
expression is increased, but not significantly.  Both miR-125a and miR-125b have 
identical seed regions, and therefore can potentially target the same mRNAs.  
However, it has been previously suggested that miR-125b is regulated in an 
alternative way to miR-125a, at least in monocytes.  Our results showed that 
miR-125b, is downregulated by LPS stimulation, and not induced during M-CSF 
differentiation.   Examining the Ct values would suggest that miR-125b is 
expressed at lower levels than miR-125a in macrophages, and that although miR-
125b has been more deeply studied, that miR-125a may play a more important 
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role within these cells.  To say for certain, it would be important in the future to 
determine copy number of the miR-125 family with SF CD14+ cells.  This would 
allow comparison between family members, and therefore allow us to speculate 
of the physiological importance, or dominance of each of these miRs.  In 
addition, it would be important to calculate copy number of miR-125b in both 
monocytes and macrophages, again to allow a comparison with miR-125a and to 
demonstrate which miR is more abundant, and potentially more physiologically 
relevant in these cells. 
In summary, we found that miR-125a is strongly upregulated in RA SF monocytes, 
thus at sites of inflammation and in PB monocytes of patients responding well to 
therapy (low disease score). Investigating the mechanisms responsible for its up-
regulation we identified TLR4 stimulation and M-CSF as potential factors 
increasing miR-125a expression.  The next part of this study will focus on the 
functional consequence of manipulation of miR-125a expression in macrophages 
and the pathways which are under the regulation of this miR. Based on the data 
obtained in this chapter showing that miR-125a in PB CD14+ cells negatively 
correlates with SJC, TJC and DAS28, whilst positively with IL-10 gives a hint 
towards protective function of miR-125a and suggests that its high-expression at 
site of inflammation could be a part of a counterbalance mechanism. This I will 
test formally in the following chapters.  
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 Chapter 4- Investigating miR-125a function   
4.1 Introduction and aims 
The previous chapter has demonstrated the dysregulation of miR-125a in both PB 
and SF CD14+ cells of RA patients, along with its upregulation by inflammatory 
mediators and growth factors.  In this chapter, I will focus on the functional 
consequences of miR-125a dysregulation on in-vitro cytokine production by 
monocytes and macrophages.  This will be investigated using a stably expressed 
miR-125a sponge transgene, and gain and loss of function experiments in human 
macrophages.   
The role of miRs in ‘fine tuning’ gene expression has led to extensive 
investigation of dysregulated expression patterns in disease states, including the 
majority of cancers, cardiovascular and rheumatic diseases [397-399].  Sequence 
analysis suggests that there are around 2,500 miRs in the human genome, and as 
each miR has the potential to regulate many mRNAs, specific functions in 
different cellular and environmental contexts are only beginning to be 
discovered  [400].  Compared to the number of computationally predicted miR 
targets, relatively few interactions have been experimentally validated.  The 
majority of in-vitro studies to date have relied on gain and loss of function 
experiments, through the transfection of double stranded miR mimics and 
antisense inhibitors to investigate the role played by miRs in specific cell types.  
Problems associated with gain of function experiments have been acknowledged, 
such as the unwanted activation of the interferon response, saturation of the 
RISC complex, due to supra-physiological concentrations of mimic, and the 
inhibition of non-physiological targets [401-403].  Under loss of function 
conditions, effect on target mRNAs is witnessed by inhibition of a physiological 
concentration of miR.  Therefore the endogenous function within a cell at a 
given time can be investigated.  There are 3 generally accepted methods to 
study loss of miR function; through the generation of gene knockouts, 
transfection of antisense inhibitors and the use of transgene encoded miRNA 
sponges.  Generating gene knockouts is a difficult, time consuming and costly 
procedure, which may not result in an obvious phenotype, due to a redundancy 
in function of closely related miRs, the fact that gene knock outs remove both 
5p and 3p miR strands, and a lack of conservation between the species. The 
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latter seems to be a case for miR-125a as human cells predominantly use miR-
125a-5p strain while in mouse antisense miR-125-3p is used.   Therefore, due to 
cost and difficulty, other options of inhibition are usually undertaken first.  
Transfection of cells with miR inhibitors, although transient, can be informative.  
However, transfection reagents are expensive and their use is complicated by 
toxicity unless concentration and time-course conditions are optimised.  In 
addition, certain cells can be difficult to transfect, limiting cell types which can 
be investigated.  Currently, creation of miR sponges, expressed from stably 
integrated transgenes appears to be the most effective method to study loss of 
specific miRs within cells.  miR sponges are transcripts expressed under the 
control of a strong promoter which contain tandem binding sites complementary 
to the target miRNA sequence.  These transcripts effectively sequester miRs, 
preventing miR binding of target genes, and creating an environment effectively 
null for the sequestered miRNAs [404].   miR sponges can be stably inserted into 
the genome of cell lines to create ongoing miR inhibition, allowing long term 
experiments to be performed.  
One of the most common applications of stably expressed sponge transgenes is 
to use these cells to mimic the down regulation, or reverse the up-regulation of 
miRs observed in various disease states.  An example of this is a study by 
Valastyan et al, which identified miR-31 as an important regulator of breast 
cancer metastasis.  The authors identified the downregulation of miR-31 in 
aggressive metastasising tumours, and so generated a stably expressing miR-31 
sponge breast cancer cell line, to mimic this environment.  These miR-31 null 
cells were injected into mice and formed macroscopic metastases in the lungs, 
indicating that miR-31 plays a role in controlling breast cancer metastasis [405].  
Macrophages are key players in the pathogenesis of RA through the production of 
pro-inflammatory cytokines such as TNFα and IL-6, and chemokines, such as 
CCL2, CCL3 and CCL4 within the inflamed synovium.  It is thought that they can 
be activated by pro-inflammatory mediators released by damaged joint tissue, 
and dead cells within the joint, resulting in the activation of TLRs and other 
receptors.  Therefore, pathways which control the activation of these cells are 
tightly regulated during normal homeostasis, to prevent an overwhelming 
inflammatory response.  During RA this normal immune homeostasis is disturbed, 
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and the reason for this altered immune response are the subject of many 
investigations.   It is well documented that miRs play a role in the response to 
infection and can regulate the production of pro-inflammatory cytokines and 
chemokines by macrophages.  For example, LPS induced upregulation of miR-132 
can cause the downregulation of TNFα production through targeting the 
signalling molecule TRAF4 [320, 406]. 
We therefore hypothesised that the dysregulation of miR-125a seen in RA CD14+ 
cells would alter their function, resulting in a difference in cytokine and 
chemokine production.  We therefore wanted to determine the role of miR-125a 
in monocytes and macrophages in resting state, and in response to activation by 
a TLR4 ligand. 
Chapter Objectives 
 Design, generate, and validate a miR-125a sponge vector which can be 
stably inserted into the genome of THP-1 cells 
 Determine the effect of a miR-125a null environment on cytokine and 
chemokine production in response to LPS by THP-1 derived macrophages  
 Determine the effect of gain and loss of miR-125a on cytokine and 
chemokine production in response to LPS by human primary macrophages 
4.2 Results 
4.2.1 Investigating miR-125a function using a miR Sponge 
miR sponges are important tools that can be designed and generated to 
investigate the long term inhibition of miRs, within specific cell types.  We 
designed a miR-125a sponge to investigate the role played by this miR in 
response to TLR4 activation, in both monocytes and macrophages.  The sponge 
vector was designed, generated and stably transfected into THP-1 cells, that 
could then be used to investigate the response of macrophages to inflammation.  
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4.2.1.1 miR-125a regulation in THP-1 cells 
We decided to use the monocytic THP-1 cell line in which to stably express the 
miR-125a sponge vector.  THP-1 cells are monocytic in origin, and importantly 
retain the ability to differentiate into cells with a robust macrophage-like 
phenotype, and as such are a well-characterised cell line commonly used as a 
surrogate to investigate the function of human monocyte and macrophages in-
vitro.   
Firstly, to ensure THP-1 cells were an appropriate choice for miR-125a sponge 
expression, we determined the expression and regulation of miR-125a within 
these cells. We wanted to examine the expression of miR-125a in response to 
TLR activation, and determine if regulation in THP-1 cells mirrored that of 
primary human monocytes.  Cells were plated and stimulated with LPS 
(100ng/ml), Pam3 (300ng/ml) and Poly I:C (50μg/ml) for 24 hours. Afterwards 
expression of miR-125a was measured by q-PCR (Figure 4.1). 
 
Figure 4.1 miR-125a expression in stimulated THP-1 Cells 
THP-1 cells were stimulated with 100 ng/ml LPS, 300 ng/ml Pam3 and 50 µg/ml Poly I:C for 24 
hours and miR-125a expression was measured by SYBR green q-PCR.  miR-125a expression is 
significantly increased by stimulation with LPS, but not Pam3 or Poly I:C.  Cells alone 
(Unstimulated) was normalised to 1, and all other conditions are expressed as a fold change 
compared to it.  Values presented as mean ± SEM of 3 separate experiments and marked bars are 
statistically different from cells alone using a paired T-test *=p <0.05.  
  
We observed that miR-125a expression in THP-1 cells mirrors that of primary 
human monocytes (Figure 3.10).  Basal expression is low, as determined by the 
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PCR Ct value.  Expression is significantly induced by LPS, but not Pam3 or Poly 
I:C stimulation (Figure 4.1).  
Next, we wanted to determine if miR-125a expression was induced in THP-1 cells 
by differentiation towards a ‘macrophage’ phenotype with phorbol myristate 
acetate (PMA).  PMA is a well-established differentiation agent, however the 
optimum concentration of PMA required to differentiate THP-1 cells has been 
the source of debate.  High concentrations of PMA induce cell activation, 
resulting in the production of TNFα and other inflammatory cytokines.  
Therefore, we sought to optimise the concentration of PMA required to induce 
differentiation, and expression of miR-125a, while keeping TNFα production low.  
We were guided by a study by Park et al, which suggested 5 ng/ml of PMA was 
sufficient to induce differentiation of THP-1 cells towards an adherent 
phenotype, without causing undesirable gene up-regulation [407].  To test this 
experimentally, THP-1 cells were differentiated for 7 days with various 
concentrations of PMA ranging from 5 ng/ml-100 ng/ml. Cells were then left 
unstimulated, or stimulated with 10 ng/ml of LPS.  TNFα expression was 
measured in these cells using an ELISA assay, and miR-125a expression was 
measured in resting cells by q-PCR. In resting cells, differentiation with 5 ng/ml 
PMA was enough to induce adherence and differentiation, while keeping low 
amounts of TNFα production. Cells differentiated under all concentrations of 
PMA are capable of responding to LPS by producing an increase amount of TNFα 
(Figure 4.2A).   
Levels of TNFα were not measured in a control which had not been treated with 
PMA as I wanted to compare TNFα production of cells which had been cultured 
for 7 days in PMA. 
To evaluate whether PMA induced THP-1 to macrophage differentiation mirrors   
M-CSF driven primary monocyte to macrophage differentiation in terms of miR-
125a expression, we looked at miR-125a expression at day 0 (monocyte), day 3 
and 7 upon culture with PMA. Expression of miR-125a increases around 10 fold by 
day 3 and is further increased by day 7, with levels of miR-125a being similar 
across different PMA concentration (Figure 4.2B).   
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Figure 4.2 TNFα and miR-125a expression in PMA differentiated THP-1 cells. 
THP-1 cells were differentiated using differing concentrations of PMA.  TNFα expression in these 
cells was measured by ELISA and miR-125a expression was measured by q-PCR.  A) 
Differentiation with 5 ng/ml induces the lowest amount of TNFα production from resting cells.  
Despite this, these cells produce similar amounts of TNFα when stimulated with10 ng/ml of LPS.  
B) miR-125a expression is increased by culture with PMA across a 7 day time period.  The up-
regulation of miR-125a is similar under all concentrations of PMA.  Values presented as mean ± 
SEM of 2 separate experiments. 
 
We concluded from these data that THP-1 cells are suitable to study the function 
of miR-125a in macrophages, as its expression in these cells appears to mirror 
that of primary human monocytes and macrophages.  In addition, we have 
concluded that 5 ng/ml PMA is sufficient to differentiate THP-1 towards 
macrophage-like phenotype cells without activating them.  Therefore cells will 
be cultured at this concentration in future experiments.      
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4.2.1.2 Generation of miR-125 sponge 
The miR-125a sponge was constructed by inserting tandem miR-125a binding 
sites downstream of a luciferase reporter gene driven by a phosphoglycerate 
kinase (PGK) promoter (Figure 4.3A).  The vector used for these experiments was 
a modified version of the pmirGLO vector used for luciferase reporter assays as 
described in section 2.5 of Materials and Methods. 
I was aided in the sponge design by Dr Derek Gilchrist of the GBRC.  The miR-
125a sponge is a reverse complementary nucleotide sequence to the full length 
mature miR-125a sequence.  To design the sponge, firstly, the sense strand of 
the mature miR was taken and the seed region identified (Figure 4.3B). A 
nucleotide sequence perfectly complementary to this region was then designed 
and inserted 7 times to introduce 7 tandem miR-125a binding sites.  This 
sequence is underlined in Figure 4.3C.  Three random nucleotides were inserted 
immediately downstream of the seed region. This “bulged” binding site has been 
proven to increase the efficacy of miR sponge sequences.  It has been 
demonstrated that perfectly complementary miR target sequences can trigger 
mRNA degradation, mediated by the RISC complex.  Gentner et al have shown 
that “bulged” binding sites within a miR sponge design are more effective and 
can mimic natural miR regulation of targets via the sequestration rather than 
degradation of sponge transcripts, preventing miR recycling [408].  These regions 
are highlighted in blue in Figure 4.3C.  Next, random spacer regions were 
designed to link the tandem repeats.  These spacers allowed the binding of the 
maximum amount of RISC complexes to the miR sponge.  
To allow directional cloning, restriction sites were added at the 5’ and 3’ ends 
of the sequence (Figure 4.3C). 
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Figure 4.3 Schematic and sequence of miR-125a Sponge 
A) Basic schematic showing the location of the 7 miR-125a binding sites downstream of a 
luciferase gene driven by a PGK promotor. B) Mature miR-125a sequence with the seed region 
underlined and highlighted.  C) Sequence of miR-125a sponge insert showing regions 
complementary to the mature miR-125a sequence highlighted in grey.  The complementary seed 
region, important for binding miR-125a is underlined.  Each seed region is separated from the rest 
of the sequence by a bulge region, highlighted in blue.  This is inserted to ensure binding of 
maximum RISC complexes.  Each section of 7 complementary sequences is separated by linker 
sequences.  The PmeI, BamHI, XhoI and SalI restriction sites used for cloning are also indicated. 
 
To generate the miR-125a sponge, the DNA sequence described above was 
ordered and resuspended in water.  This sequence was then cloned into the 
vector pCR2.1-TOPO, creating the vector pCR2.1-miR125a-SpX7. The sponge 
sequence was then excised from this vector as a PmeI/SalI fragment and cloned 
into the PmeI/XhoI sites of pmiRGLO, creating the final vector: pmiRGLO-
miR125a a functional miR-125a sponge vector containing 7 miR-125a MREs (miR-
125a-SpX7) (Figure 4.4).   
A.
PGK Luciferase Renilla
miR-125a MREs
Mature miR-125a         5’- UCCCUGAGACCCUUUAACCUGUGA -3’
Seed Region
agtttaaacggatcc ctcgag
tcacaggttaaactgctcaggga -tagc- tcacaggttaaacagctcaggga –cgag-
tcacaggttaaaatgctcaggga –gcta-tcacaggttaaaatcctcaggga –atct-
tcacaggttaaactgctcaggga –gatc-tcacaggttaaaatgctcaggga –aagt-
tcacaggttaaacagctcaggga gtcgac
SalI
PmeI     BamHI XhoI
B.
C.
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Figure 4.4 Generation of single miR-125a Sponge 
1.  The miR-125a sponge insert was resuspended in water, ligated into the subcloning vector pCR 
2.1 and transformed into competent E. coli.  2. The miR-125a insert was excised from pCR 2.1-
miR125a-SpX7 using PmeI and SalI restriction enzymes, as these sites had been inserted at either 
end of the construct.  3. pmirGLO vector was digested with the enzymes PmeI and XhoI, creating 
complementary sites for ligation of the miR-125a sponge insert. 4. The miR-125a sponge insert 
was ligated downstream of the luciferase gene of the pmirGLO vector creating a functional miR-
125a sponge vector.    
   
We hypothesised that a sponge transgene containing more miR-125a binding sites 
would increase the efficiency of inhibition; therefore we generated a sponge 
vector with 14 miR-125a binding sites.  To do this we went back to pCR 2.1-
miR125a-SpX7 vector and inserted an additional copy of the miR125a sponge 
sequence doubling the number of potential miR-125a binding sites. The resulting 
miR-125a sponge sequences contained 14 miR-125a sites, this was subsequently 
inserted as a PmeI/SalI fragment into the PmeI/XhoI sites of pmiRGLO, creating 
pmiRGLO-miR-125a-SpX14. (Figure 4.5).  
agtttaaacggatccctcgag
Tcacaggttaaactgctcaggga -tagc- tcacaggttaaacagctcaggga –cgag-
Tcacaggttaaaatgctcaggga –gcta-tcacaggttaaaatcctcaggga –atct-
Tcacaggttaaactgctcaggga –gatc-tcacaggttaaaatgctcaggga –aagt-
Tcacaggttaaacagctcaggga gtcgac
SalI
PmeI     BamHI XhoI
PmeI     SalI PmeI   XhoI
1.
2.
Sponge Insert
Pme I   XhoI
3.
Linearised vector
PGK Luciferase Renilla
miR-125a MREs
4.
  143 
 
 
Figure 4.5 Generation of miR-125a double sponge 
The double miR-125a sponge was generated by linearising the single sponge in PCR 2.1 with 
PmeI and XhoI enzymes, while the insert was also cut out using the PmeI and SalI enzymes.  The 
insert was then re-ligated in the PCR 2.1 vector and grown in competent cells.  PCR 2.1 DNA was 
then cut with PmeI and SalI enzymes to cut out the double insert which can then be ligated into 
complementary sites in the pmirGLO vector. 
  
4.2.1.3 Efficacy of miR-125 sponge 
After the generation of both sponge vectors we tested their activity to ensure 
they could bind miR-125a successfully, and also to determine which construct 
had the most significant effect. We used a luciferase reporter assay.   HEK293 
cells were co-transfected with either miR-125a-SpX7 or miR-125a-SpX14 vectors, 
and either a control mimic (Cm) or miR-125a mimic (125am), and cultured for 24 
hours. Binding of miR-125a to the complementary repeats within the sponge 
vector will cause a knockdown of luciferase activity, which can be measured by 
PmeI   XhoI
+
PmeI     SalI
Vector + Insert Insert
Ligation
PmeI     SalI
Double Sponge
Pme I   XhoI
PGK Luciferase Renilla
miR-125a MREs
  144 
 
a luminometre.  Knockdown by the miR-125a mimic is compared to luciferase 
expression after transfection with the Cm, which will be treated as 100% 
luciferase activity. 
The results showed a significant knockdown of luciferase activity in conditions.  
However, the miR-125a-SpX714 expressed the highest knockdown of luciferase 
activity (Figure 4.6).  
 
Figure 4.6 Test of miR-125a sponge construct in pmirGLO vector 
HEK293 cells were co-transfected with either a Cm or 125am and a miR-125a sponge plasmid (X7 
or X14 construct), then cultured for 24 hours.  Luciferase activity after transfection was measured 
and normalised to Renilla expression.  A) Transfection of a 125am results in a significant decrease 
in luciferase activity when compared to a Cm using the single sponge construct  B) Transfection of 
125am results in a significant decrease in luciferase activity when compared to a Cm using the 
double sponge construct. Values presented as mean ± SEM of 5 separate experiments and 
marked bars are statistically different from Cm using a paired T-test ***=p <0.0005 
 
As knockdown of luciferase activity was higher with the miR-125a-SpX14 
construct, stable transfection and subsequent assays will be performed with this 
vector. 
4.2.1.4 Generation of Stable THP-1 Cell line 
To enable the investigation of miR-125a in THP-1 derived macrophages, we 
generated a THP-1 cell line which stably expressed the miR-125a sponge. 
Plasmid DNA was linearised using AseI enzyme; DNA was then precipitated and 
introduced into THP-1 cells by electroporation (Figure 4.7A).  Alongside this 
another flask of THP-1 cells was transfected with the parental pmiRGLO vector 
the resulting cells were named Reporter Control cells. Cells were selected for 
A. B.
C
m
1
2
5
a
m
0
5 0
1 0 0
L
u
c
if
e
r
a
s
e
 A
c
ti
v
it
y
 %
 * * *
m iR -1 2 5 a -S p X 7
C
m
1
2
5
a
m
0
5 0
1 0 0
***
L
u
c
if
e
r
a
s
e
 A
c
ti
v
it
y
 %
m iR -1 2 5 a -S p X 1 4
  145 
 
resistance to the antibiotic G418, as expression of the vector confers resistance 
to this antibiotic.   
Stably transfected cells were tested for the transgene expression.  Both reporter 
control and miR-125a sponge expressing cells were plated and transfected, with 
either a Cm, 125am or a miR-125b mimic (125bm).  Cells were then cultured for 
either 24 or 48 hours, after which luciferase activity was measured.  The sponge 
vector should also bind miR-125b as it has an identical seed region to miR-125a, 
and so luciferase activity should also be decreased in these samples.    
There was luciferase expression in all conditions, which demonstrates the 
presence of both the reporter control vector and miR-125a sponge vector within 
these cells. After 24 hours culture, there was no change in luciferase activity in 
transfected reporter control cells, but there was a significant decrease in 
luciferase activity in miR-125a sponge cells which had been transfected with a 
125am, compared to a Cm (Figure 4.7B).  After 48 hours culture, again, there 
was no change in luciferase activity in transfected reporter control cells, but 
there was a significant knock down of luciferase activity in miR-125a sponge 
cells which had been transfected with both a 125am and 125bm, compared to a 
Cm (Figure 4.7C).  The knockdown of luciferase activity in cells expressing the 
miR-125a sponge, but not the reporter control vector, demonstrates that the 
miR-125a sponge is expressed and functional in response to miR-125 binding in 
these cells.  As is shown in Figure 4.7C, miR-125a sponge is able to bind miR-
125b although to a lesser extend compared to miR-125a.  This demonstrates that 
although both miRs share the same seed region, additional factors also influence 
miR binding to their target genes.  
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Figure 4.7 Generation of functional THP-1 miR-125a stable cells 
THP-1 cells which stably expressed functional miR-125a sponge transgenes were generated.  A) 
Circular plasmid DNA was linearised using the restriction enzyme AseI and DNA was transfected 
into THP-1 cells by electroporation.  B) Stable THP-1 cells were transfected with either a Cm, miR-
125am or a miR-125bm and luciferase activity was measured.  After 24 hour transfection a 
significant decrease in luciferase activity was detected in cell expressing miR-125a sponge 
transfected with miR-125am compared to Cm.  C)  . After 48 hour transfection there was a 
significant decrease in luciferase activity in cells expressing miR-125a sponge transfected with both 
miR-125a and miR-125b mimics compared to control.  Values presented as mean ± SEM of 3 
separate experiments and marked bars are statistically different from Cm using a paired T-test *=p 
<0.05. 
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4.2.2   Cytokine profile of Stable THP-1 Cells 
After generating THP-1 cells which stably expressed the miR-125a sponge vector, 
we examined the cytokine and chemokine profile of these cells.  THP-1 stable 
cells were plated and either left unstimulated or stimulated with LPS (100ng/ml) 
for a period of 24 hours and supernatants were stored for cytokine analysis.  
Next, THP-1 stable cells were differentiated towards macrophages with PMA and 
either left unstimulated or stimulated after 3 or 7 days with LPS (10ng/ml).  This 
stimulation was for a period of 6 or 24 hours.  Supernatants were taken for 
cytokine and chemokine analysis (Figure 4.8).  
 
 
Figure 4.8 Experimental setup of cytokine and chemokine expression profile of miR-125a 
sponge expressing THP-1 cells  
First THP-1 cells were left resting or stimulated with LPS for a period of 24 hours, after which 
supernatants were taken and cytokine expression was measured by ELISA.  Next, THP-1 cells 
were differentiated towards macrophages for 3 and 7 days with PMA, and left resting or stimulated 
with LPS for a period of 6 or 24 hours, after which cytokine and chemokine expression was 
measured by Luminex assay. 
1. Reporter Control
2. miR-125a Sponge
Plated +/- LPS 
for 24hr 
Day 7 +/-LPS 
for 6hr/24 hr
Plated + PMA  
Supernatants for 
Luminex analysis
Supernatants for 
ELISA analysis
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4.2.2.1 Cytokine profile of THP-1 cells which stably express miR-125a 
sponge 
We have demonstrated that whilst miR-125a expression is low in resting THP-1 
cells, it can be induced by LPS stimulation.  LPS induces the production of 
cytokines from monocytes and we therefore wanted to investigate the effect 
that loss of miR-125a would have on cytokine production in these cells.  We also 
examined the resting profile of these cells to determine if loss of miR-125a 
induced the spontaneous production of specific cytokines.  Both reporter control 
and miR-125a sponge cells were stimulated with 10 ng/ml and 100 ng/ml of LPS.  
After 24 hours, supernatants were taken from these cells, and levels of cytokines 
classically induced by LPS stimulation, TNFα, IL-6, IL-12 and IL-10, were 
measured by ELISA.  
Results demonstrated that unstimulated cells did not produce detectable levels 
of cytokines.  In addition, LPS stimulated cells did not produce detectable levels 
of IL-10 or IL-12 at either LPS concentration.  However, miR-125a sponge 
expressing cells produced significantly higher amounts of TNFα after stimulation 
with both 10 and 100 ng/ml of LPS compared to cells which expressed the 
reporter control (Figure 4.9A).  In addition, miR-125a sponge cells also produced 
significantly higher amounts of IL-6 after stimulation with 100 ng/ml of LPS 
(Figure 4.9B).  These cells did not produce detectable amounts of IL-6 when 
stimulated with 10 ng/ml of LPS.   
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Figure 4.9 Cytokine expression of miR-125a sponge THP-1 cells  
THP-1 cells expressing both the reporter control and miR-125a sponge vectors were stimulated 
with LPS and cytokines were measured.  A) Cells were stimulated with both 10 ng/ml and 100 
ng/ml LPS.  TNFα production was significantly higher in cells that expressed the miR-125a sponge 
vector when compared to those expressing the reporter control vector.  B) IL-6 production was not 
detectable when cells were stimulated with 10ng/ml of LPS.  IL-6 production after stimulation with 
100 ng/ml LPS is significantly increased in cells expressing miR-125a sponge when compared to 
the reporter control. Values presented as mean ± SEM of 4 separate experiments and marked bars 
are statistically different from reporter control using a Mann Whitney test *=p <0.05. 
 
4.2.2.2 Cytokine and chemokine profile of day 3 THP-1 differentiated miR-
125a sponge macrophages 
As miR-125a expression is increased in PMA differentiated cells by day 3 and 
further increased by day 7, we decided to examine the effect loss of miR-125a 
activity had on the cytokine profile of PMA differentiated cells, along with the 
response to LPS in these cells at both time-points. 
Differentiated cells were either left unstimulated or stimulated with 10 ng/ml of 
LPS for a period of 6 or 24 hours.  Supernatants were taken from these cells and 
analysed by a pre-designed Luminex Assay.  Out of the 25 cytokines and 
chemokines on the panel, 13 were produced at measurable levels after LPS 
stimulation.  These cytokines and chemokines will be discussed further. 
It should be noted that differentiation with PMA activates THP-1 cells.  
Therefore, although TNFα was not detectable in unstimulated cells, 8 of the 25 
cytokines and chemokines were produced at measurable levels in these 
differentiated cells.  
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Figure 4.10 Cytokine and chemokine expression of resting day 3 PMA miR-125a expressing 
sponge cells 
THP-1 sponge cells were differentiated with PMA for 3 days and cytokine expression was 
measured by Luminex assay.  There is no difference in cytokine and chemokine production in 
resting cells on day 3 using a Mann Whitney Test. Values presented as mean ± SEM of 4 separate 
experiments. 
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Although detectable, there was no significant difference in cytokine and 
chemokine production between miR-125a sponge and reporter control cells 
(Figure 4.10). 
 
After LPS stimulation, miR-125a sponge expressing THP-1 derived macrophages 
produced significantly higher levels of TNFα at both the 6 hour and 24 hour time 
points when compared to reporter control cells. Similarly, production of IL-6 
showed a tendency to be up-regulated in miR-125a sponge expressing cells 
(Figure 4.11A and B).  There was no significant difference in production of IL-12, 
IL-1β, IL-7, IL-1RA or IL-2R between miR-125a sponge and reporter control cells 
at this time-point (Figure 4.11 C-H).  
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Figure 4.11 Cytokine expression of LPS stimulated day 3 PMA miR-125a expressing sponge 
cells 
THP-1 sponge cells were differentiated with PMA for 3 days, stimulated with LPS and cytokine 
expression was measured by Luminex assay.  A) There is a significant increase in TNFα 
production in cells which express the miR-125a sponge compared to the reporter control B-H) 
There is no significant difference in the production of other cytokines measured between miR-125a 
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sponge cells and reporter control cells. Values presented as mean ± SEM of 4 separate 
experiments and marked bars are statistically different from reporter control using a Mann-Whitney 
test *=p <0.05 
 
Chemokine expression was also measured in the supernatants of these day 3 
differentiated cells.  Results showed that there was no significant difference in 
production of CCL2, CCL3, CCL4, CCL5 and CXCL10 between reporter and miR-
125a sponge cells (Figure 4.12 A-E).  However, after 24 hour stimulation with 
LPS, miR-125a sponge expressing cells appear to produce more CCL4 than those 
expressing the reporter control with a trend towards significance with p=0.059.  
In summary, neutralisation of miR-125a in THP-1, and THP-1 derived 
macrophages leads to an increase in production of TNF, IL-6 and CCL4. 
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Figure 4.12 Chemokine expression of LPS stimulated day 3 PMA miR-125a expressing 
sponge cells 
THP-1 sponge cells were differentiated with PMA for 3 days, stimulated with LPS and chemokine 
expression was measured by Luminex assay.  There was no significant difference using a Mann-
Whitney test in any of the chemokines measured. Values presented as mean ± SEM of 4 separate 
experiments.  
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4.2.2.3 Cytokine and chemokine profile of day 7 PMA differentiated miR-125a 
sponge expressing THP-1s 
As miR-125a expression in these cells is at its highest at day 7 in culture, we 
next wanted to determine the cytokine and chemokine expression of day 7 PMA 
differentiated THP-1 cells.  As previously described, this was achieved by using a 
pre-designed Luminex assay.  Cells were again stimulated with 10 ng/ml LPS for 
a period of 6 and 24 hours, after which supernatants were analysed. 
Again, results demonstrate that differentiation of cells with PMA activates cells 
to produce cytokines and chemokines.  However, in day 7 cells there was no 
significant difference in production of any of the mediators, between cells 
expressing the miR-125a sponge, or the reporter control (Figure4.13).  
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Figure 4.13 Cytokine and chemokine expression of resting day 7 PMA miR-125a expressing 
sponge cells 
THP-1 sponge cells were differentiated with PMA for 7 days and cytokine expression was 
measured by Luminex assay.  Although detectable, there was no difference in production of 
cytokines and chemokines measured.  Values presented as mean ± SEM of 4 separate 
experiments. 
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However, after LPS stimulation, cells expressing the miR-125a sponge vector 
produced significantly higher TNFα than those expressing the reporter control 
vector at 6 hours and 24 hours after stimulation (Figure 4.14A).  By day 7, miR-
125a sponge cells also produce significantly higher levels of IL-6, after 24 hour 
LPS stimulation (Figure 4.14B).  These results demonstrate a consistent increase 
in the production of TNFα and IL-6 in cells which do not express functional miR-
125a. 
 
Figure 4.14 TNFα and IL-6 expression of LPS stimulated Day 7 PMA differentiated miR-125a 
sponge cells  
THP-1 cells were differentiated using PMA for 7 days, stimulated with LPS and cytokine expression 
was measured using a Luminex assay.  A) TNFα production is significantly increased after 
stimulation with LPS in miR-125a sponge expressing cells when compared to reporter control cells 
at both 6 and 24 hour time-points. B) IL-6 production is significantly increased after stimulation with 
LPS in miR-125a sponge expressing cells when compared to reporter control cells after 24 hours. 
Values presented as mean ± SEM of 4 separate experiments and marked bars are statistically 
different from reporter control using an Mann-Whitney  *p<0.05. 
 
In addition to TNFα and IL-6 other cytokines were also evaluated.  Results 
revealed no significant difference in the production of IL-12, IL-1β, IL-15, IL-7, 
IL-1RA and IL-2 receptor (Figure 4.15 A-F).  The anti-inflammatory cytokine IL-10 
was not detectable in the supernatants of stimulated PMA differentiated cells.  
This is supported by Morris et al, who found that PMA differentiated THP-1 cells 
require stimulation with high doses of LPS (between 100ng-1μg) to produce IL-10 
[409].  
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Figure 4.15 Cytokine expression of LPS stimulated day 7 PMA differentiated miR-125a 
sponge cells 
THP-1 cells were differentiated using PMA for 7 days, stimulated with LPS and cytokine expression 
was measured using a Luminex assay. A-F) Cytokines unaltered by the expression of a miR-125a 
sponge.  Values presented as mean ± SEM of 4 separate experiments and there is no significant 
difference using a Mann-Whitney test. 
 
In addition to cytokines, cells expressing the miR-125a sponge produced 
significantly higher amounts of chemokines.  CCL4 was upregulated at both 6 
hour and 24 hour time points after LPS stimulation (Figure 4.16A).  In addition, 
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miR-125a sponge cells also produced higher levels of CCL5, this difference 
reaching significance after 24 hours stimulation (Figure 4.16B).  
 
Figure 4.16 CCL4 and CCL5 expression in day 7 PMA miR-125a sponge cells 
THP-1 cells were differentiated using PMA for 7 days, stimulated with 10 ng/ml LPS and 
chemokine expression was measured using a Luminex assay.  A)  CCL4 production was 
significantly increased in cells that expressed the miR-125a sponge when compared to reporter 
control after stimulation with LPS at both 6 hour and 24 hour time-points.  B) CCL5 production is 
increased in cells that express the miR-125a sponge when compared to the reporter control, this 
difference reaches significance after 24 hours.  Values presented as mean ± SEM of 4 separate 
experiments and marked bars are statistically different from reporter control using a Mann-Whitney 
test.  *p<0.05. 
  
We observed no difference in expression of CCL2, CCL3 and CXCL10 (Figure 4.17 
A-C). 
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Figure 4.17 Chemokine expression in LPS stimulated day 7 PMA differentiated  miR-125a 
sponge cells   
THP-1 cells were differentiated using PMA for 7 days, stimulated with LPS and chemokine 
expression was measured using a Luminex assay A-C) Production of CCL2, CCL3 and CXCL10 
was not altered by expression of the miR-125a sponge.  Values presented as mean ± SEM of 4 
separate experiments and no statistical difference was detected using a Mann-Whitney Test  
 
These data demonstrate a specific phenotype in monocytes and macrophages 
which have reduced miR-125a activity.  It is clear that in both cell types, loss of 
miR-125a results in significantly higher TNFα production and to a lesser extent 
IL-6 production.  By day 7 of differentiation miR-125a sponge cells also produce 
significantly higher amounts of the chemokines CCL4 and CCL5 suggesting miR-
125a is involved in regulating the production of these chemokines.  This pattern 
of change has been shown to be quite robust as the experiment was set up on 4 
separate occasions, with a similar result generated. 
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4.2.3 Cytokine profile of primary human macrophages after 
inhibition of miR-125a 
Although we have generated a cytokine and chemokine profile of THP-1 derived 
miR-125a null macrophages, it is important to validate this expression profile in 
primary human macrophages.  To do this human CD14+ cells were separated 
from healthy buffy coat packs and differentiated towards a macrophage 
phenotype using the growth factor M-CSF (50 ng/ml) for 3 and 7 days.  Since 
primary cells are hard to transfect with DNA vectors, we used 22 nt long miR-
125a sequence specific inhibitor or control inhibitor. Macrophages were 
transfected on either day 3 or day 7. After 24 hours transfection, macrophages 
were left for an additional 24 hours either unstimulated or LPS stimulated (10 
ng/ml) for 24 hours.  Supernatants were then harvested for analysis via ELISA 
(Figure 4.18). 
 
Figure 4.18 Experimental set-up of human macrophage transfection 
CD14+ cells were separated from buffy coat packs and differentiated for 3 and 7 days with the 
growth factor M-CSF (50 ng/ml).  Cells were transfected on day 3 or day 7 for 24 hours and then 
cultured for a further 24 hours with or without LPS (10ng/ml). Supernatants were taken from these 
cells for analysis by ELISA. 
Healthy Blood 
CD14+ Selection 
3 Day culture with 
M-CSF
7 Day culture with 
M-CSF
24 Hour 
Transfection
24 Hour 
Transfection
+/- LPS
Collect supernatant for ELISA 
analysis
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4.2.3.1 Transfection optimisation of human macrophages 
Previous transfection experiments carried out within the lab group using primary 
human macrophages had been carried out using a transfection reagent from 
Thermo Scientific – Dharmafect.  However, when this reagent was tested in 
these experiments, under conditions previously validated, we observed high 
levels of cellular toxicity.  Therefore we decided to validate transfection 
reagents.  The transfection reagents we chose were HiPerfect reagent (Qiagen) 
recommended for transfection of macrophages and TransIT TKO reagent (Mirus 
Pharmaceuticals), which was also recommended for the non-toxic transfection of 
adherent cells.   
Transfection efficiency can be determined by flow cytometry through 
transfection with a Cm labelled with a dye (547) which can be visualised by 
FACS.  Therefore, I decided to transfect cells with differing concentrations of 
this mimic (10-50 nM) with the recommended amount of transfection reagent (2 
µl HiPerfect and 2.5 µl of TransIT).  Cells were visually inspected before FACS 
analysis to determine their adherence and removed by dissociation reagent to 
minimise cell death.  Results (untransfected (red), 10 nM Cm547 (blue), 25 nM 
Cm547 (orange) and 50 nM Cm547 (green)) demonstrated that irrespective of 
mimic concentration, transfection efficiency of cells was low when transfected 
with HiPerfect reagent, reaching only 11% at the highest concentration (Figure 
4.19A).  In contrast, TransIT reagent achieved transfection efficiency of 68% with 
25 nM Cm547 concentration (Figure 4.19B).  This was marginally higher than with 
50 nM Cm547 (64%), and had been previously shown by our lab group to be 
effective at knocking-down specific miR targets (Kurowska-Stolarska, 
unpublished results).  In addition, previous experiments within our lab 
demonstrated that a transfection efficiency of over 60% is enough to 
demonstrate target knockdown, therefore I decided to use this concentration of 
mimic in further experiments.  Percentage of positively transfected cells are 
shown in    
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Figure 4.19 Transfection optimisation of human macrophages 
Human macrophages were transfected with a labelled control mimic and differing concentrations of 
transfection reagent.  Untransfected (red), 10 nM Cm547 (blue), 25 nM Cm547 (orange) and 50 nM 
Cm547 (green).  A) Transfection efficiency with HiPerfect reagent was low, reaching only 11% with 
the 50 nM concentration.  B) Transfection efficiency with TransIT reagent was satisfactory, 
reaching 67% with 25 nM Cm547. 
 
Table 4.1 Percentage of cells transfected using HiPerfect or TransIT reagent 
Transfection optimisation was performed using human macrophages and two transfection 
reagents.  Human macrophages were transfected with differing concentrations of Cm547, and the 
suggested amount of transfection reagent.  Percentage of transfected cells was measured using 
Flow Cytometry 
 Percentage Transfected Cells 
Concentration of cm547 
(nM) 
HiPerfect Reagent TransIT Reagent 
10 6 56 
25 8 68 
50 11 64 
 
For each macrophage donor, transfection efficiency was confirmed using either 
this FACS based method, or by validating miR-125a expression by q-PCR, or both.  
The FACS based method gives a good indication of how effective transfection is, 
however it is important to verify miR-125a knockdown by q-PCR.  Q-PCR analysis 
demonstrated that macrophages transfected with a miR-125a mimic expressed 
significantly higher miR-125a, and cells transfected with a miR-125a inhibitor 
expressed significantly lower miR-125a as expected, demonstrating that 
transfection was effective (Figure 4.20 A and B).  Additionally, for all 
Cm547
HiPerfect TransIT
Cm547
A. B.
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experiments verified by FACs, transfection efficiency was above 65% and in some 
cases reached 90% (Figure 4.20 D).  An example of a FACS plot showing 
transfection efficiency is shown in Figure 4.20 C, the red histogram represents 
cells transfected with Cm, whilst the blue histogram represents cells transfected 
with the labelled Cm (547). 
 
Figure 4.20 Transfection efficiency of human macrophages 
Human macrophages were transfected with miR-125a mimic and inhibitors and transfection 
efficiency was measured by q-PCR and FACS. A) macrophages transfected with a miR-125a 
mimic express significantly higher levels of miR-125a as measured by q-PCR B) macrophages 
transfected with a miR-125a inhibitor express significantly lower miR-125a as detected by q-PCR 
C) Example of measurement of transfection efficiency by FACS D) Table showing the transfection 
efficiency of human macrophages as determined by FACS analysis.  Values represent mean ± 
SEM of 8 experiments, with marked bars being significantly different when using a Paired T test. 
*=p<0.05, =p<0.0005. 
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4.2.3.2 Cytokine and chemokine expression of day 3 macrophages 
transfected with a miR-125a inhibitor 
Once we had determined the correct reagents for transfection we wanted to 
verify if the expression profile observed in the miR-125a sponge cells was also 
present in human macrophages transfected with a miR-125a inhibitor.  We 
determined cytokine expression in day 3 differentiated cells, as we have already 
shown that miR-125a expression is at its highest in these cells (Figure 3.12A).  
Guided by data obtained using miR-125a sponges, we tested production of TNFα, 
IL-6, IL-12, CCL4 and IL-10. 
Unstimulated cells did not produce detectable levels of TNFα, IL-6, IL-10 or CCL4 
(data not shown). Upon LPS stimulation, Day 3 macrophages transfected with a 
125ai did not produce significantly different amounts of TNFα, IL-6, IL-10 or 
CCL4 when compared to those cells transfected with a Ci (Figure 4.21 A-D).  
However, as with miR-125a sponge cells, there is a trend towards higher 
production of TNFα, IL-6 and especially CCL4 (p=0.08).  Interestingly it appeared 
that, conversely to the production of pro-inflammatory cytokines, production of 
IL-10 was lower in cells transfected with 125ai (p=0.08). 
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Figure 4.21 Cytokine and chemokine profile of day 3 macrophages transfected with a miR-
125a inhibitor 
Human macrophages were differentiated with 50 ng/ml M-CSF and transfected with either Ci or 
miR-125ai, after which cells were stimulated with 10 ng/ml LPS.  Cytokines were measured by 
ELISA after 24 hours in culture A-D) Transfection with a miR-125ai does not significantly alter 
cytokine or chemokine expression in day 3 macrophage.  Values presented as mean ± SEM of 4 
separate experiments and no statistical difference was detected from Cm using a Wilcoxon 
matched-pairs signed rank test. 
   
4.2.3.3 Cytokine and chemokine expression of day 7 macrophages 
transfected with a miR-125a inhibitor 
Next we investigated the cytokine and chemokine expression profile of day 7 
fully differentiated human macrophages transfected with a 125ai as we have 
shown that the copy number of miR-125a remains high in these cells. 
As with day 3 macrophages, unstimulated cells did not produce detectable levels 
of TNFα, IL-6, IL-12, IL-10 and CCL4.  However, upon LPS stimulation human 
macrophages transfected with a 125ai produce significantly higher amounts of 
TNFα and CCL4 (Figure 4.22 A, C and E), and significantly lower amounts of IL-10 
(Figure 4.22D).  There was no significant difference in production of IL-6 or IL-12 
(Figure 4.22 B and C). 
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Figure 4.22 Cytokine and chemokine expression of day 7 human macrophages transfected 
with a miR-125a inhibitor  
Human macrophages were differentiated with 50 ng/ml M-CSF and transfected with either a Ci or 
miR-125ai, after which cells were stimulated with 10 ng/ml LPS.  Cytokines were measured by 
ELISA after 24 hours in culture A) TNFα production was significantly higher in cells transfected with 
a miR-125ai B and C) There was no significant difference in the production of IL-6 and IL-12 
between Ci and miR-125ai transfected cells D) IL-10 production was significantly decreased in cells 
transfected with a miR-125ai E) CCL4 production was significantly increased in cells transfected 
with a miR-125ai when compared to Ci. Values presented as mean ± SEM of 8 separate 
experiments and marked bars are  statistically different from Ci using a paired T test, 
*<p,0.05,**p<0.005 ***p<0.005. 
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In summary, primary human macrophage produce significantly higher amounts of 
pro-inflammatory TNFα, CCL4 and IL-6 (PMA cells) upon miR-125a inhibition, 
whilst producing significantly lower levels of IL-10. 
4.2.3.4 Cytokine and chemokine expression of day 3 human macrophages 
transfected with a miR-125a mimic 
Finally, I wanted to determine whether overexpression of miR-125a would have 
the opposite effect on the expression of TNFα, IL-6, IL-10, IL-12 and CCL4.  
Previously I have demonstrated that transfection with a 125am increased the 
amount of miR-125a within a sample by up to 200 fold.  Taking this approach 
permits the identification of potential miR-125a targets, but also may highlight 
off target effects.  As before, cells were differentiated using 50 ng/ml M-CSF for 
3 and 7 days, transfected for 24 hours with either a Cm or 125am and then left 
unstimulated, or stimulated for 24 hours with 10 ng/ml LPS, with supernatants 
taken for ELISA.  
As in previous experiments, unstimulated cells did not produce detectable levels 
of cytokines or chemokines.  Results demonstrated that as with 125ai 
transfection, expression of TNFα, IL-6, IL-10 and CCL4 were not significantly 
altered in day 3 human macrophages by transfection with a miR-125a mimic 
(Figure 4.23).  
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Figure 4.23 Cytokine and chemokine profile of day 3 human macrophages transfected with a 
miR-125a mimic 
Human macrophages were differentiated with 50 ng/ml M-CSF and transfected with either a Cm or 
miR-125am, after which cells were stimulated with 10 ng/ml LPS. A-D) Expression of TNFα, IL-6, 
IL-10 and CCL4 were not significantly altered by transfection with a miR-125am. Values presented 
as mean ± SEM of 4 separate experiments and no statistical difference was detected from Cm 
using a Wilcoxon matched-pairs signed rank test 
 
4.2.4 Cytokine and chemokine expression of day 7 human 
macrophages transfected with a miR-125a mimic 
The most remarkable differences induced by the inhibition of miR-125a were 
observed at day 7 in both PMA differentiated THP-1 cells and M-CSF 
differentiated primary macrophages.  Therefore, we decided to investigate 
these cytokines in the context of day 7 differentiated macrophages that had 
been transfected with a miR-125a mimic. I hypothesised that the significant 
increase in production of TNFα, IL-12 and CCL4 seen in these cells would be 
reversed in mimic transfected cells.This was the case for CCL4 as overexpression 
of miR-125a in day 7 human macrophages resulted in lower production of CCL4, 
this difference trended towards significance with a p=0.07 (Figure 4.24E).  
Interestingly TNFα production was not reduced, but was significantly increased 
in these cells (Figure 4.24A).   
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Based on the miR-125a inhibitor data which demonstrated a decrease in IL-10 
production, I hypothesised that miR-125a overexpressing macrophages will 
produce more IL-10.  This was also proven correct, as day 7 human macrophages 
transfected with a miR-125a mimic produce increased levels of IL-10 (Figure 
4.24D). 
 
Figure 4.24 Cytokine and chemokine profile of day 7 human macrophages transfected with a 
miR-125a mimic 
Human macrophages were differentiated with 50 ng/ml M-CSF and transfected with either a Cm or 
miR-125am, after which cells were stimulated with 10 ng/ml LPS. A) Overexpression of miR-125a 
resulted in significantly higher production of TNFα  B) Overexpression of miR-125a  did not alter IL-
6 production C) Overexpression of miR-125a did not alter IL-12 production D) Overexpression of 
miR-125a resulted in a significant increase in IL-10 production E) Overexpression of miR-125a did 
not significantly down-regulate CCL4 production. Values presented as mean ± SEM of 8 separate 
experiments and marked bars are statistically different from Cm using a Paired T Test, 
*p,0.05,**p<0.005. 
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One of the many problems associated with the use of miR mimics is the possible 
undesirable immunogenicity of the double stranded RNA mimic itself.  Due to 
the increased TNFα witnessed in cells transfected with both miR-125a mimics 
and inhibitors we wanted to investigate the immunogenicity of this mimic.   
To do this we wanted to measure a variety of interferon response genes by q-
PCR.  Interferons are the host’s first line of defence again viral infection, and 
can be activated by dsRNA, a common viral replicative intermediate, through 
TLR 3, 7 and 8.  TLR 7 and 8 also recognise UG-rich motifs which exist in mature 
miR-125a. 
To investigate immunogenicity, I measured the interferon response genes OAS1, 
OAS2, MX1, IRF9 and IFITM1 in transfected macrophages (125am v Cm), and THP-
1 cells stimulated with Poly I:C, an activator of TLR3 as a positive control.  This 
immunogenicity assay was used in a study by Haraguchi et al to ensure that their 
novel synthetic miR did not induce these IFN response genes.  THP-1 cells 
stimulated with Poly I:C demonstrate an induction of OAS1, MX1 and IRF9.  
Haraguchi et al also demonstrated an induction of IFTIM1, which was not 
observed in this study (Figure 4.25B).  Both OAS1 and IFTIM1 are downregulated 
in miR-125a transfected cells and although MX1 is induced to similar levels as in 
stimulated THP-1s, this is only in one out of 2 donors (Figure 4.25A).  Due to the 
difference between the positive control of Poly I:C stimulation and 125am 
transfected cells, I can confidently say that the 125am does not induce an 
interferon response.   
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Figure 4.25 Immunogenicity assay 
RNA from human macrophages transfected with a Cm and miR-125am was analysed by q-PCR to 
measure levels of IFN response genes, OAS1, OAS2, MX1, IRF9 and IFITM1.  Additionally these 
genes were measured in THP-1 cells, stimulated with Poly I:C as a positive control.  A) OAS2, MX1 
and IRF9 expression was induced in 1 of 2 donors, however both OAS1 and IFTIM1 were down-
regulated in these cells. B)  In THP-1 cells stimulated with Poly I:C all genes except OAS2 were 
induced in both donors.  Values presented as mean ± SEM of 2 separate experiments. 
 
4.3 Discussion 
In this chapter, we demonstrated that miR-125a plays a role in regulating the 
cytokine and chemokine production by macrophages in response to LPS.  It is 
clear from the results, that inhibition of miR-125a results in the establishment of 
a pro-inflammatory phenotype in these cells.  Stable miR-125a inhibition, 
through a miR-125a sponge, in THP-1 cells resulted in increased TNFα and IL-6 
production.  This profile was also present in THP-1 derived macrophages in 
which miR-125a inhibition resulted in a significant increase in TNFα, IL-6, CCL4 
and CCL5 production. This pro-inflammatory phenotype was also present in 
primary human macrophages in which miR-125a was inhibited.   These 
macrophages produced significantly higher amounts of TNFα, IL-12 and CCL4 and 
also lower amounts of anti-inflammatory IL-10.  Interestingly, overexpression of 
miR-125a in human macrophages demonstrated a significant upregulation of IL-
10 and TNFα, suggesting a dual role for miR-125a in TNFα regulation.   
The alteration of miR expression is crucial in determining its function within a 
cell.  The majority of previous studies have relied solely on gain and loss of 
function experiments in-vitro, through transfection of double stranded miR 
mimics and single stranded antisense inhibitors. In this study we used a novel 
method for inhibiting miR expression, first introduced by Ebert et al in 2007, and 
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generated a functional miR-125a sponge.  This miR sponge vector was stably 
inserted into the genome of the THP-1 cell line to allow the study of miR-125a 
function in THP-1 derived macrophages where expression is high.  The miR-125a 
sponge vector contained a luciferase reporter gene which allowed the activity of 
the construct to be measured.  Vectors can also be created which express a 
fluorescent marker such as GFP.  This allows the construct to be visualised by 
other techniques such as FACS and under a light microscope and would be useful 
for further experiments.    
Due to metabolic and morphological similarities, the human monocytic cell line, 
THP-1, can be differentiated to macrophages by PMA.  High levels of PMA have 
been shown to upregulate the production of pro-inflammatory cytokines and 
chemokines, whilst masking the response to other activatory factors such as LPS.  
Park et al reported that 5 ng/ml of PMA was enough to stably differentiate THP-
1 cells towards macrophages without overexpression of TNFα, CCL5, IL-1, 
CXCL10 or CCL4.  As we wanted to examine the response of miR-125a sponge 
cells to LPS, we set out to optimise the differentiation of THP-1 cells.  We found 
that 5 ng/ml PMA was sufficient to induce the cells to become adherent, while 
producing lower amounts of TNFα, detectable by ELISA but not Luminex.  We 
examined the response of both day 3 and day 7 differentiated cells with or 
without stimulation, at both 6 and 24 hours.  These two time-points were chosen 
to investigate both early and late response to LPS.  Results demonstrated that 
PMA itself induced cells to produce specific cytokines and chemokines.  This was 
not surprising as PMA is routinely used along with ionomycin to activate T cells.  
However, reassuringly, there was no difference in cytokine and chemokine 
production between miR-125a sponge and reporter expressing cells.  
Additionally, the level of soluble mediators within the supernatant had 
decreased by day 7, consistent with 5 days in media without PMA.   
At day 3 only TNFα production was significantly higher in miR-125a sponge 
expressing cells.  By day 7, there was also a significant increase in IL-6, CCL4 
and CCL5 in these cells.  Both IL-6 and CCL5 were increased only after 24 hours 
stimulation, suggesting that miR-125a may indirectly regulate these mediators. 
PMA differentiated macrophages did not express IL-10 at detectable levels.  
Reports of IL-10 production from PMA differentiated THP-1s are contradictory 
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depending on the stimulus used, concentration of PMA and culture duration [409, 
410].  We can therefore speculate that LPS stimulus at 10ng/ml was not high 
enough to activate this pathway.  In fact, Morris et al have hypothesised that 
high concentrations of LPS are required to induce production of IL-10 from these 
cells [409].  Future studies could therefore investigate IL-10 production from 
miR-125a sponge expressing cells stimulated with higher concentrations of LPS. 
The pro-inflammatory phenotype of miR-125a sponge expressing PMA cells was 
mirrored by primary human macrophages transfected with a miR-125a inhibitor.  
By day 7, miR-125a inhibited macrophages produced significantly higher levels of 
TNFα, IL-12 and CCL4.  Interestingly, production of IL-10 in these cells was 
significantly downregulated.  Transfection of these cells with a miR-125a mimic 
did not produce the results expected with regards to TNFα, which was also 
significantly increased in these cells, suggesting a dual role for miR-125a in TNFα 
regulation.  Transfection of macrophages with a miR-125a mimic did however 
significantly increase production of IL-10, suggesting regulation of this cytokine. 
miRs alter cytokine and chemokine production by either directly targeting these 
molecules themselves, or regulators within the signalling cascades of these 
responses.  Based on the profile of these cells in response to LPS, we can 
hypothesise molecules which would account for this pro-inflammatory phenotype 
and propose models by which miR-125a may regulate these important mediators.   
The dual role of miR-125a in regulating cytokine production has been hinted at 
previously, through the regulation of NFκB in CD34+ cells of myelodysplastic 
syndrome.  Gomez et al demonstrated that overexpression of miR-125a in normal 
cells resulted in an increase in NFκB activity, whereas after TLR activation, it 
was inhibition of miR-125a that had this effect [393].  Additionally, there have 
been previous conflicting studies detailing the role played by miR-125a in 
polarisation of macrophages.  Banerjee et al have demonstrated a decrease in 
TNFα and IL-12 production after overexpression of miR-125a in LPS stimulated, 
GM-CSF, differentiated murine macrophages. On the other hand, Graff et al 
demonstrated a slight increase in TNFα in M1 polarised macrophages after LPS 
stimulation [339, 368].  The differences in results from these experiments may 
be due to their choice and characterisation of cells.  The Graff study of 
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macrophage polarisation also used human M-CSF differentiated macrophages 
which would explain the similar results to this study.   
The list of predicted targets for miR-125a also suggests this miR may play 
differing roles in regulation of inflammatory cytokine production.  According to 
prediction algorithms (TargetScan and RNA22), miR-125a can potentially target 
pro-inflammatory mediators TNFα, TLR4, TRAF6 and NFκB essential modulator 
kinase (NEMO).  On the other hand miR-125a also potentially targets negative 
regulators of inflammatory signalling TNFAIP3, interferon regulatory factor 4 
(IRF4), Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) and 
TNFAIP3-interacting protein 2 (TNIP2).  We can therefore speculate that miR-
125a, depending on cell type and cellular environment may play differing roles 
in regulating the inflammatory response.  Interestingly TRAF6 also mediates IL-
12 production in response to infection, which may explain the upregulation of 
this cytokine after miR-125a inhibition [411].    
The increased expression of TNFα in culture may also have effects on the 
production of other inflammatory mediators such as IL-6 and CCL4.  However the 
list of potential miR-125a targets again allows us to construct hypotheses which 
can explain alterations in these molecules.  
We have demonstrated that miR-125a is a negative regulator of CCL5 expression 
in response to LPS.  CCL5, a chemokine with chemoattractant properties for T 
cells has been found to be upregulated in a number of autoimmune diseases, 
including RA and Systemic Lupus Erythematosus (SLE) [216, 343].  miR-125a 
regulation of CCL5 has also been observed by another group.  Zhao et al have 
shown a downregulation of miR-125a in SLE CD4+ T cells, which correlates with 
an upregulation of CCL5. They demonstrate that miR-125a directly targets the 
transcription factor (tf) kruppel like factor 13 (KLF13) which binds the CCL5 
promoter and induces its expression in T cells.  Overexpression of miR-125a 
results in a decrease in both this tf and CCL5 protein [343].  KLF13 is also 
expressed in both PMA differentiated THP-1 cells and primary human 
macrophages [339, 412].  We can therefore speculate that miR-125a regulates 
CCL5 production, through the targeting of KLF13 in these cells in a similar 
manner to T cells.  In addition to CCL5 it appears CCL4 expression is also 
negatively regulated by miR-125a.  CCL4, a chemoattractant for a variety of 
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immune cells, is a potential target of miR-125a.  Direct targeting of this 
chemokine would explain the early upregulation (after 6 hours) witnessed post 
LPS stimulation, in miR-125a expressing sponge cells. 
Another important pro-inflammatory cytokine upregulated after the inhibition of 
miR-125a is IL-6.  This may be the result of miR-125a targeting of molecules 
involved in the IL-6 signalling pathway.  miR-125a is predicted to bind both 
membrane bound IL-6R and also gp130.  In addition to the receptor, miR-125a 
also potentially targets the downstream signalling molecule STAT3.  It is known 
that IL-6 can have autocrine effects on macrophages, therefore we can 
hypothesise that under miR-125a inhibition, levels of STAT3 increase, allowing 
production of higher amounts of IL-6, which can then be responded to in 
macrophages, as levels of IL-6R and gp130 also increase.   
This data suggests that loss of miR-125a results in an increased inflammatory 
response to LPS through the increased production of pro-inflammatory cytokines.  
What is interesting however, is the production of IL-10 in these cells.  IL-10 is a 
potent anti-inflammatory cytokine which regulates inflammation.  It is important 
that inflammation in response to injury or infection is regulated, to prevent an 
unreasonable immune response, which can result in autoimmunity.  Only 3 
families of miR contain conserved binding sites within the IL-10 3’UTR, miR-27, 
miR-194, and interestingly the Let-7 family.  The relationship between miR-125a 
and IL-10 production suggests miR-125a directly targets a negative regulator of 
IL-10 production.  From the list of miR-125a targets we have hypothesised a 
number of negative regulators, which may account for this IL-10 expression 
pattern.  miR-125a potentially targets IL-10R itself and negative regulators of IL-
10 production- V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog  (ETS-1) 
and histone deacetylase 11 (HDAC11).  
The phenotype observed in miR-125a mimic transfected macrophages highlights 
the limitations of these types of studies.  Firstly, the mimic used for transfection 
is a double stranded RNA molecule and previous studies have demonstrated the 
ability of these mimics to activate the interferon response through TLR3 and 
therefore disrupt any functional analysis.  To attempt to address this possibility 
we measured levels of INF response genes, OAS1, OAS2, MX1, IFTIM1 and IRF9 in 
transfected cells and also in Poly I:C stimulated THP-1 cells as a positive control.  
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The results from the transfected cells were different than the positive control, 
in which there was an induction of OAS1, MX1, IFTIM1 and IRF9.  In transfected 
cells there was a downregulation of OAS1 and IFTIM1.  However on closer 
inspection, these 2 genes are potential miR-125a targets.  The induction of IRF9 
was not to the same level as witnessed in the positive control, therefore we 
cannot conclude that miR-125a itself is immunogenic.  Another limitation of 
mimic studies is that the introduction of high levels of mimic into a cell results 
in non-physiological levels of miR which can then have off target effects.  We 
can therefore also speculate that the effect of miR-125a on TNFα production is 
one of these off-target effects.   
To my knowledge this study is the first to generate and use a functional miR-
125a sponge to investigate the role of this miR in the response to LPS in 
macrophages.  miR-125a regulation of NFκB, TNFα, IL-12 and CCL5 have been 
identified previously.  However no concrete pathway of regulation of TNFα, or 
IL-12, have been identified to date.  This is the first study to identify a link 
between miR-125a expression and regulation of IL-6, IL-10 and CCL4.  From this 
data, so far, we can speculate that upregulation of miR-125a in SF CD14+ cells 
forms part of an attempt at regulating the high levels of inflammation within the 
joint.  As previously demonstrated miR-125a expression is increased in PB CD14+ 
cells of those responding well to DMARD therapy. This functional study suggests 
that in these patients miR-125a may contribute to increased levels of IL-10 
production, whilst applying a break to the production of pro-inflammatory IL-12, 
IL-6 and CCL4 by macrophages, however its role in TNFα production remains to 
be elucidated.   
The following chapter will go onto test the hypotheses identified here with 
regards to miR-125a regulation of its potential targets.  
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Chapter 5 – miR-125a is a Regulator of TLR4 
Signalling 
  
5.1 Introduction and aims 
The previous chapter has demonstrated that dysregulation of miR-125a in 
macrophages alters the cytokine and chemokine response to LPS in these cells.  
Inhibition of endogenous miR-125a results in the development of a hyper 
inflammatory phenotype manifested by increased production of TNFα, IL-6, IL-12 
and decreased production of anti-inflammatory IL-10.  Interestingly, superfluous 
overexpression of miR-125a results in increased production of both IL-10 and 
TNFα.  This chapter will therefore investigate potential mechanisms underlying 
miR-125a mediated phenotypes, through the use of online prediction algorithms 
and then validation experiments. 
MiRs function to regulate gene expression through targeting complementary 
sequences, usually within the 3’UTR of target genes, resulting in their down-
regulation.  A major goal of miR research is therefore to attribute a functional 
role to a miR within a given cell type, as by understanding its function, it may 
prove therapeutically useful in disease.  To understand miR functions, their 
predicted target genes must be identified and validated.  As one miR can target 
many different mRNAs, it is therefore possible that miRs can regulate different 
pathways concurrently, making them attractive molecules for therapy.  An 
example of this is miR-34a in cancer development.  This miR has been shown in 
various studies to function as a tumour suppressor in many forms of cancer, 
including breast, brain and liver malignancies, and multiple targets of this miR 
have been identified.  Diage et al have recently demonstrated that delivering a 
miR-34a mimic to mice suffering from hepatocellular carcinoma (HCC) causes 
regression of tumours.  A single delivery has been shown to inhibit genes in 5 
oncogenic pathways: Wnt/Catenin, Hedgehog, VEGF, c-Met and MAPK, whilst 
stimulating the activation of the suppressed p53 pathway [413].   Concurrently, 
miR-34a replacement therapy for liver cancer has now entered phase I human 
clinical trials, demonstrating the importance of these molecules in the 
regulation of almost all cellular processes [337].  
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As we have identified an up-regulation of miR-125a in RA CD14+ cells, and 
demonstrated a pro-inflammatory phenotype in macrophages after miR-125a 
inhibition, it is important to identify and validate direct targets of this miR, to 
determine its functional role within these cells in both health and disease.  
miR target identification is accomplished by using computer-based algorithms 
that identify MREs within mRNAs (reviewed in 1.6.3).  Additionally, many studies 
also begin by using transcriptomic analysis such as microarrays to investigate 
mRNA expression after transfection of a miR of interest.  This method narrows 
down the number of potential targets, as it is based on experimental changes in 
mRNA.  However, microarrays remains relatively expensive and, as some miRs 
show only modest effects on degradation of target transcripts, it is feasible to 
use only online prediction algorithms to identify targets responsible for the miR 
driven cell phenotypes.    
Chapter objectives - 
 Identify and validate miR-125a targets in macrophages.  
 Functionally demonstrate miR-125a regulation of candidate targets. 
5.2 Results 
5.2.1 miR-125a potentially targets members of the TLR4 signalling 
pathway 
As the pro-inflammatory macrophage phenotype was witnessed after activation 
with the TLR4 ligand LPS, we searched for potential miR-125a targets related to 
the activation and function of this signalling pathway.  Using in-silico analysis by 
using the TargetScan and RNA22 online algorithms, we identified 6 molecules 
which were potential miR-125a targets, but were also fundamental in the 
activation and regulation of the TLR4 signalling pathway.  These targets were 
TLR4 itself, and the downstream signalling molecules IRAK1, IRAK4, TRAF6, 
NEMO (Inhibitor of nuclear factor kappa-B kinase subunit γ) kinase and the 
inhibitor of NFκB, TNFAIP3 (Figure 5.1).  
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Figure 5.1 Simplified schematic of potential miR-125a targets involved in TLR4 signalling 
miR-125a potentially targets at least 7 members of the TLR4 signalling pathway (highlighted within 
red boxes). NEMO, Inhibitor of nuclear factor kappa-B kinase subunit γ; Ub, ubiquitin. 
For each of the potential targets we examined their characteristics using the 
TargetScan and RNA22 algorithms (Table 5.1).  Firstly we used the TargetScan 
algorithm to determine if miR-125a potentially targeted the molecule and 
examined its context score.  The context score is the sum of the contribution of 
six features: site-type, 3' pairing contribution, local AU contribution, position, 
TA (target site abundance) and SPS (seed-pairing stability).  The higher the 
context score, the more likely that it will be a positive miR-125a target.  
Additionally, we examined the seed match that was predicted, 8mer displays 
perfectly complementary binding to the seed region, and 7mer and exact match 
to 7 of the nucleotides within the seed region.   
Next, we identified if the binding site was conserved across species, and finally 
if the predicted target was also predicted by the RNA22 algorithm. 
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Table 5.1 In-Silico Analysis of TLR4 signalling pathway 
Potential 
Target 
Targetscan Context 
Score/Percentage 
Seed 
Match 
Conserved RNA22 
TLR4 Yes -0.05/33 7mer-1A Poorly Yes 
IRAK1 Yes -0.17/78 7mer-1A Poorly Yes 
IRAK4 No    Yes 
TRAF6 Yes -0.14/65 8mer Conserved No 
NEMO Yes -0.33/94 8mer Poorly Yes 
TNFAIP3 Yes -0.33/94 8mer Conserved Yes 
Context Score-indicates how likely it is that the molecule will be a positive target based on the 
contribution of different features including seed pairing, AU content, stability and abundance. Seed 
Match-identifies the complementarity of binding between the miR seed region and the site in the 
mRNA 3’UTR (7mer-7 nucleotide match, 8mer-8nucleotide match). 
Based on this information we decided to investigate miR-125a targeting of TLR4, 
TRAF6 and TNFAIP3.  The 3’UTRs of TRAF6 and TNFAIP3 both contain conserved 
miR-125a binding sites, with context score percentage above 60%.  Although the 
context score of miR-125a binding of TLR4 is low, the presence of 3 potential 
binding sites identified by the RNA22 algorithm, and it’s importance in the 
activation of inflammatory pathways suggested it would be important to 
investigate the potential regulation of this molecule by miR-125a. 
 
5.2.1.1 miR-125a potentially regulates TLR4 expression 
As it was beyond the scope of this project to investigate each of these molecules 
individually, we decided to begin at the receptor level and validate TLR4 as a 
miR-125a target gene.  Using the RNA22 algorithm, we identified 3 potential 
miR-125a binding sites in the 3’ UTR of TLR4 (Figure 5.2A), designed a G-Block® 
construct (as described in 2.5.1) which would include these binding sites, and 
inserted this sequence downstream of a luciferase reporter gene (as described in 
2.5.1).  This construct was termed wild-type (WT) as it contained the miR-125a 
MREs.  Concurrently, we designed a sequence in which these binding sites were 
altered, termed mutated (Mut) (sequences of G-Block fragments detailed in 
2.5.1).  If miR-125a directly targets the TLR4 gene, luciferase activity should be 
decreased with the WT construct.  Alterations in the binding sites, as in the Mut 
construct, would prevent miR-125a binding, and therefore rescue 
downregulation of luciferase, confirming direct targeting of TLR4 by miR-125a.  
  182 
 
To analyse luciferase expression, HEK 293 cells were co- transfected with either 
the WT or Mut TLR4 construct, and either a Cm or 125am, and cultured 
overnight.  After this, cells were lysed, and luciferase expression was measured 
(Figure 5.2B).   
 
Figure 5.2 Targeting of TLR4 by miR-125a 
A) Using the RNA22 algorithm we identified 3 potential miR-125a binding sites (shown in red) in the 
3’UTR of the TLR4 gene.  B) HEK293 cells were transfected with either WT or Mut constructs 
along with a Cm or miR-125am and luciferase expression was measured after 24 hours in culture. 
Luciferase expression was downregulated by125am in only cells transfected with WT construct, 
this downregulation was rescued in cells which were transfected with Mut construct.  Values 
presented as mean ± SEM of 4 experiments. p=0.07 unpaired t-test WT vs. Mut. Cm: Control 
mimic, 125am: miR-125a mimic. 
 
Results demonstrated that cells transfected with the WT TLR4 construct and a 
125am displayed slightly lower luciferase expression than those transfected with 
a Cm, suggesting miR-125a may directly target TLR4.  In this experiment we 
compared the luciferase expression between WT and Mut constructs which have 
been co-transfected with a miR-125a mimic, and found that knockdown of 
luciferase expression in the WT was rescued by mutation of the miR-125a binding 
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sites within the 3’UTR in the Mut construct.  This suggests that knock down of 
luciferase is dependent on the presence of miR-125a MREs.  This difference did 
not reach significance (p=0.07) when analysed by an unpaired t-test, and 
therefore we cannot confidently conclude that miR-125a directly targets TLR4.  
However, this knockdown in luciferase expression suggests a potential 
relationship, which may be elucidated through further experiments. Therefore, 
we decided to investigate this relationship further at the protein level by flow 
cytometry. 
Before the manipulation of miR-125a levels, we firstly wished to determine the 
expression of surface TLR4 on resting healthy macrophages, and its expression 
after activation with LPS (10ng/ml).  To do this we differentiated CD14+ cells 
towards a macrophage phenotype with M-CSF (50 ng/ml), as described previously 
(in 2.2.2.4).  On day 7, we removed the adherent macrophages using a 
dissociation solution, stained for TLR4, and analysed by flow cytometry.  We 
gated on live cells based on size (FSC) and granularity (SSC) (Figure 5.3A), and 
results showed that almost all macrophages expressed TLR4 on their surface 
(Figure 5.3B blue histogram).  The results also demonstrated that macrophage 
surface TLR4 expression is significantly decreased by 24 hour LPS stimulation, in 
keeping with the role of TLR4 expression in the induction of LPS tolerance 
(Figure 5.3 B orange histogram and C).  
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Figure 5.3 Macrophage surface TLR4 expression 
Macrophages were differentiated using M-CSF (50ng/ml) and stimulated with LPS (10ng/ml) for 
24hr or left unstimulated. Cells were then stained for surface TLR4 expression.  A) Live cells were 
gated on based on size and granularity B) Representative histogram showing TLR4 staining of 
macrophages. Almost 100% of human macrophages express surface TLR4 (blue histogram).  This 
expression is decreased by stimulation with LPS (orange histogram).  C) Mean Fluorescence 
Intensity (MFI) values show that TLR4 expression is significantly downregulated by LPS 
stimulation. Values presented as mean ± SEM of 4 experiments, ** = p<0.005, paired t-test. 
 
As we could measure TLR4 on the surface of human macrophages, we next set 
out to determine if the manipulation of miR-125a levels within these cells would 
change expression of surface TLR4.  To examine the effect of overexpression of 
miR-125a, healthy day 7 macrophage cells were transfected with a Cm or miR-
125am, and to examine the effects of inhibition, cells were transfected with 
either a Ci or miR-125ai.  After transfection, cells were cultured overnight.  
Results demonstrated that although macrophages express high levels of surface 
TLR4, manipulation of miR-125a in these cells did not alter TLR4 expression.  
There was no significant difference in expression between cells overexpressing 
miR-125a (Figure 5.4A and C), or in cells in which miR-125a was inhibited (Figure 
5.4B and C), shown by comparison of histograms, and comparison of MFI values.  
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Figure 5.4 Surface TLR4 expression of resting transfected macrophages 
Levels of miR-125a were manipulated in macrophages through transfection, after which TLR4 
expression was measured by flow cytometry. A) Overexpression of miR-125a does not alter 
surface TLR4 expression.  B) Inhibition of miR-125a does not significantly alter surface TLR4 
expression. C) MFI values confirm that manipulation of miR-125a does not alter surface TLR4 
expression.  Values presented as mean ± SEM of 4 experiments, and no significant difference was 
observed using a paired t test. 
 
As the pro-inflammatory phenotype was witnessed in activated macrophages, in 
subsequent experiments we examined the expression of surface TLR4 in LPS 
stimulated macrophages (10ng/ml).  Again, results demonstrated that 
overexpression and inhibition of miR-125a by transfection had no effect on 
surface TLR4 on activated macrophages (Figure 5.5 A-C), comparing both cell 
percentage and MFI values. 
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Figure 5.5 Surface TLR4  expression of LPS stimulated transfected macrophages 
Levels of miR-125a were manipulated in macrophages through transfection, after which cells were 
stimulated with LPS (10ng/ml) and TLR4 expression was measured by flow cytometry.  A) 
Overexpression of miR-125a does not alter surface TLR4 expression.  B) Inhibition of miR-125ai 
does not alter surface TLR4 expression.  C) MFI values confirm that manipulation of miR-125a 
does not alter surface TLR4 expression.  Values presented as mean ± SEM of 4 experiments, with 
no significance detected after analysis with a paired t-test. 
 
In the final testing of our hypothesis we examined TLR4 expression on miR-125a 
sponge containing THP-1 cells, as sponge technology is more efficient in 
inhibiting miRs than anti-miRs. Firstly, we examined undifferentiated cells and 
found that although these cells express high levels of TLR4, there is no 
difference between reporter control, or miR-125a sponge expressing cells, 
regardless of LPS stimulation (Figure 5.6 A and B).   
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Figure 5.6 TLR4 expression of miR-125a THP-1 sponge cells 
Reporter control and miR-125a sponge expressing THP-1 cells were stained for surface TLR4 
expression, and analysed by flow cytometry.  A) Representative histogram of TLR4 staining in 
unstimulated cells.  Although cells expressed high levels of TLR4 compared to isotype (blue 
histogram), there was no difference in TLR4 expression between reporter control (red histogram) or 
miR-125a sponge (orange histogram) expressing THP-1 cells, as also shown by MFI values.  B) 
There was also no difference in TLR4 expression between reporter control (red histogram) or miR-
125a sponge (orange histogram) expressing LPS stimulated THP-1 cells, as also shown by MFI 
values.  Values presented as mean ± SEM of 2 experiments.    
 
As we could not identify a direct relationship between miR-125a and TLR4 we 
next examined the mRNA transcript of TLR4.  We wanted to investigate 
polyadenylation of TLR4 in macrophages, to determine if different transcripts of 
this molecule were expressed by the cell under different conditions.   
A number of different polyadenylation sites have been identified within TLR4  
(Figure 5.7), which would cause the expression of a shorter transcript, that 
would not contain miR-125a binding sites.   
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We therefore wanted to determine if indeed these shorter transcripts were 
expressed by macrophages after LPS stimulation, removing the ability of miR-
125a to regulate TLR4. 
We designed PCR primers which would amplify total TLR4 (a region of the mRNA 
expressed by all transcripts) and long TLR4 ( a longer version of the transcript) 
which would contain miR-125a binding sites (Figure 5.7). 
 
Figure 5.7 Validated TLR4 polyadenylation sites 
NCBI details polyadenylation sites within the 3’UTR of TLR4.  These sites are indicated in red in 
the figure above, and show that at least 3 of these variants would cause the loss of sites required 
for miR-125a regulation.  Additionally PCR primers for different transcript variant sites are indicated 
with blue arrows. 
 
Macrophages were cultured for 7 days as previously described, and on day 7 they 
were either left unstimulated, or LPS stimulated for 24 hours, after which TLR4 
variant expression was measured by q-PCR. 
 
 
 
  189 
 
 
Figure 5.8 TLR4 variants expressed by resting and LPS stimulated macrophages 
q-PCR primers were designed that would amplify total TLR4 expression and the expression of a 
long variant of TLR4.  These variants were measured in both unstimulated and LPS stimulated 
macrophages. A) Expression of total TLR4 is significantly decreased after stimulation with LPS. B) 
Expression of the longer variant of TLR4 appears to increase after LPS stimulation. Values 
presented as mean ± SEM of n=4 experiments (total TLR4) and n=3 experiments (Long TLR4) and 
marked bars are statistically different from each other using a paired T-Test **=p<0.005      
Results showed that LPS stimulation of macrophages significantly decreases the 
expression of total TLR4 in macrophages (Figure 5.8A).  Additionally, it appears 
that although total TLR4 is downregulated after LPS expression, levels of the 
longer variant appear to increase when compared to unstimulated cells (Figure 
5.8 B). 
As we could not identify a direct relationship between miR-125a and TLR4 we 
next wanted to investigate miR-125a targeting of additional molecules within 
the TLR4 pathway, which may be responsible for the phenotype, we have 
identified. 
5.2.1.2 miR-125a regulates TRAF6 expression 
Using the TargetScan algorithm, we identified a highly conserved miR-125a MRE 
in the 3’UTR of the TRAF6 gene.  TRAF6 is a key transduction molecule in the 
TLR signalling pathway.  This site was conserved between human, mouse and 
chimpanzee, suggesting an important regulatory function of this site within 
mammals (Figure 5.9 A).  Again, we designed a G-Block® construct which would 
include this binding site, and a separate construct in which this MRE was 
mutated.  This sequence was then inserted downstream of a luciferase reporter 
gene.   As previously, to analyse miR-125a binding potential, a luciferase 
reporter assay was carried out.   
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Figure 5.9 Targeting of TRAF6 by miR-125a 
A) Using the TargetScan algorithm we identified a potential miR-125a binding site in the 3’UTR of 
TRAF6  (shown in red) which was highly conserved across vertebrate species (shown in orange) 
B) HEK293 cells were transfected with either WT or Mut constructs along with a Cm or miR-125am 
and luciferase expression was measured after 24 hours in culture. Luciferase expression was 
downregulated by125am in only cells transfected with WT construct.  However results shown 
represents only 1 preliminary experiment. 
 
Results demonstrated that transfection of the WT construct along with a miR-
125am resulted in a decrease in luciferase expression when compared to a Cm.  
This decrease in luciferase expression was then rescued by mutation of the miR-
125a MRE (Figure 5.9 B).  Due to time constraints and HEK293 cell culture 
problems, this experiment was only performed once. We are confident however 
that miR-125a does in fact target TRAF6 in macrophages, as a recent study led 
by Guo et al confirmed that miR-125a directly targets TRAF6 in monocyte 
derived-osteoclasts, and its overexpression can prevent osteoclastogenesis [370]. 
Therefore, we next wanted to determine if PMA differentiated miR-125a sponge 
expressing cells expressed higher levels of TRAF6.  As miRs have been shown to 
repress translation and cause a measurable downregulation of mRNA, we 
differentiated cells for 7 days as previously, and analysed the expression of 
TRAF6
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TRAF6 mRNA by q-PCR.  We investigated TRAF6 expression in unstimulated cells, 
and cells stimulated with LPS for both 6 and 24 hours, as we had previously 
witnessed differences in pro-inflammatory cytokine production at these time 
points. 
 
 
Figure 5.10 TRAF6 mRNA expression of miR-125a sponge expressing cells 
Expression of TRAF6 mRNA was measured by q-PCR in 7 day PMA differentiated THP-1 cells 
expressing miR-125a sponge.  A) The expression of TRAF6 mRNA is not altered between reporter 
control and miR-125a sponge expressing unstimulated cells.  B-C) Cells were stimulated with LPS 
(10ng/ml) for 6 and 24h.  The expression of TRAF6 mRNA appears significantly lower in miR-125a 
sponge expressing cells compared to reporter control cells when stimulated with LPS for 6 hours.  
There is no significant difference in the expression of TRAF6 mRNA between reporter control and 
miR-125a sponge expressing cells after 24 hour LPS stimulation. Values presented as mean ± 
SEM of 4 experiments and marked bars are statistically different from each other using an unpaired 
t-Test **=p<0.005   
 
Results demonstrated that expression of TRAF6 was not significantly altered 
between differentiated reporter control and miR-125a sponge expressing cells 
when in a resting state, or stimulated with LPS for 24 hours (Figure 5.10 A and 
C). However, results showed that TRAF6 mRNA is significantly downregulated in 
differentiated miR-125a sponge expressing cells 6 hours after LPS stimulation 
R
e
p
o
r t
e
r  
C
o
n
tr
o
l
m
iR
-1
2
5
a
 S
p
o
n
g
e
0 .0
0 .5
1 .0
1 .5
T R A F  6  U n s tim u la te d
F
o
ld
 C
h
a
n
g
e
(n
o
r
m
a
li
s
e
d
 t
o
 G
A
P
D
H
)
R
e
p
o
r t
e
r  
C
o
n
tr
o
l
m
iR
-1
2
5
a
 S
p
o
n
g
e
0 .0
0 .5
1 .0
1 .5
T R A F  6  (6  H o u rs  L P S )
F
o
ld
 C
h
a
n
g
e
(n
o
r
m
a
li
s
e
d
 t
o
 G
A
P
D
H
)
**
R
e
p
o
r t
e
r  
C
o
n
tr
o
l
m
iR
-1
2
5
a
 S
p
o
n
g
e
0 .0
0 .5
1 .0
1 .5
T R A F 6  (2 4  h o u r s  L P S )
F
o
ld
 C
h
a
n
g
e
(n
o
r
m
a
li
s
e
d
 t
o
 G
A
P
D
H
)
A. B.
C.
  192 
 
when compared to reporter control (Figure 5.10 B).  This suggests that miR-125a 
may indeed interact with TRAF6 in the early response to LPS.  
Next, we wanted to determine whether similar miR-125a/TRAF6 mRNA 
relationship exists in primary human macrophages in which miR-125a levels had 
been manipulated.  We prepared cDNA of cells from earlier phenotyping 
experiments showing an inhibitory effect of miR-125a on cytokine production 
(Chapter 4).  Briefly, healthy CD14+ cells were separated and differentiated, as 
previously described, and miR-125a levels were manipulated by transfection on 
day 7.  Cells were left unstimulated, or stimulated with LPS for 24 hours, after 
which levels of TRAF6 mRNA was measured by q-PCR. 
 
Figure 5.11 TRAF6 mRNA in miR-125a transfected human macrophages 
Human macrophages were differentiated for 7 days, after which miR-125a expression was 
manipulated by transfection followed by stimulation with LPS (10 ng/ml) for 24hrs and levels of 
TRAF6 mRNA were measured by q-PCR. A) Expression of TRAF6 mRNA is significantly 
downregulated in non-simulated macrophages overexpressing miR-125a.  B)  TRAF6 expression is 
not altered in unstimulated macrophages in which miR-125a is inhibited.  C) TRAF6 mRNA 
expression is lower in LPS stimulated macrophages which overexpress miR-125a.  D) There is no 
difference in TRAF6 mRNA expression in LPS stimulated macrophages in which miR-125a is 
inhibited. Values presented as mean ± SEM of 4 experiments (apart from D, n=2 experiments) and 
marked bars are statistically different from each other using a paired T-Test **=p<0.005. 
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Results demonstrated that overexpression of miR-125a significantly decreased 
the expression of TRAF6 mRNA in resting cells, with this downregulation trending 
towards significance in cells stimulated with LPS (p=0.06) (Figure 5.11 A and C) 
supporting the hypothesis that miR-125a has potential to regulate TRAF6.  
However, there appeared to be no difference in TRAF6 mRNA expression 
between cells that were transfected with a Ci or miR-125ai, regardless of LPS 
stimulation (Figure 5.11 B and D).  Levels of TRAF6 mRNA in LPS stimulated 
macrophages was only measured in 2 samples, due to RNA quality from cells, and 
time constraints.  Moreover, the lack of TRAF6 inhibition upon endogenous miR-
125a neutralisation could be due to the selection of a time-point in which 
conditions have not been optimised (24hr). We showed that in LPS stimulated 
miR-125a sponge THP-1 cells interaction occurred at 6 but not 24hr time point. 
Therefore, this requires additional time course experiments, that will include 
more donors and early time points. 
We have shown that miR-125a has the potential to bind TRAF6, demonstrated by 
the preliminary luciferase assay and miR-125 overexpression experiments in 
macrophages.  Further studies are required to fully dissect the role of TRAF6 in 
the pro-inflammatory phenotype seen when endogenous miR-125a is inhibited in 
our system. 
5.2.2 miR-125a potentially targets pro-inflammatory TNFα and 
CCL4 
In addition to signalling molecules, we also investigated whether miR-125a can 
directly target pro-inflammatory cytokines themselves, which would explain an 
increase in these cytokines when miR-125a is inhibited. 
Again, we used the target algorithms TargetScan and RNA22 to determine if miR-
125a could potentially regulate any of the cytokines we have identified as 
significantly altered in macrophages in which miR-125a is inhibited, TNFα, IL-12, 
IL-6 and CCL4.  
From this search we determined that there are no potential binding sites in the 
3’ UTRs of IL-12 or IL-6, and therefore increases in these cytokines must be due 
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to indirect interactions.  However, predication algorithms suggested that miR-
125a may directly regulate both TNFα and CCL4 (Table 5.2). 
Table 5.2 In-Silico analysis of cytokines potentially targeted by miR-125a 
Potential 
Target 
Targetscan Context 
Score/Percentage 
Seed 
Match 
Conserved RNA22 
TNF No N/A N/A N/A Yes 
CCL4 Yes -0.15/68 7mer-1A Poorly Yes 
Context Score-indicates how likely it is that the molecule will be a positive target based on the 
contribution of different features including seed pairing, AU content, stability and abundance. Seed 
Match-identifies the complementarity of binding between the miR seed region and the site in the 
mRNA 3’UTR (7mer-7 nucleotide match, 8mer-8nucleotide match). 
 
5.2.2.1 miR-125a does not directly target TNFα mRNA 
The RNA22 algorithm shows a potential miR-125a binding site in the 3’ UTR of 
the TNFα gene (5.12 A).  Again, to confirm this functionally we used a luciferase 
reporter assay.  As previously, we generated WT and Mut constructs which 
contained either a sequence with the WT binding site, or a sequence in which 
this site was altered. 
 
Figure 5.12 Luciferase reporter assay of TNFα  
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A) Using the RNA22 algorithm we identified a potential miR-125a binding site in the 3’UTR of TNFα 
(shown in red) B) HEK293 cells were transfected with WT or Mut construct and Cm or miR-125a 
mimic. 24hrs later, luciferase activity was measured by a luminometre.  Luciferase reporter assay 
of both WT and Mut constructs suggests TNFα is not a direct target of miR-125a. Values presented 
as mean ± SEM of 4 experiments; with no significant difference observed between WT and Mut 
using an unpaired t-test   
 
Results demonstrated no difference in luciferase activity in samples which were 
transfected with either the WT construct and a miR-125a mimic or the Mut 
vector and miR-125a mimic (Figure 5.12 B).  Therefore, we concluded that miR-
125a does not directly target and regulate TNFα, and this interaction cannot be 
responsible for the increase of TNFα witnessed in macrophages in which miR-
125a is inhibited.  
5.2.2.2 miR-125a potentially regulates CCL4 expression 
Next, using the TargetScan algorithm we identified a poorly conserved site in the 
3’ UTR of the CCL4 gene, conserved between humans and chimpanzees, but not 
present in mouse (Figure 5.13A).  To determine if miR-125a can directly target 
the 3’ UTR of CCL4, again we used a luciferase reporter assay. 
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Figure 5.13 Luciferase reporter assay of CCL4 
A) Using the TargetScan algorithm we identified a potential miR-125a binding site in the 3’UTR of 
CCL4 (shown in red) which is partially conserved across vertebrates (shown in orange).  B) 
HEK293 cells were transfected with either WT or Mut constructs along with a Cm or miR-125am 
and luciferase expression was measured after 24 hours in culture. Luciferase expression was 
downregulated by125am in only cells transfected with WT construct.  Values presented as mean ± 
SEM of 4 experiments. p=0.09 unpaired t-test. WT vs. Mut. Cm: Control mimic, 125am: miR-125a 
mimic 
  
Results showed that cells transfected with the WT construct and a miR-125a 
mimic had a lower luciferase expression when compared to a Cm.  Additionally 
this downregulation was rescued when the miR-125a binding site was mutated, 
suggesting that CCL4 is a potential target of miR-125a, however this difference 
was not significant (p=0.09) and therefore further experiments are required to 
fully validate this interaction (figure 5.13 B). We next examined the mRNA level 
of this chemokine in differentiated miR-125a sponge expressing cells.  As 
previously, cells were differentiated with PMA for 7 days, and CCL4 mRNA was 
measured by q-PCR. 
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Figure 5.14 CCL4 mRNA expression of miR-125a sponge expressing cells 
Expression of CCL4 mRNA was measured by q-PCR in PMA differentiated THP-1 cells expressing 
miR-125a sponge and stimulated with LPS (10ng/ml) for 6 or 24h or left unstimulated  A) The 
expression of CCL4 mRNA is not significantly altered between reporter control and miR-125a 
sponge expressing unstimulated cells.  B) The expression of CCL4 is significantly increased in 
miR-125a sponge expressing cells when compared to reporter control after 6 hour LPS stimulation 
C) The expression of CCL4 is significantly increased in miR-125a sponge expressing cells when 
compared to reporter control after 24 hour LPS stimulation.  Values presented as mean ± SEM of 4 
experiments and marked bars are statistically different from each other using an un-paired T-Test 
*=p<0.05   
 
Results demonstrated that miR-125a sponge expressing cells show higher levels 
of CCL4 mRNA when compared to reporter control cells (Figure 5.14 A-C).  This 
difference becomes significant after LPS stimulation (Figure 5.14 B and C).   
Next, we examined CCL4 mRNA levels in healthy human macrophages in which 
miR-125a levels were manipulated by transfection.  Cells were differentiated as 
previously described, and transfected on day 7. 
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Figure 5.15 CCL4 mRNA expression of miR-125a transfected human macrophages 
Human macrophages were differentiated for 7 days after which miR-125a expression was 
manipulated by transfection and stimulated with LPS (10 ng/ml) for 24h or left un-stimulated. The 
levels of CCL4 mRNA were measured by q-PCR. A) Expression of CCL4 mRNA is significantly 
downregulated in macrophages overexpressing miR-125a.  B)  CCL4 expression is not altered in 
unstimulated macrophages in which miR-125a is inhibited.  C) CCL4 mRNA expression is not 
significantly altered in LPS stimulated macrophages which overexpress miR-125a.  D) There is no 
difference in CCL4 mRNA expression in LPS stimulated macrophages in which miR-125a is 
inhibited. Values presented as mean ± SEM of 4 experiments and marked bars are statistically 
different from each other using a paired T-Test **=p<0.005. 
 
Results showed that overexpression of miR-125a in human macrophages results 
in decreased CCL4 mRNA expression.  This mRNA downregulation is significant in 
resting cells (Figure 5.15 A and C).  However, CCL4 mRNA does not appear to be 
significantly higher in cells in which miR-125a is inhibited, regardless of LPS 
stimulation (Figure 5.15 B and D).  
We have shown that upon strong neutralisation of endogenous miR-125a as seen 
in miR-125a sponge transfected cells, CCL4 mRNA levels are increased and upon 
overexpression of miR-125a in human macrophages, CCL4 mRNA levels are down-
regulated supporting the hypothesis of miR-125a and CCL4 interaction. However, 
determining whether this is due to a direct targeting of CCL4 or a result of miR-
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125a fine tuning LPS signalling pathway, requires additional luciferase assay and 
functional experiments that include more donors, time points and broader 
concentration of inhibitor.  
5.2.3 miR-125a overexpression downregulates TNFAIP3, an 
important negative regulator of NFκB signalling 
In addition to investigating the pro-inflammatory phenotype caused by inhibition 
of endogenous miR-125a, we wanted to further investigate the mechanism 
behind the unexpected phenotype of macrophages overexpressing miR-125a, in 
terms of TNFα production. We have clearly demonstrated that macrophages 
which overexpress miR-125a produce significantly higher levels of not only IL-10 
but also TNFα after LPS stimulation. We felt that this requires further 
investigation as this may preclude use of miR-125a mimic as a potential therapy 
in chronic inflammation.  
As we outlined in point 5.2, TargetScan algorithm identified an important 
regulator of NFκB signalling, the E3 ubiquitin ligase TNFAIP3 as a potential miR-
125a target.  The 3’UTR of TNFAIP3 contains a highly conserved potential miR-
125a binding site, which is conserved between human, mouse and chimpanzee, 
again, indicating its potential importance in the regulation of this gene in 
mammals (Figure 5.16 A).   
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Figure 5.16 Luciferase reporter assay of TNAIP3 
A) Using the TargetScan algorithm we identified a potential miR-125a binding site in the 3’UTR of 
TNFAIP3  (shown in red) which was highly conserved across vertebrate species (shown in orange) 
B) B) HEK293 cells were transfected with either WT or Mut constructs along with a Cm or miR-
125am and luciferase expression was measured after 24 hours in culture. Luciferase expression 
was downregulated by125am in only cells transfected with WT construct.  However results shown 
represents only 1 preliminary experiment. 
 
As previously, to analyse miR-125a binding potential, a luciferase reporter assay 
was carried out.  Results demonstrated that transfection of the WT construct 
along with a miR-125am resulted in a decrease in luciferase expression, which 
was rescued by mutation of the miR-125a MRE (Figure 5.16 B).  However, again, 
due to time constraints this experiment was only performed once, and requires 
repetition to conclusively validate miR-125a targeting of TNFAIP3. 
We are confident however that miR-125a directly targets TNFAIP3 in 
macrophages as our data was confirmed recently by Kim et al, who have shown 
that miR-125a directly targets TNFAIP3 in DLBCL cells, resulting in constitutively 
active NFκB signalling [369].  
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To investigate whether this is a case in our experimental system, we first 
investigated levels of TNFAIP3 mRNA in differentiated miR-125a sponge 
expressing cells by q-PCR.  
 
Figure 5.17 TNAIP3 mRNA expression of miR-125a sponge expressing cells 
Expression of TNFAIP3 mRNA was measured by q-PCR in PMA differentiated THP-1 cells 
expressing miR-125a sponge.  A) The expression of TNFAIP3 mRNA is not altered between 
reporter control and miR-125a sponge expressing unstimulated cells.  B) The expression of 
TNFAIP3 is not significantly altered between reporter and miR-125a sponge expressing sponge 
cells after 6 hour LPS stimulation C) There is no significant difference in the expression of TRAF6 
mRNA between reporter control and miR-125a sponge expressing cells after 24 hour LPS 
stimulation. Values presented as mean ± SEM of 4 experiments;   
Results demonstrated a trend towards higher levels of TNFAIP3 in miR-125a 
sponge expressing cells, when compared to the reporter control (Figure 5.17A).  
This difference also appeared to increase after exposure to LPS (Figure 5.17 B 
and C).  However, these differences were not significant at any of the time 
points analysed. 
We next wanted to measure the mRNA levels and protein in healthy 
macrophages in which miR-125a expression was manipulated.  As before, 
macrophages were differentiated for 7 days, and miR-125a levels were 
manipulated by transfection.  
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Figure 5.18 TNFAIP3 mRNA expression of miR-125a transfected human macrophages 
Human macrophages were differentiated for 7 days, after which miR-125a expression was 
manipulated by transfection and levels of TNFAIP3 mRNA were measured by q-PCR. A) 
Expression of TNFAIP3 mRNA is significantly downregulated in macrophages overexpressing miR-
125a.  B)  TNFAIP3 expression is not altered in unstimulated macrophages in which miR-125a is 
inhibited.  C) TNFAIP3 mRNA expression is significantly decreased in LPS stimulated 
macrophages which overexpress miR-125a.  D) There is no difference in TNFAIP3 mRNA 
expression in LPS stimulated macrophages in which miR-125a is inhibited. Values presented as 
mean ± SEM of 4 (D n=2) experiments and marked bars are statistically different from each other 
using a paired T-Test *=p<0.05. 
 
Results demonstrated that TNFAIP3 mRNA is significantly decreased in 
macrophages which overexpress miR-125a, in both resting and LPS stimulated 
cells (Figure 5.18 A and C).  However, similarly to miR-125 sponge THP-1 cells, 
there appears to be no difference in the expression of TNFAIP3 mRNA between 
cells when endogenous miR-125a is inhibited, regardless of LPS stimulation 
(Figure 5.18 B and D).  These results suggest that miR-125a targeting of TNFAIP3 
in macrophages, which overexpress miR-125a, may account for the increase in 
TNFα production witnessed in these cells after LPS stimulation.  Again, levels of 
TNFAIP3 mRNA in LPS stimulated macrophages was only measured in 2 samples, 
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due to RNA quality from cells, and time constraints, and so this experiment 
requires repetition. 
As we had demonstrated a significant decrease in mRNA expression, we next 
wanted to confirm this targeting at the protein level in macrophages by western 
blot (WB). Healthy CD14+ cells were differentiated as previously described, and 
miR-125a expression was manipulated by transfection on day 7.  Cells were 
cultured overnight, after which they were left under resting conditions, or 
stimulated with LPS for 6 hours.  After this, cells were lysed, proteins extracted, 
and TNFAIP3 expression was measured by WB. 
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Figure 5.19 TNFAIP3 protein expression in macrophages  
Macrophages were differentiated for 7 days with M-CSF (50 ng/ml). On day 7 miR-125a expression 
was manipulated by transfection.  Cells were cultured overnight, and then stimulated for 6 hours 
with LPS (10ng/ml) after which TNFAIP3 expression was measured using a Western Blot using 
fluorescence infrared detection. A) WB analysis showed that cells transfected with a miR-125am 
expressed lower TNFAIP3 protein when compared to a Cm.  Additionally there was no detectable 
difference in TNFAIP3 expression between cells transfected with a Ci and miR-125ai.  B) Analysis 
of WB protein expression, through ‘integrated intensity’ values, when compared to β-actin 
housekeeping shows a decrease in TNFAIP3 protein expression in those cells in which miR-125a 
was overexpressed.  C) Analysis of WB protein expression, when compared to β-actin 
housekeeping shows no difference in TNFAIP3 protein expression in those cells in which miR-125a 
was inhibited.  Values presented from1 preliminary experiment.  
 
Results from the WB experiment demonstrated that TNFAIP3 protein expression 
is low in resting macrophages, and we were not able to detect its expression.  
However, along with q-PCR data, we can demonstrate that TNFAIP3 expression is 
increased in response to LPS.  In LPS stimulated macrophages overexpression of 
miR-125a leads to lower levels of TNFAIP3, whereas there was no significant 
increase in TNFAIP3 expression in macrophages were miR-125a was inhibited 
(Figure 5.19 A-C).  These data further suggests that superficial high levels of 
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miR-125a can directly target TNFAIP3 in human macrophages after LPS 
stimulation, resulting in a downregulation of transcription and protein 
expression, and thus leading to high TNFα production. However, the endogenous 
miR-125a at the levels induced by M-CSF and TLR stimulation is not involved in 
TNFAIP3 regulation.   
5.3 Discussion 
In this chapter we aimed to identify direct mechanisms responsible for the anti-
inflammatory role of miR-125a in macrophages.  We selected potential targets 
through the use of the online algorithms, TargetScan and RNA22.  These targets 
were tested in luciferase reporter assays, and then functionally validated 
through the analysis of mRNA and protein levels.  We were able to show 
potential targeting of CCL4, by miR-125a, by luciferase assay and also provided 
some preliminary data on miR-125a targeting of members of the TLR4 signalling 
pathway such as TRAF6.  We can therefore postulate that under inflammatory 
conditions miR-125a functions in an anti-inflammatory manner, by regulating 
important pro-inflammatory pathways. 
Firstly, we identified TLR4 itself as a potential miR-125a target, and this target 
interaction was suggested further by the luciferase reporter assay.  However, 
this interaction was weak, and when surface protein expression was measured by 
flow cytometry, both in human macrophages and miR-125a sponge expressing 
cells, no significance difference in expression could be detected.  This was 
interesting as the slight decrease in luciferase activity observed during the 
reporter assay suggested a potential level of targeting of TLR4 by miR-125a.  We 
therefore interrogated the TLR4 gene for alternative polyadenylation sites, to 
ascertain if this may affect miR binding.  Many protein-coding genes contain a 
number of polyadenylation sites which allow one gene to code for several 
different mRNA isoforms, which differ at the 3’ end.  As polyadenylation changes 
the length of the 3’ UTR, it can therefore remove miR binding sites within the 
mRNA.  This phenomenon has been identified in cancer cells, where a 
transformed cell lines have been shown to broadly express mRNA isoforms with 
shorter 3 ‘UTRs.  This allows oncogenic activation through the removal of miR 
regulation, increased mRNA stability, and increased protein expression [414].   
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We therefore wished to investigate which variants of TLR4 were expressed on 
human macrophages, as if the 3’UTR was shortened, this may account for the 
lack of miR-125a regulation of TLR4.  The National centre for biotechnology 
(NCBI) website contains information which identifies 11 validated 
polyadenylation sites for TLR4, 3 of which would cause the expression of a 
truncated TLR4 mRNA, resulting in a loss of miR-125a binding sites (Figure 5.7).  
Due to this, it is important to validate which variant of TLR4 is expressed by 
macrophages, both under resting and stimulated conditions, to determine the 
regulative capabilities of any miR on this gene. 
We tried to address this question close to the end of this project.  We designed 
two sets of primers which would amplify total TLR4 (part of the mRNA which all 
variants expressed) and a longer variant of TLR4 (which would contain miR-125a 
binding sites).  Firstly, we wanted to investigate the effect LPS stimulation 
would have on these transcripts.  Our data demonstrates that LPS stimulation 
significantly decreases the amount of total TLR4 expression when compared to 
unstimulated cells.  This observation was also shown at the surface level using 
FACs analysis.  However, although total TLR4 was decreased by LPS, it appeared 
that the longer variant increased when compared to unstimulated cells.  This is 
interesting as it perhaps points to the regulation of TLR4, in that after activation 
of the cell expression of the longer variant continues, creating an additional 
level of miR regulation, to help resolve inflammation after the initial phase of 
the response.  However, this preliminary experiment was only carried out on 3 
samples, and therefore requires repetition before any conclusions can be drawn.   
Future experiments could still be designed in which specific PCR primers would 
amplify only specific variants of TLR4 from macrophage DNA.  These products 
could then be sequenced, allowing identification of the length of the 3’UTR 
within these cells.  This data may prove important as studies have previously 
demonstrated that LPS stimulation of murine monocytes and macrophages, 
unlike in this current study, results in the upregulation of a truncated TLR4 
isoform, which functions as a negative regulator of inflammation by preventing 
NFκB activation and TNFα production [415].  This is important as Jaresova et al 
have shown a failure to up-regulate this variant in human monocytes from cystic 
fibrosis patients, resulting in a pro-inflammatory phenotype of these cells within 
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disease.  These studies indicate that identifying expression isoforms may prove 
important in understanding inflammatory responses within responsive cells under 
both health and disease states [416].   
It would therefore be interesting to examine expression of TLR4 variants after 
miR-125a manipulation, as although miR125a may not have a measurable effect 
on total TLR4, it may regulate expression of the longer TLR4 variant, indicating a 
role for the resolution of inflammation. Additionally, as LPS decreased TLR4 
surface expression in our macrophage cultures (Figure 5.3), it would be also be 
interesting to investigate whether there are other miRs involved in TLR4 down-
regulation that is contributes to the formation of LPS tolerance. 
The activation of TLR4 and the consequent signalling pathway is important in the 
activation of the transcription factor NFκB, essential for the production of pro-
inflammatory cytokines.  We identified the signalling molecule TRAF6 as a 
potential target of miR-125a.  TRAF6 is an E3 ubiquitin ligase molecule which is 
essential for LPS induced production of TNFα and IL-6 by macrophages [417].  
Due to the key role of these cytokines in inflammation, it is important that their 
production is regulated.  We therefore hypothesised that miR-125a played a key 
role in this regulation by targeting of TRAF6 post LPS stimulation.  Inhibition of 
miR-125a would therefore remove this level of regulation, resulting in a pro-
inflammatory phenotype.  We demonstrated by luciferase reporter assay that 
TRAF6 appears to be a direct target of miR-125a.  However, this preliminary 
assay was only performed once and therefore needs to be repeated in the 
future, to definitively validate this target.   
The potential of miR-125a to target TRAF6 was further demonstrated by 
overexpression studies within human macrophages.  Overexpression of miR-125a 
in resting human macrophages results in significantly decreased TRAF6 mRNA 
expression, suggesting miR-125a is directly repressing this molecule.  However, 
there is no reciprocal increase in expression at the mRNA level when miR-125a is 
inhibited in these cells. The latter could be explained by multiple reasons.  Data 
demonstrated by Guo et al who have shown that miR-125a directly targets TRAF6 
at the protein level, by WB in osteoclast cells, where overexpression causes a 
downregulation of the protein, whilst blocking miR-125a causes an increase 
[370].  Interestingly, it has been documented that miR target regulation does not 
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always result in a measurable change in mRNA levels, therefore future 
experiments should be undertaken to examine the protein level of TRAF6 by WB 
in these cells [418].  
 Additionally, it would be important for any future work to examine the 
expression of TRAF6 after manipulation of miR-125a at a number of time points 
post LPS stimulation, as it is possible that the lack of alteration at the mRNA 
level is due to the 24 hour time point that we have chosen to examine.  A study 
by Nahid et al has shown that miR-146a, another miR which directly targets 
TRAF6, demonstrates its regulatory effect on protein expression in macrophages 
at as early as 5 hours post LPS stimulation [419] .  Therefore, it is possible that 
at 24 hours TRAF6 expression has returned to resting levels in the macrophages.   
We can therefore hypothesis that miR-125a may target TRAF6 early in the 
response to LPS to prevent overactive signalling, and pro-inflammatory cytokine 
production.  Interestingly, when we examined early time-point mRNA in miR-
125a sponge expressing cells, we showed that after 6 hours, TRAF6 mRNA is 
downregulated in these cells when compared to the reporter control.  Due to the 
environment of engineered cells, it may be possible that other miRs may be 
functionally compensating for the loss of miR-125a, resulting in increased 
regulation of TRAF6.  It would be interesting to examine levels of other miRs 
within these cells, which have been shown to target TRAF6, such as miR-146a.   
In addition to signalling molecules, we wanted to examine the potential of 
miR-125a to directly regulate pro-inflammatory cytokines themselves.  There is 
evidence within the literature that miR-125b, a homologue of miR-125a, targets 
TNFα directly, resulting in its downregulation [296].  Therefore we hypothesised 
that miR-125a targets TNFα, with inhibition removing this layer of regulation.  
However as our luciferase reporter assay demonstrated variable results, we do 
not believe that miR-125a directly targets TNFα.  This result again demonstrates 
that although miRs within the same family may possess identical seed regions, 
they do not necessarily regulate the same molecules.   
Next, we identified the chemokine CCL4 as a potential target of miR-
125a.  In this case there was a more convincing knock down of luciferase activity 
within the reporter assay, however this knock down again was not significant.  In 
  209 
 
order to confirm targeting via luciferase reporter assay it may be important to 
optimise the concentration of mimic used to witness knock down, as it is 
possible that there is interference in this assay with endogenous miRs and 
mRNAs. 
  However, we were able to demonstrate that differentiated miR-125a 
sponge cells express significantly higher CCL4 mRNA than reporter cells, in line 
with the higher production of CCL4 protein witnessed in these cells by ELISA. 
This suggests that miR-125a indeed regulates CCL4. However, more studies are 
required to dissect the exact nature of interaction between miR-125a and CCL4 
in human macrophages.  This includes use of MRE protector that will allow us to 
distinguish the direct effect of miR-125a on CCL4 mRNA from the effect of miR-
125 on LPS signalling pathway. 
CCL4 mRNA was significantly downregulated only in resting macrophages in 
which miR-125a was overexpressed. A downregulation was also demonstrated 
after overexpression in LPS stimulated cells. This difference was however not 
significant, as with CCL4 protein by ELISA in these cells.  We could therefore 
investigate a broader range of time-points in the future.  
As miRs can target many different mRNAs it is important to view these 
molecules as wide regulators of pathways, and not just concentrate on the 
interaction between one miR and one specific molecule, at a given time.  It was 
beyond the scope of this study to investigate and validate all potential targets of 
miR-125a involved in TLR4 signalling, however the number of these potential 
targets within the one pathway suggests an important role for miR-125a in 
regulating this pro-inflammatory signalling pathway.  It is also probable that the 
list we have identified is not exhaustive, and that further in-silico analysis and 
use of sequencing technology, such as microarray would identify further 
potential targets within this, and related pathways.    
We can therefore hypothesis that miR-125a endogenously functions in an 
anti-inflammatory manner, by regulating members of the TLR4 signalling 
pathway post LPS stimulation resulting in the regulation of the production of 
pro-inflammatory cytokines.  
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 In addition to this regulation of pro-inflammatory cytokines and 
chemokines, we have identified a role for miR-125a in regulating the production 
of anti-inflammatory IL-10.  Although we were unable to functionally test and 
validate predicted mRNA targets which could account for this regulation, 
extensive literature searching identified a potential candidate for this expression 
pattern.  miR-125a is predicted to target histone deacetylase 11 (HDAC11), with 
2 predicted sites conserved between humans and chimpanzee (TargetScan).  
HDAC11 is a recently discovered deacetylase which compacts chromatin around 
the IL-10 promoter, preventing the binding of transcription factors such as 
STAT3, and the production of IL-10 by macrophages (Figure 5.20) [420].  
 
Figure 5.20 Potential miR-125a regulation of IL-10 production through inhibiting HDAC11. 
miR-125a potentially targets HDAC11.  This HDAC molecule inhibits expression of IL-10.  
Therefore miR-125a regulation of HDAC11 potentially leads to higher IL-10 production in human 
macrophages.  
A previous study by Lin et al has demonstrated targeting of HDAC11 by 
another miR, miR-145.  They have shown that miR-145 promotes IL-10 
production after LPS stimulation, through the targeting of HDAC11, releasing its 
gene silencing effect on IL-10.  They were also able to shown a secondary effect 
on IL-12 production, which was increased by these cells post miR-145 inhibition, 
as we have demonstrated with an inhibition of miR-125a [421]. We can therefore 
hypothesise that miR-125a functions in a similar manner in relation to IL-10, and 
promotes its expression through the targeting of HDAC11, and this would be an 
interesting hypothesis to test in the future. Additionally it would be interesting 
to measure levels of HDAC11 in the cohort of patients discussed in Chapter 3  
(Figure 3.7), in which we demonstrated higher levels of miR-125a in PB CD14+ 
cells of RA patients who respond well to conventional therapy.  We could 
IL-10 miR-125a HDAC11 
IL-10 HDAC11 
A.
B.
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hypothesis that higher levels of miR-125a in these cells results in lower HDAC11 
expression, allowing increased production of anti-inflammatory IL-10.  
Although we have proposed an anti-inflammatory role for endogenous miR-125a 
in macrophages, overexpression of this miR has also been shown to result in 
increased TNFα production.  It is important to understand this result, as 
although the loss of miR-125a appears pro-inflammatory, any attempt to use a 
miR-125a mimic as a potential disease therapy may result in off target effects 
through the concurrent increase of TNFα production.  Therefore, we wished to 
confirm the potential mRNAs which may be regulated by miR-125a at these 
supra-physiological levels.   
In addition to regulation by the miRs, the activation of pro-inflammatory 
signalling pathways is negatively regulated by additional molecules that help 
prevent excessive inflammation, and aid its resolution.  We identified TNFAIP3, 
a negative regulator of NFκB, as a target of miR-125a.  This molecule is essential 
for the termination of TLR4 induced NFκB activity in macrophages.  It functions 
as an ubiquitin editing enzyme, by removing ubiquitin tails from signalling 
molecules, such as TRAF6, therefore terminating NFκB activity, and aiding in the 
resolution of the inflammatory response [422].  Polymorphisms within this gene 
have been associated with many inflammatory diseases including RA and SLE, 
and mice deficient in TNFAIP3 develop a TLR4-MyD88 dependent destructive 
polyarthritis, characterised by high serum levels of TNFα, IL-6 and IL-1β [30, 
423].  Therefore, due to the function of TNFAIP3 and the phenotype witnessed 
after its loss, we were interested in the relationship between miR-125a and this 
molecule within our experimental system.  
 We have demonstrated that miR-125a directly targets TNFAIP3 by 
luciferase reporter assay.  Although this is only preliminary data, it is supported 
by existing data by Kim et al, who have shown that miR-125a does in fact 
directly target TNFAIP3 by this method.  Kim et al also showed that 
overexpression of miR-125a resulted in increased NFκB activity and resistance to 
apoptosis, thereby enhancing the aggressive phenotype of diffuse large B cell 
lymphoma cells (DLBCL).  However, this study did not demonstrate any 
functional effect on cytokine production after manipulation of miR-125a 
expression within these cells [369].  
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These results have lead us to hypothesise that when expressed at supra-
physiological levels (after mimic transfection), miR-125a can directly bind 
TNFAIP3, resulting in protein degradation, preventing negative regulation of the 
TLR4 pathway, resulting in increased TNFα production by these cells.  Our 
preliminary mRNA and protein data on macrophages overexpressing miR-125a 
supported this assumption.  As some of the experiments were performed only 
once, it is important to repeat and extend the experimentation including the use 
of specialised target protectors to protect the miR-125a binding site of TNFAIP3 
during transfection. This would identify whether or not targeting of TNFAIP3 is 
causing the increase of this pro-inflammatory cytokine after transfection.   
Therefore, from our data we postulate that under normal endogenous levels 
miR-125a functions to limit (fine tune) the monocyte and macrophage response 
to LPS, by regulating members of the TLR4 signalling pathway and pro-
inflammatory chemokines themselves.  However, under conditions in which the 
level of miR-125a is increased above physiological expression, such as after 
mimic transfection, off-target effects are witnessed, and the excess of miR-125a 
begins to target the anti-inflammatory TNFAIP3 molecule, resulting in increased 
TNFα production.  
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Chapter 6 - Summary and Conclusions 
This study set out to identify miR species which were dysregulated in RA 
macrophages, to identify the functional role of these miRs, and to thereafter 
determine if they play a role in maintaining the pro-inflammatory nature of 
macrophages in RA.  To my knowledge this is the first miR profile of SF CD14+ 
cells thus far identified.  From this profile, we hypothesised that differentially 
expressed miR would affect the differentiation and effector function of 
macrophages within the RA joint. 
MiRs have been shown to regulate around 60% of protein coding genes, and as 
such have been identified as powerful regulators of general cell biology and thus 
inflammatory and disease-related processes.  By corollary, dysregulated 
expression of miRs is well documented in many inflammatory diseases and 
cancers.  Therefore, it is important to study miRs within the context of RA, as 
aberrant expression may identify novel disease associated pathways which may 
not have been previously obvious.  Also as one miR can target many mRNAs, 
usually within the same effector pathway, these molecules may prove an 
interesting therapeutic targets, leading to the regulation of a whole pathway 
instead of a single, albeit important molecule, such as TNF or IL-6R.  
Additionally as many studies continue to search for biomarkers that identify 
particular disease states, the simplicity of identifying miRs in blood or serum 
samples demonstrates a potential for a non-invasive clinical application.  
One identified miR up regulated in this study in synovial CD14+ cells was miR-
511.  It is encoded within the CD206 gene and expressed in M2 macrophages.  
This finding may prove important, as although their potential role via M2 
macrophage maturation in RA is under debate, emerging evidence points 
towards their role in early arthritis.  Based on this notion a novel diagnostic 
technique has been proposed by the company Navidea.  They will identify early 
RA patients by fluorescently labelling CD206 expressing macrophages present in 
affected joints.   Therefore we postulate that high levels of miR-511 within 
synovial cells could potentially be used as a biomarker to identify early RA 
patients in the future.  By virtue of time and scope constraints however I was 
required to focus in my current studies on other miRs.  
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The majority of my study therefore concentrated on the expression and 
functional role of miR-125a in macrophages.  We identified this miR, along with 
its family member miR-99b to be significantly upregulated in SF CD14+ cells; the 
majority of our activities focused on this miR, as its expression pattern 
suggested it may be the dominant miR within this cluster [395].  In addition, we 
observed that changes in miR-125a expression are detected in RA PB CD14+ cells 
when compared to healthy donors. Indeed, one of the key and novel 
observations made on my examination of a cross-sectional RA patient cohort was 
that miR-125a expression is increased in PB CD14+ cells of patients who respond 
well to cDMARD therapy when compared to healthy controls, and patients 
resistant to biologic therapies.  In these cells, expression of miR-125a negatively 
correlates with clinical measures of disease activity, DAS28 ESR, SDAI, CDAI, TJC 
and SJC, suggesting increased miR-125a expression in patients with lower levels 
of on-going inflammation.  Additionally, miR-125a expression positively 
correlated with serum levels of the anti-inflammatory cytokine, IL-10.  This 
expression pattern suggests that miR-125a expression may prove protective 
against inflammation in these cells by forming part of an anti-inflammatory 
regulatory loop.  Moreover in the context of on-going inflammatory disease this 
may represent an attempted resolution pathway that is functionally incompetent 
in the context of overwhelming synovial inflammation.  
This information is important, as although biologic therapies have revolutionised 
treatment of RA, there is currently a considerable unmet need in the 
identification of new therapeutic targets and biomarkers, based upon response 
to therapy that is moderated when remission becomes the prime focus.  
Currently only 60-70% of patients respond to anti-TNFα therapy when high hurdle 
responses are implicated, and this treatment is associated with infectious risk 
e.g. recurrence of latent TB in some recipients of anti-TNFα treatment [248, 
249]. Therefore it is important to find a way to identify patients who will “not” 
or partially respond to biologic therapies, or who will experience an adverse 
reaction. Thus, it would be interesting to investigate the potential of miR-125a 
as a predictive marker of disease progression in a prospective RA cohort.  In 
addition to my studies, the involvement of miR-125a in RA has been recently 
supported by Murata et al, who suggest that circulating miR-125a levels, 
measured in the plasma, can be used as a biomarker to identify patients 
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suffering from RA [396].  However, this study did not take into consideration the 
treatment regimens of these patients.  
 To determine the functional role of miR-125a we took advantage of new 
technology and generated a miR-125a sponge.  The miR-125a sponge is a vector 
containing multiple sites that are complementary to the seed region of miR-
125a, stably expressed at high levels in THP-1 cells.  This inhibits miR-125a, 
resulting in a loss of activity.  To my knowledge, this is the first study to 
generate a miR-125a sponge, and use it thereafter to investigate its functional 
role.  This technology, first described by Ebert et al, has been used successfully 
in the study of other miRs to determine their function within specific cell types 
[424].  For example a study by Valastyan et al, demonstrated the role of miR-31 
in controlling breast cancer metastasis.  The authors identified the 
downregulation of miR-31 in aggressive metastasising tumours, and generated a 
stably expressing miR-31 sponge breast cancer cell line, to mimic this 
environment.  These miR-31 null cells were injected into mice and formed 
macroscopic metastases in the lungs, indicating that miR-31 plays a role in 
controlling breast cancer metastasis [404, 405].  Using the miR-125a sponge 
vector, we generated a THP-1 cell line that stably expressed this miR sponge and 
using PMA differentiation we created a macrophage like cell that effectively 
expressed a miR-125a null environment. These cells exhibited a clear pro-
inflammatory phenotype when stimulated with LPS, producing significantly 
higher levels of TNFα, IL-6, CCL4 and CCL5.  A similar phenotype was noted with 
human macrophages transfected with a miR-125a specific inhibitor.  Again, we 
demonstrated a clear pro-inflammatory phenotype, with significantly higher 
production of TNFα, IL-12, and CCL4 after LPS stimulation.  Interestingly, along 
with high levels of pro-inflammatory cytokines, these cells produced significantly 
lower levels of anti-inflammatory IL-10.  This result was interesting as miR-125a 
expression correlates with serum IL-10 concentration in RA patients.   
 These data suggested that indeed miR-125a plays a regulatory role in 
human macrophages and the removal of this miR from the system would result in 
a hyper-inflammatory response to LPS, or other agonistic stimuli, with increased 
production of pro-inflammatory cytokines and a decrease in IL-10 production.   
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There are conflicting data within the literature with regards to the role of miR-
125a in human macrophages.  A study by Graff et al suggests that miR-125a can 
be used as a marker of M1 macrophage polarisation, with overexpression studies 
in PMA differentiated THP-1 cells, resulting in increased expression of CXCL9, an 
M1 marker [368].  On the other hand, a study by Banerjee et al suggests that 
miR-125a is a marker of M2 macrophages, with overexpression studies in GM-CSF 
differentiated murine macrophages (GM-BMM), resulting in decreased TNFα and 
IL-12 production.  This study also demonstrates that overexpression of miR-125a 
in GM-BMMs results in decreased bactericidal properties, but increase phagocytic 
capabilities, associated with the M2 phenotype [339].  The differences between 
Banerjee et al and my current study may be accounted for by the different 
growth factors used for macrophage differentiation, as the current study was 
performed in M-CSF differentiated macrophages, as opposed to GM-CSF 
macrophages.  Additionally, the problems associated with overexpression studies 
have now been well documented, with off target effects frequently 
demonstrated.  Indeed, when inhibiting miR-125a in mouse M-CSF differentiated 
bone marrow macrophages, Banerjee et al demonstrated an increase in TNFα, 
IL-12, MHC Class II and CD40, in line with the current cytokine profile observed 
in my own studies.  
 We identified potential miR-125a targets underlying its anti-inflammatory 
action using computer based algorithms and functional validation.  We identified 
a novel potential relationship between miR-125a and TLR4 and also miR-125a 
and CCL4.  Additionally, through Targetscan and RNA22 we also identified 
further potential targets such as TRAF6, a molecule involved in the TLR4 
signalling pathway, suggesting that miR-125a plays a key role in the regulation of 
this pathway.    
Based on our data we postulate that, under normal conditions miR-125a fine 
tunes the macrophage response to LPS/TLR activation, preventing an overactive 
inflammatory response by regulating NFκB activation, and the production of pro-
inflammatory cytokines.  This is accomplished by targeting members of the TLR4 
signalling pathway and pro-inflammatory chemokines themselves.  Additionally 
miR-125a allows the increased expression of anti-inflammatory IL-10 through 
targeting of HDAC11, allowing further regulation of inflammation (Figure 6.1 A).  
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However at sites of chronic inflammation, such as in RA, in macrophages this 
regulation is impaired.  This may be due to the masking of the effect of miR-
125a by the increased expression of its targets during chronic inflammation, and 
the lack of response to IL-10 of macrophages within the RA joint [202, 203].  
Additionally miR-125a regulation may be impaired due to the dysregulation of 
other important miRs within the RA macrophage (Figure 6.1 B).   
It has been demonstrated by this lab group that miR-155 is upregulated in SF 
macrophages, where it targets a regulator of pro-inflammatory signalling, SHIP1, 
allowing constitutive expression of pro-inflammatory cytokines [320].  Also the 
miR profile identified at the beginning of this study suggests the upregulation of 
the miR-125a homologue, miR-125b in these cells.  This miR has been shown to 
target TNFAIP3, allowing continual NFκB activation, and also the adoption of an 
activated phenotype through the targeting of IRF4 [369, 372].  Finally, 
unpublished data from this lab group, has also demonstrated a downregulation of 
miR-223 in RA macrophages, which results in increased expression of the NLRP3 
inflammasome, a direct miR-223 target, and increased IL-1β production.  
Therefore the dysregulation of these other miRs may mask the regulatory effect 
of miR-125a within these cells.  
Although the regulatory mechanism of miR-125a appears impaired at sites of 
chronic inflammation, understanding miR-125a expression may prove important 
in terms of endotoxin tolerance in monocytes and macrophages.  The specific 
molecules of the TLR4 signalling pathway that are potential miR-125a targets, 
indicate that this miR may have a specific role in regulating the response of 
macrophages to LPS. Therefore, it would be interesting to study the functional 
consequence of miR-125a manipulation under conditions such as bacterial 
infection and in the context of sepsis. 
We believe that endogenous miR-125a acts as a negative regulator of pro-
inflammatory signalling pathways in activated macrophages.  However, 
therapeutic alteration of this miR should be considered with caution.  In this 
study we demonstrated, that overexpression of miR-125a results not only in 
increased IL-10, but also increased TNFα.  It has been previously demonstrated 
that miR-125a can target the inhibitor of NFκB signalling, TNFAIP3.  Kim et al 
have shown that both miR-125a and miR-125b are upregulated in diffuse large B 
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cell lymphomas (DLBCL), where targeting of TNFAIP3 results in constitutively 
active NFκB, contributing to the aggressive phenotype of these cells [369].  
Additionally, Gomez et al have demonstrated high miR-125a expression in CD34+ 
cells from MDS patients, with high levels of miR-125a correlating with poor 
survival [393].  They have proposed a model whereby miR-125a plays dual roles 
with regards to NFκB activity, depending on cell activation.   Inhibition of miR-
125a after activation with TLR ligands results in increased NFκB activity, 
suggesting a fine-tuning mechanism in which miR-125a plays a critical role.  We 
hypothesised that targeting of TNFAIP3 by miR-125a in human macrophages after 
overexpression is an “off-target” effect of supra-physiological levels of miR (up 
to 200 fold) after transfection.  However, with reports of targeting of this 
molecule by miR-125a in other cells, it is important to determine if this is the 
case.  Therefore additional experiments should be undertaken to settle these 
contradictory reports.  For example a protector against the miR-125a binding 
site in TNFAIP3 should be used to ascertain if high levels of TNFα witnessed in 
these experiments are a result of miR-125a targeting.  Also the concentration of 
mimic could be titred, with TNFAIP3 expression measured by WB, after 
transfection with different concentrations of mimic.  These experiments would 
then determine if miR-125a targeting of TNFAIP3 in human macrophages is 
indeed an “off-target” effect.   
These studies also highlight how important it is to understand the expression 
pattern of miRs before they may be used therapeutically, as miRs may play very 
different roles in depending on cell type.  Therefore any attempt to manipulate 
their expression needs to be cell specific and undertaken with caution.   
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Figure 6.1 The role of miR-125a in normal and RA macrophages 
Under acute inflammatory conditions miR-125a functions to regulate the immune response to 
infection, by dampening inflammation.  However under chronic inflammatory conditions this 
regulatory mechanism fails due to high levels of inflammation, and dysregulation of other miRs 
 
As previously discussed, future work on this project could be undertaken in many 
different directions.   
Firstly, it would be interesting to undertake a microarray analysis of healthy 
macrophages which have been transfected with a Ci or miR-125ai.  Pathway 
analysis software could then be used to identify mRNA transcripts increased in 
the presence of miR-125ai.  This may identify novel miR-125a targets which may 
be  responsible for the proinflammatory phenotype witnessed in these cells.  
Additionally, it would be interesting to determine if the molecules postulated 
within this work, such as TRAF6, TLR4 and HDAC11 were identified.  
 It is also important that targets postulated within this work are validated 
further.  As suggested, the transcript variant of TLR4 expressed on LPS 
stimulated macrophages could be validated, and its 3’UTR sequenced to 
determine its size, and therefore probability that it is regulated by miR-125a or 
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other miR species.  Along with regulation of proinflammatory molecules, miR-
125a regulation of IL-10, through HDAC11 should be confirmed.  
As the original observation within this study was the upregulation of miR-125a in 
SF CD14+ cells, I believe it will be important to investigate the response of miR-
125a to DAMPs present within the joint, such as Tenascin-C.   We have 
hypothesised that within the proinflammatory environment of the joint, 
upregulation of miR-125a within these cells represents a failed mechanism of 
regulation, or that the dysregulation of other miRs within these cells prevents 
miR-125a acting in its usual role.  Therefore, in the future, miR-125a levels 
could be manipulated within SF CD14+ cells themselves to determine if these 
observations are proven correct.  The long term future direction of this work will 
therefore depend on the outcome of these suggested experiments. 
In summary, this study has generated new evidence with regards to the miR 
profile of SF CD14+ cells.  It has identified a potential biomarker for response to 
therapy in RA patients, and a clear regulator of TLR4 signalling in macrophages; 
however several avenues remain to be explored.  Future studies are required to 
conclusively identify miR-125a targets within the RA synovium and understand 
the functional consequence of high levels of this miR within macrophages, in RA. 
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